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HISTORICAL PERSPECTIVES
The 'Three Princes of Serendip' is an old Persian fairy tale about three men who
were on a mission and encountered things that looked irrelevant at first sight but
which turned out to be important later on. They discovered things by serendipity
and sagacity. Serendip is the Persian name for Sri Lanka. Later, in 1754 Horace
Walpole coined the word serendipity. One of the founders of pediatric oncology
Giulio D'Angio1 pointed to this fable when he analyzed the discovery of treatment
tools in pediatric oncology. It has often happened that serendipitous observations
lead to a break-through in quite another field. This story includes the discovery of
L-Asparaginase:
The enzymatic deamination of asparagine was already studied by Clementi2 in
1922. In 1952 Kidd3 discovered that the injection of guinea pig serum inhibited the
growth of murine lymphomas. His experiments indicated that a protein was
responsible for the antilymphoma activity. In 1956, Neuman and McCoy4 showed
that Walker carcinoma tissue cultures had an absolute requirement for asparagine.
It took until 1961 before an explanation was found for these observations:
Broome,5 working in Kidd's laboratory, presented evidence that the enzyme L-
Asparaginase was responsible for the antitumor activity of guinea pig serum. An
effective drug was discovered by serendipity.
The next big step in the development of L-Asparaginase as an effective
antitumor agent took place in 1964. Mashburn et al. demonstrated that L-
Asparaginase produced by the microorganism Escherichia coli (E. coli) had the
same antitumor activity as that gained from guinea pig serum.6 L-Asparaginase
could be extracted from two bacterial sources: Escherichia coli 6 and Erwinia
chrysanthemi.7 The bacterial source made it possible to produce and utilize larger
quantities of the enzyme and a series of preclinical and clinical studies was
initiated.8,9 A polyethylene glycol modified version of the enzyme (PEG-
Asparaginase) was developed in the 1970s and 1980s and was first used in clinical
trials in the 1980s.
The importance of L-Asparaginase in the treatment of acute lymphoblastic
leukemia (ALL) was demonstrated.10,11 ALL is the most common cancer in
childhood with 110 - 120 newly diagnosed children in the Netherlands each year.
The 5-year disease free survival for children with ALL could be improved with more
intensive combination chemotherapy from 4% in the early 1960s to more than
80% in the 1990s.12 The continuously improving treatment results through the
years are an example of accurate registration, medical development and the
handling of therapeutic schedules according to often international treatment
protocols. L-Asparaginase was used as a single agent or in combination with other
drugs to treat ALL. This drug appeared to be highly effective especially in children
with newly diagnosed ALL.13 Prolonged L-Asparaginase intensification improved the
outcome significantly as was demonstrated in the Dana-Farber Cancer Institute
ALL Consortium Protocol 91-01.14 Nowadays, L-Asparaginase is an essential drug
that is used to treat children with ALL all over the world.
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DRUG PROPERTIES AND PHARMACOLOGY
Chemistry
The chemical properties of L-Asparaginase are extensively described in several
biochemical reviews.15-17 The enzymatic hydrolysis of the non-essential amino
acids asparagine and glutamine to aspartic acid, glutamic acid and ammonia
causes a depletion of the corresponding serum amino acids. The glutaminase
activity amounts about 3 - 4 % of the L-Asparaginase activity.18 Therefore, high
doses of L-Asparaginase will also reduce the level of glutamine in serum. Complete
asparagine depletion is already achieved within a few minutes after administration
of L-Asparaginase whereas complete glutamine depletion is not achieved because
of an excess of glutamine in the serum.
Pharmacokinetics
Different L-Asparaginase preparations have different half-lives.19-21 Asselin et al.
found that native E. coli preparations had a half-life of 1.24 ± 0.17 days (i.e. 29.8
± 4.1 hours) in blood, whereas the half-life of identically applied Erwinia
chrysanthemi Asparaginase, Erwinase® (Ipsen, Maidenhead, UK) was much
shorter. Different half-lives of the L-Asparaginase preparations lead to different
durations of asparagine depletion (Table 1.1).
Pegylation, i.e. the covalent binding of monomethoxy-polyethylene glycol (PEG)
molecules to proteins, is a common method to reduce the immunogenic potential
of therapeutically applicable proteins. Pegylation of L-Asparaginase extended the
half-life of the enzyme activity to more than 5 days.19 The longer half-life of PEG-
Asparaginase is caused by the higher molecular weight, the slower degradation of
the enzyme by proteases and a reduced absorption in the reticular endothelial
system.22
Table 1.1 Half-lives of different L-Asparaginase preparations
Asselin et al.19
Elimination half-life (hours)
Dose: 25,000 IU/m2 i.m.
Werber et al.21
Elimination half-life (hours)
Dose: 10,000 IU/m2 i.v.
PEG-Asparaginase
(Oncaspar®)
137.5 ± 77.8
E. coli L-Asparaginase
(Medac® / Paronal®)
23 ± 2.5
E. coli L-Asparaginase
(Crasnitin® / Elspar®)
29.8 ± 4.1 17.7 ± 2.5
E. chrysanthemi L-Asparaginase
(Erwinase®)
15.6 ± 3.1 7.2 ± 4.1
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L-Asparaginase

H2O + asparagine aspartic acid + NH3
aspartic acid+ ATP + amine glutamic acid + asparagine + AMP
(from glutamine) 
asparagine synthetase
Plasma L-Asparaginase activity levels of  100 IU/L guaranteed complete
plasma asparagine depletion, i.e. < 0.2 µmol/L.23 The established dosage scheme
should therefore be adapted to the different half-lives of the different products.
The German BFM studies on the native E. coli L-Asparaginase preparation L-
Asparaginase medac® and on Erwinase®, originally both dosed as 10.000 IU/m2
intravenously, led to the recommendation of reducing the dose of L-Asparaginase
medac® to 5000 IU/m2 and increasing the Erwinase® dose to 20.000 IU/m2 in
order to achieve complete asparagine depletion in serum. 1000 IU/m2 PEG-
Asparaginase resulted in L-Asparaginase activities > 100 IU/L and thus complete
asparagine depletion in serum.24
It has been suggested that L-Asparaginase hardly penetrates the central
nervous system (CNS).25 The activity of native E. coli L-Asparaginase in the
cerebro-spinal fluid (CSF) was less than 1% of the corresponding serum activity.
Yet, L-Asparaginase is believed to play a role in the prevention of meningeal
leukemia.25
Intravenous versus intramuscular application of both L-Asparaginase medac® or
Erwinase® application revealed no difference in pharamacokinetics.26,27
Pharmacodynamics
Asparagine depletion
The effectiveness of L-Asparaginase therapy in ALL is said to be a result of
depletion of asparagine within leukemic cells. L-Asparaginase hydrolyzes
asparagine to aspartic acid and ammonia and as a consequence asparagine in
serum will be depleted promptly (Figure 1.1). In normal cells asparagine is a non-
essential amino acid because cells use the enzyme asparagine synthetase to
synthesize asparagine. Asparagine synthetase, encoded by a single gene located
on chromosome 7q21.3,28 is the only enzyme available for the synthesis of
asparagine. This enzyme adds an amine from glutamine to aspartic acid, thereby
forming the characteristic amide group of asparagine. In contrast to normal cells,
asparagine is supposed to be an essential amino acid for leukemic cells because of
their relative lack of asparagine synthetase.29 Asparagine depletion inhibits protein
and RNA synthesis30 and induces cell cycle arrest and apoptosis in murine
leukemia cell lines.31 Complete asparagine depletion in the human circulation will
be reached as long as the L-Asparaginase activity level in serum is > 100 IU/L.23
Figure 1.1 Mechanism of action of L-Asparaginase
General introduction
5
glutaminase

H2O + glutamine glutamic acid + NH3
glutamic acid + NH3 + ATP ADP + glutamine + H2O

glutamine synthetase
Glutamine depletion
Glutamine levels will also drop upon L-Asparaginase exposure, an effect explained
by the low glutaminase activity of L-Asparaginase32 (Figure 1.2). A reduction in
glutamine levels also contributes to the antileukemic effect of L-Asparaginase,
since glutamine plays a role in cellular metabolism and protein synthesis. Serum
levels of glutamine (650 mol/L) are about tenfold higher than the amount of
asparagine. Glutamine hydrolysis leads to an increase in glutamic acid. However,
glutamine concentrations rapidly return to normal levels and remain normal during
prolonged L-Asparaginase activity.18 This is due to the fact that the body can
increase its rate of glutamine synthesis by glutamine synthetase.33
Asparagine synthetase and resistance to L-Asparaginase
Cell line studies showed that L-Asparaginase sensitive leukemic cells had low
intracellular asparagine synthetase activity and were dependent on the availability
of extracellular asparagine.34 Complete in vitro depletion of asparagine resulted in
an amino-acid dependent upregulation of both mRNA, protein and activity of
asparagine synthetase.28 Resistance to L-Asparaginase in leukemic cell lines has
been associated with upregulation of asparagine synthetase mRNA.28,35 However,
Fine et al. showed that L-Asparaginase results differ between leukemic cell lines
and primary samples from leukemic patients and hence, cell line data can not be
easily extrapolated to primary patient's cells.36
The relevance of in vitro resistance to antileukemic drugs in pediatric ALL was
demonstrated by the fact that clinical outcome of patients resistant to
L-Asparaginase, vincristine and prednisone was significantly worse than of
sensitive patients.37-39 In contrast, the prognostic favourable subtype of TEL-AML1
positive ALL is associated with in vitro L-Asparaginase sensitivity.40,41 However, a
high baseline intracellular asparagine synthetase level was not related to in vitro
L-Asparaginase resistance in children with TEL-AML1 positive ALL,40 whereas the
two factors were correlated in other genetic subclasses of precursor B-ALL.42 These
data suggest that mechanisms other than high asparagine synthetase activity are
important to L-Asparaginase resistance in TEL-AML1 rearranged ALL. These factors
may probably also contribute to L-Asparaginase resistance in other types of ALL.
Knowledge of resistance mechanisms to L-Asparaginase is therefore important for
improving outcome of childhood ALL.
Figure 1.2 Mechanism of action of glutaminase
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Interaction of L-Asparaginase with amino acids other than asparagine and
glutamine
In 1969 Miller et al. already determined the serum levels of other amino acids
during treatment with E. coli L-Asparaginase in two patients.18 Besides the well-
known effects on the level of asparagine and glutamine no significant changes
were observed in the concentrations of other amino acids. With more modern
techniques the group of Avramis monitored a decrease of 19% - 83% in serine,
threonine, histidine, proline and arginine serum levels of 73 pediatric ALL
patients.43,44 It has been suggested that this effect on other amino acids is
involved in the antileukemic activity of L-Asparaginase through interference with
protein synthesis. In addition, acute leukemic cells had consistently lower taurine
levels compared to normal cells and required L-cysteine probably due to a tenfold
decrease in the activity of -cystathionase45 (Figure 1.3).
Depletion of asparagine by L-Asparaginase resulted in decreased glycine
concentrations in an animal model presented by Ryan.46 In this model
intraperitoneally injected glycine or asparagine effectively eliminated the antitumor
effect of L-Asparaginase. However, Chakrabarti et al. could not confirm these
results.47 They found that the transamination of glyoxylate to glycine was
significantly decreased in sensitive cells compared to cells resistant to
L-Asparaginase.48 This made them suggest that an increase in glyoxylate content
in sensitive cells might attribute to the antileukemic effect.
methionine
homocysteine
cystathionine
cysteine
-glutamylcysteine
glutathione
MTHFR
tetra-hydrofolate
5-methyl-tetra-
hydrofolate
taurine
-cystathionase
serine
glutamic acid
glycine
L-Asparaginase
asparagine
aspartic acid
glutamine
glyoxylate
protein
synthesis
threonine / histidine / proline / arginine / valine ?
Figure 1.3 Interference of L-Asparaginase with the metabolism of amino acids
The interference of L-Asparaginase with serum amino acid levels: squares point to increased
levels upon L-Asparaginase exposure, circles to decreased levels upon L-Asparaginase exposure.
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L-ASPARAGINASE AND HEMOSTASIS
The depletion of asparagine and glutamine is followed by metabolic and cellular
events leading to clinical side effects of therapy such as neurotoxicity and
hepatotoxicity,32 hyperglycemia, pancreatitis and alterations in hemostasis.49,50
The duration of asparagine depletion in serum of patients correlated with the
incidence of coagulation disorders.51 Changes in laboratory parameters of
coagulation were related to the L-Asparaginase activity in plasma.52 Because the
administration of L-Asparaginase takes place in conjunction with other drugs,
especially corticosteroids, it is difficult to relate adverse reactions in hemostasis to
L-Asparaginase only.
Most of the thrombotic events occur during induction therapy. The rate of
clinical thrombosis was 5.2% in a meta-analysis of 1752 children.53 Studies have
been performed to investigate the role of L-Asparaginase therapy alone54-56 or in
combination with other drugs, especially corticosteroids.57,58 The decrease in
coagulation proteins upon L-Asparaginase exposure is in part counterbalanced by
corticosteroids which increase procoagulant factors.59 There are no data showing
that different kinds of corticosteroids e.g. prednisone or dexamethasone interfere
in different ways with L-Asparaginase.
The degree of disturbance of the coagulation system is dependent on the dose
and on the type of L-Asparaginase preparation51,60 and is mainly attributed to a
decrease in coagulation protein synthesis. This will generate a disturbance in the
hemostatic balance between bleeding and thrombosis. Increased thrombin
generation and a decreased antithrombotic potential of the plasma are thought to
be of critical importance in generating thrombo-embolic complications in children
with ALL treated with chemotherapy. There are no data on changes in the
coagulation profile after the administration of PEG-Asparaginase only.
The results of a randomized study on the use of antithrombin supplementations
aiming to reduce the incidence of thrombo-embolic events were not conclusive
(PARKAA study).61 The incidence of thrombosis in patients treated with
antithrombin was 28%, compared to 37% in the non-treated arm. However, no
significant differences were seen in levels of markers of endogenous thrombin
generation indicating that the suppression of antithrombin by L-Asparaginase was
not the critical event in the development of thrombo-embolism. Replacement
therapy with fresh frozen plasma62,63 was also ineffective to correct for
L-Asparaginase-induced coagulation factor deficiency.
The prophylactic use of Enoxaparin®, a low molecular weight heparin, during
L-Asparaginase treatment seemed safe and might be effective in preventing
thrombotic events.64 Thrombotic events were not found in 41 children with ALL
analyzed. However, also in a historical control group of 50 children without
prophylactic low molecular weight heparin treatment only two events were
observed. Therefore, there is currently no solid data indicating which strategy may
prevent thrombo-embolic events caused by L-Asparaginase.
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OUTLINE OF THE THESIS
In Part I we studied pharmacokinetic and pharmacodynamic aspects of a
monotherapy with PEG-Asparaginase.
In Part II the main toxic side effect of L-Asparaginase treatment related to
changes in hemostasis was studied.
Part I
Resistance to L-Asparaginase has in vitro been attributed to high levels of
intracellular asparagine synthetase (AS). However, it was unknown whether
baseline and/or L-Asparaginase induced AS mRNA levels were linked to the clinical
response to this drug. We investigated in chapter two whether in vivo baseline
and/or L-Asparaginase induced AS mRNA levels were related to the clinical
response to a single dose of 1000 IU/m2 PEG-Asparaginase in children (1 - 18
years) with newly diagnosed ALL before starting combined chemotherapy. Changes
in AS mRNA expression were analyzed in time during this investigational window
and related to the clinical response after 5 days. Because proB ALL is not
frequently found in children older than 1 year, we additionally measured the
baseline AS mRNA expression in 23 infants with proB ALL to compare data of this
type of leukemia with those of other subtypes of ALL patients enrolled in the
window study.
In chapter three we investigated the clinical and biological effects of this single
dose of PEG-Asparaginase in children with newly diagnosed ALL. We compared the
clinical response to PEG-Asparaginase with the in vitro sensitivity to
L-Asparaginase at diagnosis and with clinical long-term outcome. The relationship
between immunophenotype, genotype and clinical response was studied. In vivo
response to PEG-Asparaginase was studied in relationship with baseline as well as
L-Asparaginase-induced changes in serum and intracellular amino acid levels, and
with parameters of apoptosis. In addition, clinical toxicity and changes in
coagulation profiles were analyzed both after one single infusion with PEG-
Asparaginase and after the combination chemotherapy given thereafter.
Pharmacokinetics and pharmacodynamics of L-Asparaginase in the cerebro
spinal fluid (CSF) had not been characterized well for PEG-Asparaginase. In
chapter four we monitored L-Asparaginase activity levels and asparagine
concentrations in plasma and CSF after the administration of 1000 IU/m2 PEG-
Asparaginase on day -5. Regular chemotherapy according to the DCOG-ALL-9
schedule was started at day 0. From day -5 till day 0 blood samples were collected
daily, and later on twice a week. A lumbar puncture was performed at diagnosis
(day -5), at day 0 and at day 15 when intrathecal therapy was administered and
asparagine levels in the CSF could be monitored.
Part II
A main side effect of L-Asparaginase is the increased risk of thrombo-embolic
complications. In part II of this thesis we focused on the effects of L-Asparaginase
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on coagulation parameters. We performed a randomized study between native E.
coli L-Asparaginase and Erwinia L-Asparaginase (chapter five) to evaluate
differences in the risk on thrombo-embolic complications. The study was
performed during induction therapy of the DCOG-ALL-7 protocol. L-Asparaginase
was administered 8 times as 10.000 IU/m2 intravenously every three days starting
at day 19. Thrombin generation and fibrinolysis was studied in blood samples
taken before each L-Asparaginase infusion.
The concept of developmental hemostasis points to age-related changes in the
coagulation system. Infants and adolescents are at risk for thrombo-embolic
events due to physiological changes in their coagulation profile. Most serious
thrombo-embolic complications during L-Asparaginase treatment are seen in
adolescence. We hypothesized that these physiological changes in the coagulation
system might influence the risk on thrombosis during L-Asparaginase therapy. In
chapter six we describe the differences in changes in coagulation between
patients in different age groups: 1 - 5, 6 - 10 and 11 - 16 years old. The children
were treated according to the DCOG-ALL-9 protocol with four doses of E. coli
L-Asparaginase Paronal during induction. Procoagulant and anticoagulant factors
and parameters of thrombin generation and fibrinolysis were monitored.
There is an interaction between the effects of corticosteroids and
L-Asparaginase on the coagulation system. Different schedules are used during
anti-leukemic treatment including differences in dosages of corticosteroids and
L-Asparaginase, but also different timing and duration of administering these
drugs. We analyzed two different regimens of concomitant use of these drugs in
chapter seven in a group of high-risk ALL patients receiving dexamethasone and
L-Asparaginase during induction and during intensification treatment of ALL
according to the DCOG-ALL-9 protocol. We monitored procoagulant and
anticoagulant factors and parameters of thrombin generation and fibrinolysis.
Finally, all results are discussed in Part III, chapter eight and summarized in
chapter nine in English and Dutch.
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ABSTRACT
L-Asparaginase (L-Asp) is an effective drug for
treatment of children with acute lymphoblastic
leukemia (ALL). The effectiveness is generally
thought to result from a rapid depletion of
asparagine in serum and cells. Asparagine
synthetase (AS) opposes the action of L-Asp by
resynthesis of asparagine. In vitro, resistance to L-
Asp has been associated with up-regulation of AS
mRNA expression. We monitored AS mRNA levels in
leukemic cells before and during 5 days after
intravenous administration of 1000 IU/m² of
pegylated L-Asparaginase (PEG-Asp) in a
therapeutic window in children with ALL at initial
diagnosis. Within 24 hours, AS mRNA levels
increased by 3.5-fold and remained stable in the
following 4 days. Baseline and L-Asp-induced
expression levels of AS did not differ between
clinically good, intermediate, and poor responders
to PEG-Asp. No significant difference of AS mRNA
up-regulation was found between precursor B- and
T-ALL or between hyperdiploids, TEL-AML1
rearranged ALL or absence of genetic abnormalities.
In 3 of 12 patients with T-ALL even a slight down-
regulation of AS mRNA expression upon L-Asp
exposure was found. In conclusion, although L-Asp
exposure induces the expression of AS mRNA, the
up-regulated gene expression does not correlate
with an early clinical poor response to this drug in
children with ALL.
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INTRODUCTION
L-Asparaginase (L-Asp) is an effective drug for the treatment of children with acute
lymphoblastic leukemia (ALL).1,2 In newly diagnosed patients with ALL, 25% to
60% will reach a complete remission after monotherapy with L-Asp.1 The efficacy
of this drug is generally thought to result from a rapid and complete depletion of
asparagine in plasma by hydrolyzing this amino acid to aspartic acid.
L-Asp resistance has been attributed to high levels of intracellular asparagine
synthetase (AS).3 Cell line studies showed that L-Asp sensitive leukemic cells have
low intracellular AS activity and are dependent on the availability of extracellular
asparagine.4 Andrulis et al. demonstrate that complete asparagine depletion in
vitro results in an amino-acid dependent up-regulation of mRNA, protein and
activity of AS.5 Resistance to L-Asp in cell lines is in vitro mediated by an up-
regulation of AS expression in response to asparagine depletion of culture
medium.6,7 Whereas these cell line studies suggest that up-regulation of AS
expression is an important mechanism of L-Asp resistance, clinical evidence is
lacking for this assumption. In recent studies we found evidence that a high
baseline intracellular AS gene expression is related to in vitro L-Asp resistance in
children with TEL-AML1 negative ALL,8 but not in TEL-AML1 positive children.9 This
suggests that the genotype plays an important role in the cause of L-Asp
resistance. However, it is yet unknown whether baseline and/or L-Asp induced AS
mRNA levels are linked to the clinical response to this drug given as a therapeutic
window upfront of combination chemotherapy.
In the present in vivo study we investigate whether baseline and/or L-Asp-
induced AS mRNA levels are related to the clinical response to a therapeutic
window with L-Asp in children with newly diagnosed ALL.
PATIENTS, MATERIALS, AND METHODS
Patients and therapeutic window with PEG-Asp
In close collaboration between our institution and the Dutch Childhood Oncology
Group (DCOG; the former Dutch Childhood Leukemia Study Group) a window
study with pegylated Escherichia coli L-Asp (PEG-Asp) upfront to the ALL-9
treatment schedule was initiated in July 2000. The DCOG ALL-9 study was
implemented in the Netherlands to confirm the good results of the ALL-6 study,10
which was originally based on the German ALL-BFM strategy. The aim of our study
is to determine the clinical response as well as molecular determinants of L-Asp
response in ALL. Children with ALL at initial diagnosis and presenting with white
blood count (WBC) greater than 10 x 109/L were eligible. Similar to a study from
the Dana Farber Cancer Institute,11 we assessed a 5-day investigational window. A
complete and persistent depletion of asparagine is considered to be the
mechanism of action of L-Asp treatment. Boos et al.12 showed that a plasma E coli
Asp activity of more than 100 IU/L leads to an asparagine depletion of less than
0.2 μM in plasma. Muller demonstrated that one dose of 1000 IU/m2 PEG-Asp
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resulted into more than 100 U/L serum enzyme activity of L-Asp for 3 weeks.13 In
a previous study we confirmed that 1000 IU/m2 PEG-Asp given as a therapeutic
window at day -5 (ie, 5 days before starting combined chemotherapy) results in
more than 100 U/L L-Asp activity for at least 10 days in children with ALL at initial
diagnosis.14 In the present study patients received a single dose of 1000 IU/m2
PEG-Asp in a 1-hour infusion 5 days before starting the DCOG-ALL-9 combination
chemotherapy treatment schedule. PEG-Asp, kindly provided by Medac (Hamburg,
Germany), was used mainly because of its lower immunogenicity than native
(unpegylated) L-Asp.15 This lower immunogenicity is important since these
patients will be treated with unpegylated L-Asp as part of their regular combination
chemotherapy hereafter.
We decided to use the same definition for clinical response that is used for
response to prednisone:16 more than 1 x 109 leukemic blasts per liter (1000/L) of
peripheral blood has been shown to be highly predictive for an inferior outcome.
So, the clinical response on day 0 (5 days after the PEG-Asp infusion) was defined
as good when the number of leukemic cells had declined to less than 1 x 109/L of
peripheral blood, as intermediate when leukemic cells were 1 x 109/L to 10 x
109/L, and as poor when leukemic cells were greater than 10 x 109/L.
Between July 2000 and October 2002, 31 patients with ALL were enrolled in the
study. Of these, 25 children were diagnosed in the Erasmus MC-Sophia Children's
Hospital, Rotterdam, and 6 children in 3 other university hospitals in the
Netherlands. Patients' characteristics are shown in Table 2.1.
Table 2.1 Characteristics of 31 patients treated with one dose of PEG-Asp before the
DCOG-ALL-9 study
Characteristic Value
Male / Female 17/14
Age, median, y (range) 4.2 (1.2 - 13.1)
Median WBC count at diagnosis, x 109/L (range) 47 (11.4 - 417)
Immunophenotype
Pro-B-ALL 1
common ALL 9
Pre-B-ALL 9
T-ALL 12
Cytogenetic characteristics
Hyperdiploid 9*
TEL-AML 1 fusion 5
BCR-ABL fusion 1*
MLL gene rearranged 0
others 17
CNS involvement**
Yes 0
No 31
Patients were administered one intravenous dose of 1000 IU/m2 pegylated L-Asparaginase
before undergoing combination chemotherapy as part of the DCOG (Dutch Childhood Oncology
Group) ALL-9 study.
* one patient had both a hyperdiploidy and a BCR-ABL fusion,
** CNS involvement defined as more than 5 cells/μL with blasts in the cerebrospinal fluid
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Because pro-B-ALL is not frequently found in children older than 1 year, we
additionally measured the baseline AS mRNA expression in 23 infants with pro-B-
ALL (Interfant-99) to compare data of this type of leukemia with those of other
subtypes of ALL patients enrolled in the window study.
The immunophenotyping was performed at reference laboratories of the
participating groups. The B-lineage ALL cells (CD19+, HLA-DR+) were classified into
the following differentiation stages: pro-B-ALL cells were CD10-, cytoplasmic μ
chain-negative (cμ-), and surface immunoglobulin-negative (sIg-); cALL cells were
CD10+/cμ-/sIg-; pre-B-ALL cells were CD10+/-/cμ+/sIg-. B-ALL cells characterized
by CD10-/cμ-/sIg+ were excluded from the study.
The window study on PEG-Asp and the Interfant study on infants with pro-B-
ALL were approved by the local ethical committee and by the institutional research
board of the DCOG. The patient and/or the parents and guardians have given
informed consent for these studies in accordance with the Declaration of Helsinki.
Patient samples
Bone marrow and peripheral blood samples were obtained at initial diagnosis of
ALL (day-5) before the administration of PEG-Asp. To perform daily analyses of
asparagine synthetase (AS) expression in leukemic cells we decided for ethical
reasons that daily collection of bone marrow was unacceptable. Stams et al.9 have
shown that purified leukemic cells out of peripheral blood revealed comparable AS
mRNA levels compared with leukemic cells isolated out of bone marrow. Therefore,
blood samples were collected during 5 consecutive days until the start of
combination chemotherapy at day 0. Within 24 hours after sampling, mononuclear
cells were isolated by density gradient centrifugation using Lymphoprep (density
1.077 g/mL; Nycomed Pharma, Oslo, Norway) and centrifuged at 480g for 15
minutes at room temperature. The collected mononuclear cells were washed twice
and kept in culture medium consisting of RPMI 1640 medium (Dutch modification
without L-glutamine; Gibco BRL, Life Technologies, Breda, MD), 20% fetal calf
serum (FCS; Integro, Zaandam, The Netherlands), 2 mM L-glutamine (Gibco BRL,
Life Technologies), 5 μg/mL insulin, 5 μg/mL transferrin, 5 ng/ml sodium selenite
(ITS media supplement; Sigma, St Louis, MO), 100 IU/mL penicillin, 100 μg/mL
streptomycin, 0.125 μg/mL amphotericin B (Life Technologies), and 0.2 mg/mL
gentamycin (Life Technologies). Contaminating nonleukemic cells in the ALL
samples were removed by immunomagnetic beads as described by Kaspers et al.17
All samples contained more than 90% leukemic cells, as determined
morphologically on May-Grünwald-Giemsa-stained (Merck, Darmstadt, Germany)
cytospins.
RNA extraction and cDNA synthesis
Total cellular RNA was extracted from a minimum of 5 x 106 cells using Trizol
reagent (Life Technologies) according to the manufacturer's protocol, with minor
modifications as reported previously.9 The concentration of RNA was quantified
spectrophotometrically and the quality was checked on agarose gels. Following a
denaturation step of 5 minutes at 70 ºC, 1 μg of RNA was reverse-transcribed into
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single-stranded cDNA. The reverse transcription (RT) was performed in a total
volume of 25 μL, containing 2.5 nM random hexamers and 20 nM oligo dT primers
(Amersham Pharmacia Biotech, Piscataway, NJ), 200 U Moloney murine leukemia
virus reverse transcriptase (Promega, Madison, WI), and 25 U RNAsin (Promega)
and was incubated at 37 ºC for 30 minutes, 42 ºC for 15 minutes and 94 ºC for 5
minutes. The obtained cDNA was diluted to a final concentration of 8 ng/μl and
stored at -80 ºC.
Quantitative real-time PCR
The mRNA expression levels of AS and the endogenous housekeeping gene
encoding for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as a reference,
were quantified using real-time polymerase chain reaction (RTQ-PCR) analysis
(TAQMAN chemistry) on an ABI Prism 7700 sequence detection system (PE Applied
Biosystems, Foster City, CA).
Amplification of specific PCR products was detected using dual-fluorescent
nonextendable probes labeled with 6-carboxyfluorescein (FAM) at the 5' end and
6-carboxytetramethylrhodamine (TAMRA) at the 3' end. The primers and probe
combinations were designed using OLIGO 6.22 software (Molecular Biology
Insights, Cascade, CO) and have been published elsewhere.9 Because all PCRs
were performed with equal efficiencies (> 95%), relative mRNA expression levels
of AS for each patient could directly be normalized for input RNA using the GAPDH
expression of the patient. The relative mRNA expression level of the target gene in
each patient was calculated using the comparative cycle time (Ct) method.18
Briefly, the target PCR Ct values (ie, the cycle number at which emitted
fluorescence exceeds 10 x the standard deviation [SD] of baseline emissions, as
measured from cycles 3 to 12) are normalized by subtracting the GAPDH Ct value
from the target PCR Ct value, which gives the ΔCt value. From the ΔCt value, the
relative expression level to GAPDH for AS is calculated using the following
equation: relative mRNA expression = 2-ΔCt x 100%.
Statistics
Differences in mRNA expression levels measured at different days were analyzed
using the Wilcoxon matched-pairs signed rank test. The relationship between AS
mRNA expression and in vivo PEG-Asp response and between AS expression and
immunophenotype or cytogenetic subtype was analyzed with the Mann-Whitney U
(MWU) test.
RESULTS
Children with newly diagnosed ALL and WBC greater than 10 x 109/L were
consecutively enrolled into the study. As is shown in Table 2.1, 31 children were
eligible at the moment of analysis: 1 with pro-B-ALL, 9 with common ALL, 9 with
pre-B-ALL, and 12 with T-ALL.
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Similar to day 7 for a prednisone window response, we evaluated the in vivo
response to PEG-Asp by counting the number of leukemic blasts in the peripheral
blood at day 0, 5 days after PEG-Asp was given. As can be seen in Figure 2.1, the
leukemic cells in the peripheral blood dropped continuously over 5 days. The
number of leukemic cells reduced 224-fold from median 44.7 x 109/L at day-5 to
median of 0.2 x 109/L at day 0. This was more than a 2-log decrease in leukemic
cell burden. There were 21 (68%) children who were PEG-Asp good responders
(blast number < 1 x 109/L at day 0), 6 (19%) who were intermediate responders
(blasts 1 x 109/L to 10 x 109/L at day 0) and 4 (12%) children who were poor
responders (blasts > 10 x 109/L at day 0) (Figure 2.1).
The baseline expression level of AS mRNA relative to GAPDH was median
0.26% (range 0.05% - 2.5%) in leukemic cells (> 90% purity). This was in the
range of healthy controls as described in our previous study.9 The expression
levels of AS in leukemic cells relative to GAPDH increased significantly median 3-
fold, from 0.26% (basal expression) to 0.75% 24 hours later (P < 0.001; Figure
2.2). During the following 4 days the expression of AS mRNA remained stable at
the level of 24 hours (Figure 2.2; Table 2.2).
Figure 2.1 Clinical response to pegylated L-asparaginase (PEG-Asp) in pediatric
acute lymphoblastic leukemia (ALL)
Clinical response to 1000 IU/m2 intravenous PEG-Asp, measured as the decrease in the absolute
number of leukemic cells in peripheral blood of 31 children with ALL. The final values at day 0
are shown for each individual by dots. The clinical response line shows the median and 25th and
75th percentiles. A good clinical response is defined by < 1 x 109 blasts/L at day 0, an intermediate
response by 1 x 109 blasts/L to 10 x 109 blasts/L on day 0, and poor response by more than 10 x
109 blasts/L at day 0. Dotted lines indicate the cut-off values for these clinical responses.
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Table 2.2 Asparagine synthetase (AS) mRNA expression values in time
Median expression values (and 25th - 75th percentiles) of AS mRNA compared with GAPDH in
time in leukemic cells of 31 children induced by pegylated L-asparaginase (PEG-Asp). Wilcoxon
signed rank test compared between successive days, and day -5 values compared to levels of
day -4, day -3, day -2, day -1, and day 0, NA indicates not applicable.
The baseline expression level of AS mRNA did not differ between good and
intermediate (P = 0.614), good and poor (P = 0.852) responders, and
intermediate and poor (P = 1.0) responders; nor did the up-regulated AS levels
after 24 hours of PEG-Asp differ between good and intermediate (P = 0.614)
responders, good and poor (P = 0.737) responders, and intermediate and poor (P
= 0.914) responders (Figure 2.3A-B). The fold-change in AS mRNA expression
levels was also not related to the relative (P = 0.997) or absolute (P = 0.804)
decrease in leukemic cells in all 31 patients.
The AS expression for the different immunophenotypic ALL subgroups at
diagnosis is shown in Figure 2.4. The median levels of AS mRNA relative to GAPDH
mRNA for c/pre-B-ALL patients (0.21%) and for the T-ALL patients (0.28%) did
not significantly differ (P = 0.376). One window patient had a pro-B-ALL for which
the baseline expression of AS mRNA was 3-fold higher than the other c/pre-B-ALL
patients. To explore whether pro-B-ALL is associated with a high AS mRNA
expression we analyzed the AS expression of 23 infant pro-B-ALL cases. Infants
with pro-B-ALL had a median 0.15% (range, 0.07% - 1.43%) AS mRNA expression
level, which was not significantly different from the baseline AS expression values
in non-infants with c/pre-B- or T-ALL (Figure 2.4A). The c/pre-B-ALL group had a
median baseline AS expression level of 0.21% that rose significantly to a median
of 0.72% 1 day later (median 3.99-fold individual up-regulation, P = 0.001).
Patients with T-ALL demonstrated a significant increase from baseline 0.28% to
0.68% 1 day later (median 1.94-fold individual up-regulation, P = 0.012). Patients
with T-ALL tended to have a lower individual up-regulation of AS mRNA compared
with the children with c/pre-B-ALL, but this was not statistically different (P =
0.107; Figure 2.4B). Only 3 cases had a slight down-regulation of the AS mRNA
expression (-1.6-, -1.2-, and -1.05-fold). These 3 cases were all patients with T-
ALL, of whom 2 were clinically good responders.
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Figure 2.2 Asparagine synthetase (AS) mRNA expression induced by pegylated L-
Asparaginase (PEG-Asp) in time
Time-response curves of AS mRNA expression in leukemic cells of 31 children after one single
dose of PEG-Asp (1000 IU/m2 given intravenously at day -5).
* 3-fold increase in AS mRNA from day-5 to day-4 (P < 0.001).
The baseline and PEG-Asp induced expression levels of AS mRNA did not differ
between hyperdiploid (n = 9), TEL-AML1 positive (n = 5) and other B-lineage ALL
(n = 5). For infants with MLL gene-rearranged ALL, no data were available for the
effect of L-Asp on AS mRNA levels, because these patients were not eligible for the
PEG-Asp window study.
DISCUSSION
Studies on putative causes of L-Asp resistance have been performed most
extensively in mouse cell lines.5,6 L-Asp sensitive tumor cells that did not contain
detectable levels of AS developed resistance to L-Asp through exposure of cells to
sublethal concentrations of this drug.19 Resistant cells up-regulated AS expression
and activity by 60-fold. It is well known that AS plays a crucial role in maintaining
amino acid homeostasis in cells.20 A rapid transcriptional control of the AS gene
occurs following deprivation of any single essential amino acid.6,21 In 1997, Hutson
et al.6 demonstrated that depletion of the intracellular asparagine pool by L-Asp
was sufficient to activate in vitro AS expression in human leukemic cell lines. The
increase in AS mRNA expression also resulted in a simultaneous up-regulation of
AS protein levels and AS enzyme activity.6,7 The direct correlation among mRNA,
protein, and activity levels was confirmed by Irino et al.22 The activity of AS was
inversely related to the sensitivity to L-Asp in human leukemia cell lines.6,23 These
studies suggest that the expression of the AS gene is linked to resistance to L-Asp.
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Figure 2.3 Relationship between clinical response and asparagine synthetase (AS)
mRNA expression
(A) Baseline AS mRNA expression levels. (B) PEG-Asp-induced changes in AS mRNA expression
levels measured after 24 hours of in vivo exposure to PEG-Asp compared to baseline expression
levels. Dots represent individual expression values; solid lines, represent the median expression
value per group. For definition of clinical response: see Figure 2.1.
In addition to the fact that these studies dealt not with primary patient samples
but with cell lines, Wagner and Boos24 argued that the test conditions in Hutson's
experiments were not comparable with in vivo situations, where various products
and substrates (such as aspartate, glutamate, glutamine, and ammonia, among
others) are all part of metabolic pathways and equilibrium conditions.5
In 1969 Haskell et al. studied in vivo AS activity in 18 patients with leukemia.3
Prior to therapy, AS activity was nearly undetectable in leukemic cells. Patients
were treated with 200 IU/kg E coli L-Asp daily for 3 days to 3 weeks. A 7-fold
increase in AS activity was found in 5 L-Asp-resistant compared to 4 L-Asp
sensitive patients (mixed cohort of ALL, acute myeloid leukemia [AML], chronic
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myelogenous leukemia [CML], and chronic lymphocytic leukemia [CLL]). Haskell et
al.3 suggested that L-Asp resistance was related to the capacity of leukemic cells to
up-regulate AS expression for asparagine biosynthesis. However, besides the
limited number of patients in a very heterogeneous group, the criteria used to
determine whether the patient was resistant or sensitive to L-Asp were not
described by Haskell.
In order to study the effect of monotherapy with L-Asp on leukemic blasts we
used PEG-Asp. The effectivity of different L-Asp products like Erwinase, E coli, or
PEG-Asp is the same if the serum enzyme activity of L-Asp is higher than 100
IU/L.13 We studied whether baseline levels or up-regulated levels of AS mRNA
expression in leukemic cells after an in vivo treatment with PEG-Asp monotherapy
were associated with short-term clinical response to this drug in children with ALL.
The baseline AS expression levels were in the same range as healthy controls, as
reported before.9 Up-regulation of AS mRNA occurred already within 24 hours after
PEG-Asp exposure and thereafter no further changes were found. Because the
drop in leukemic cells was seen during the whole window period (Figures 2.1 and
2.2), it is unlikely that only leukemic cells resistant to PEG-Asp with intrinsic higher
AS expression levels were left over on day -4. Baseline and L-Asp induced AS
mRNA expression levels did not differ between patients with good, intermediate, or
poor response (Figure 2.3). So, L-Asp-induced up-regulation of AS mRNA is not
related to early in vivo blast reduction in childhood ALL and thus not predictive for
the short-term clinical response to L-Asp. As mentioned earlier, cell line studies
showed that mRNA, protein, and activity levels of AS are correlated,6,7,23 but at
present it is unknown whether this is also the case for clinical samples because
only limited amounts of patients' samples can be obtained.
Immunophenotypic and genetic abnormalities are related to drug resistance
and outcome in childhood ALL.25-27 T-ALL cells from children are, in vitro, more
resistant to L-Asp than cells from children with precursor B-lineage ALL.28 The
relative resistance to L-Asp of T-ALL cases can not be explained by altered
expression of the AS gene, since both baseline and L-Asp induced changes in AS
mRNA expression did not differ between T- and c/pre-B-ALL patients (Figure 2.4).
Remarkable was the finding that 3 out of 12 children with T-ALL even
demonstrated a slight AS mRNA down-regulation, which would, in vitro, even point
to sensitivity for L-Asp. Hyperdiploidy and the TEL-AML1 fusion are related to
favorable outcome in childhood ALL,26,29 and are both in vitro sensitive to L-
Asp.9,30,31 In a previous study in TEL-AML1 positive ALL, Stams et al.9 showed that
TEL-AML1 positive children expressed 5-fold more AS mRNA compared to TEL-
AML1 negative patients and healthy controls. In the present study, TEL-AML1 and
hyperdiploid cases do not show an impaired in vivo up-regulation of AS that might
have explained their high sensitivity to L-Asp. Taken together, both studies
suggest that sensitivity to L-Asp as found in TEL-AML1 positive and hyperdiploid
cells is not linked to decreased AS mRNA expression.
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Figure 2.4 Relationship between immunophenotype and asparagine synthetase (AS)
mRNA expression
(A) Baseline AS mRNA expression levels. (B) PEG-Asp induced changes in AS expression levels in
ALL cells. Dots represent individual expression values; solid lines, represent the median
expression value per group.
AS mRNA up-regulation in ALL cells occurs very rapidly (< 24 hours) after
cellular asparagine depletion following PEG-Asp administration. Amino acids are
required for protein synthesis, but they also play a role in the control of gene
expression.6,20 The promotor of AS contains a nutrient-sensing response unit
(NSRU) that is responsible for the induction of AS gene transcription upon amino
acid deprivation.32 Iiboshi et al. showed that withdrawal of asparagine and
glutamine by L-Asp resulted in a rapid inactivation of p70 S6 kinase.33 P70 S6
kinase participates in the mammalian target of rapamycin (mTOR) protein
synthesis by controlling translational initiation and elongation factors as well as
protein kinases that affect ribosomal assembly. Recently, gene expression profiling
revealed that L-Asp resistant ALL cells overexpressed several ribosomal protein-
encoding genes as well as initiation factors.34 Using gene expression profiling, Fine
et al. showed that L-Asp resistant cell lines expressed more baseline AS mRNA
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than sensitive leukemic cell lines, whereas no such association was found for
primary pediatric ALL samples.35 This study emphasizes the fact that leukemic cell
lines and primary samples from leukemic patients are different from each other
and cell line data can not be extrapolated to primary patient's cells that easily.
Exposure to L-Asp altered in primary patient's samples the expression of a number
of genes related to protein synthesis (ie, tRNA synthetases and amino acid
transporters). However, no genes discriminative for L-Asp resistance in patient's
samples were found. These data point to a consistent coordinated response to
amino acid starvation, which occurs irrespective of the level of resistance to L-Asp
in patient's cells. Therefore, AS up-regulation may be a consequence of amino acid
deprivation by L-Asp but is not the limiting key-factor explaining resistance to L-
Asp in pediatric ALL.
We conclude that up-regulation of AS mRNA in childhood ALL cells occurs within
24 hours after in vivo exposure to PEG-Asp, but these up-regulated levels are not
associated with an early (poor) response to PEG-Asp in this small group of
children.
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ABSTRACT
L-Asparaginase is an effective drug for treatment of
children with acute lymphoblastic leukemia. The
effectiveness is thought to result from depletion of
asparagine in serum and cells. We investigated the
clinical response in vivo of 1000 IU/m2 PEG-
Asparaginase and its pharmacokinetic,
pharmacodynamic and intracellular effects in
children with newly diagnosed ALL before start of
combination chemotherapy. The in vivo window
response was significantly related to
immunophenotype and genotype: 26/38
common/pre B–ALL cases, especially those with
hyperdiploidy and TEL-AML1 rearrangement,
demonstrated a good clinical response compared to
8/17 T-ALL (P = 0.01) and BCR-ABL positive ALL
(P = 0.04). A poor in vivo clinical window response
was related to in vitro resistance to L-Asparaginase
(P = 0.02) and both were prognostic factors for
long-term event-free survival (Hazard ratio 6.4;
P = 0.004 and Hazard ratio 3.7; P = 0.01). After
administration of one in vivo dose of PEG-
Asparaginase no changes in apoptotic parameters
or in intracellular levels of twenty amino acids in
leukemic cells could be measured, in contradiction
to the changes found after in vitro exposure. This
may be explained by the rapid removal of apoptotic
cells from the circulation in vivo. One additional
dose of PEG-Asparaginase upfront ALL treatment
did not lead to other severe toxicities.
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INTRODUCTION
L-Asparaginase is an effective drug to treat newly diagnosed acute lymphoblastic
leukemia (ALL).1 Prolonged L-Asparaginase intensification significantly improved
the outcome of ALL patients as was demonstrated in the Dana-Farber Cancer
Institute ALL Consortium Protocol 91-01.2 Several studies have shown that in vitro
resistance to this drug is an independent prognostic factor in ALL.3-8 Also a poor
early in vivo response to L-Asparaginase as a single drug has been linked to an
unfavourable outcome in pediatric ALL.9
The administration of L-Asparaginase results in the deamination of asparagine
into aspartic acid leading to a rapid and complete depletion of serum asparagine,
which ultimately affects the intracellular asparagine levels.10,11 L-Asparaginase also
has 3 - 4% glutaminase activity leading to serum glutamine depletion.12
L-Asparaginase enzymatic activity should be > 100 IU/L in order to sufficiently
diminish the asparagine serum levels required to induce leukemic cell kill.13 Amino
acid deficiency impairs protein synthesis and leads to apoptosis and cell death.14
In vitro studies demonstrated that cellular deprivation of asparagine and
glutamine leads to increased levels of asparagine synthetase.15 This enzyme
opposes the action of L-Asparaginase and, thereby can rescue cells from the effect
of L-Asparaginase.16 Human leukemia cell line studies suggested that only
L-Asparaginase resistant cells upregulate the activity of asparagine synthetase.15
However, we recently demonstrated that up-regulation of asparagine synthetase
mRNA occurs in both sensitive and in resistant cases within 24 hours of in vivo
exposure to L-Asparaginase.17 These data imply that mechanisms other than
increased expression levels of asparagine synthetase contribute to cellular
L-Asparaginase resistance.
Recently, gene expression profiling studies by microarray analysis revealed that
leukemic cells of L-Asparaginase resistant ALL patients express higher levels of
genes involved in protein synthesis than L-Asparaginase sensitive cells.18 A
deficiency in amino acids finally induces apoptosis in malignant cells.
L-Asparaginase activates caspase 3 and inactivates poly-ADP-ribose-polymerase
(PARP) in patients leukemic cells and resistance to L-Asparaginase is linked to an
impaired capacity of cells to trigger the apoptotic pathway.19 Hypothetically, an
altered intracellular amino acid composition might rescue cells from the effects of
L-Asparaginase. It is yet unknown whether the amino acid metabolism of
L-Asparaginase differs between resistant and sensitive leukemic cells of patients.
In the present study we investigated pharmacokinetic and pharmacodynamic as
well as intracellular effects of one in vivo dose of pegylated-L-Asparaginase
(PEG-Asparaginase) in children with newly diagnosed ALL. In vivo response to
PEG-Asparaginase was monitored by analyzing the decrease in leukemic cells
during a therapeutic window of 5 days before start of combination chemotherapy.
In vivo response to PEG-Asparaginase was compared with the baseline as well as
PEG-Asparaginase-induced changes in serum and intracellular amino acid levels
and with parameters of apoptosis. In vitro resistance to L-Asparaginase was
determined and compared to the mentioned factors that might influence drug
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resistance. In addition, the influence of PEG-Asparaginase given upfront regular
antileukemic treament was evaluated on the incidence of allergic reactions during
treatment and changes in hemostasis.
METHODS
Patients and treatment
In close collaboration between our institution and the Dutch Childhood Oncology
Group (DCOG), a window study with PEG-Asparaginase upfront to the ALL-9
treatment schedule was initiated in July 2000. The ALL-9 protocol was based on the
ALL-6 treatment strategy of the DCOG.20 Non-high risk ALL was defined as white
blood count (WBC) < 50 x 109 /L, no mediastinal mass, absence of t(9;22), t(4;11)
or other MLL rearrangements, no T-cell phenotype and no central nervous system
(CNS) or testicular involvement. All other leukemias were defined as high risk.
Eligible for the window study with PEG-Asparaginase were children with newly
diagnosed ALL and presenting WBC > 10 x 109 /L. Patients received a single dose
of 1000 IU/m2 PEG-Asparaginase in an one hour infusion 5 days before starting
combination chemotherapy. PEG-Asparaginase (Oncaspar), kindly provided by
Medac (GmbH, Hamburg, Germany), was used because of its lower
immunogenicity than native (unpegylated) L-Asparaginase,21 which was important
since native E. coli L-Asparaginase was used as part of the regular combination
chemotherapy given after the investigational window.
The window study with PEG-Asparaginase was approved by the local ethical
committee and by the institutional research board of the DCOG. The patient and/or
the parents/guardians gave informed consent for this study.
The immunophenotyping and cytogenetic characterizations were performed at
the central reference laboratory of the DCOG and at laboratories of the participating
centers. B-lineage ALL (CD19+, HLA-DR+) was classified into the following
differentiation stages: proB-ALL cells were CD10-, cytoplasmic μ chain – (cμ-) and
surface immunoglobulin– (sIg-); c-ALL cells were CD10+/cμ-/sIg-; pre-B cells were
CD10+or-/cμ+/sIg-. B-ALL cells characterized by CD10-/cμ-/sIg+ were excluded from
the study. Cytogenetic analyses were done by regular karyotyping and FISH.22
Patient samples
Bone marrow and peripheral blood samples were obtained at initial diagnosis of
ALL before the administration of PEG-Asparaginase. Serum and leukemic cells from
peripheral blood were collected one hour after the end of the infusion with PEG-
Asparaginase and thereafter daily during 5 consecutive days till the start of
combination chemotherapy at day 0. Mononuclear cells were isolated by density
gradient centrifugation using Lymphoprep (density 1.077 g/ml; Lucron
bioproducts, Gennep, The Netherlands) as described before.17 Contaminating non-
leukemic cells were removed by immunomagnetic beads as described earlier.23 All
samples contained over 90% of leukemic cells, as determined morphologically on
May-Grünwald-Giemsa (Merck, Darmstadt, Germany) stained cytospins.
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Clinical response
In correspondence with the definition of the window response to prednisone in
ALL24 the clinical window response to PEG-Asparaginase on day 0 (5 days after the
PEG-Asparaginase infusion) was defined as good when the number of leukemic
cells was < 1 x 109 /L of peripheral blood, as intermediate when leukemic cells
were 1 - 10 x 109 /L, and as poor when leukemic cells were > 10 x 109 /L.
In vitro cytotoxicity
In vitro L-Asparaginase cytotoxicity in leukemic cells taken at initial diagnosis
(untreated) was determined using the MTT assay. Cells were exposed to six
different concentrations of L-Asparaginase (Paronal, Christiaens B.V., Breda, The
Netherlands) ranging from 0.0032 - 10 IU/ml in duplicate. Control cells were
cultured without L-Asparaginase. After four days of incubation at 37 °C in
humidified air containing 5% CO2, the MTT-assay was performed. Drug sensitivity
was assessed by the LC50, the drug concentration lethal to 50% of the cells.
Evaluable assay results were obtained when a minimum of 70% of leukemic cells
was present in the control wells after 4 days of incubation and when the control
OD was  0.050.8
In vitro sensitivity towards L-Asparaginase was defined as LC50  0.033 IU/ml,
in vitro resistance towards L-Asparaginase was defined as LC50  0.912 IU/ml, and
intermediate sensitive was defined as LC50 0.033 - 0.912 IU/ml.8
Since LC50 values were highly correlated between Paronal and L-Asparaginase
Medac (Rs 0.93, P < 0.002) and between Paronal and PEG-Asparaginase
(Oncaspar) (Rs 0.86, P < 0.002) all consecutive MTT-assays were performed
using Paronal.3,8
Apoptotic features
Determination of Annexin V, DIOC6, cleaved-caspase-3 and cleaved-PARP were
done by FACS analysis as described earlier.19
For ex vivo exposure to L-Asparaginase, cells were incubated with culture
medium as control or incubated with 10 IU/ml of L-Asparaginase (Paronal) in
culture medium. 5 x 106 cells were harvested after 18, 24, 30 and 44 hours of
incubation with L-Asparaginase and apoptotic markers were analyzed.
L-Asparaginase activity and amino acid levels in serum
Serum levels of L-Asparaginase and asparagine, glutamine, aspartic acid and
glutamic acid were determined in the laboratory of Prof Dr J. Boos (University
Children's Hospital Muenster, Department of Pediatric Hematology/Oncology,
Germany). Blood samples were taken daily from day -5 to day 0, and twice a week
from day 0 to 28. L-Asparaginase activity was analyzed as described before;25
serum levels of asparagine, aspartic acid, glutamine and glutamic acid were done
using HPLC.26 The lower limit of detection was 0.2 µM for all amino acids;
glutamine levels higher than 250 µM were not further analyzed and reported as
> 250 µM. The serum levels of asparagine and the L-Asparaginase activity in a
part of the patients included in the present study have been published before.27
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Intracellular amino acid levels
Intracellular levels of all essential and non-essential amino acids were measured
by liquid column chromatography on a Biochrome 20 amino acid analyzer with
ninhydrin detection (Biochrome, Cambridge). Blood samples were taken daily from
day -5 at diagnosis to day 0. At each time-point 5 x 106 leukemic cells were lysed
in 100 l of lysis buffer (150 ml NaCl, 30 mM Tris (pH 7.6), 10% glycerol, 1%
Triton X-100, 1 mM PMSF, 2 μg/ml aprotinin, 2 μg/ml leupeptine) for 15 minutes
on ice. Cleared supernatants were stored at -80 0C until the time of analysis. The
intracellular amounts of amino acids were expressed as mol of amino acid per mg
of protein. The lower limit of detection was 7 mol (coefficient of variation 10%).
Intracellular protein content was measured using the bicinchoninic acid (BCA)
assay (Interchim Omnilabo28).
For ex vivo exposure to L-Asparaginase, cells were incubated with culture
medium as control or incubated with 0.1 IU/ml or 10 IU/ml of L-Asparaginase
(Paronal) in culture medium. 5 x 106 cells were harvested after 1, 3, 6, 24, and
30 hours, and if possible after 48 and 72 hours of incubation with L-Asparaginase
and amino acid levels were analyzed.
Clinical toxicity
Clinical manifestations of diabetes mellitus, pancreatitis, hyperlipidemia,
neurotoxicity and stroke were monitored. Changes in coagulation and fibrinolysis
were monitored throughout induction therapy. On day -5, day 0 and during
induction on days 29, 33, 36, 40 and 43 peripheral blood samples were collected
from the infusion line just before each Paronal® infusion. All coagulation assays
were done with commercially available reagents and methods as described in
detail previously.29 Reference values were applied from the literature.30-32
Statistics
Differences between multiple groups were calculated using the Kruskal-Wallis test.
The Mann-Whitney U test was used when 2 groups were compared. P = 0.05 (two
sided) was used as level of significance.
Median follow-up time of patients at risk of an event was 4.1 years (range 1.9
to 5.5 years). Event-free survival defined as relapse-free survival was calculated
according to Kaplan Meier (± SE). Multiple regression was conducted using Cox
proportional hazards regression models to assess prognostic factors for event-free
survival.
RESULTS
Patients
Between July 2000 and July 2004, 57 children with newly diagnosed ALL were
enrolled in the PEG-Asparaginase-window study (Table 3.1). Since only patients
with initial WBC > 10 x 109 /L were eligible for this study, more than half of these
children were high-risk patients according to ALL-9 criteria.
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Table 3.1 Patient characteristics of PEG-Asparaginase window study
Clinical response
Administration of PEG-Asparaginase at day -5 resulted in a steadily drop in the
number of leukemic cells in the peripheral blood over 5 consecutive days. The
median leukemic cell count was reduced 192-fold from 34.5 x 109 /L at day -5 to
0.18 x 109 /L at day 0 (Figure 3.1). 35 (61%) out of 57 children were defined as
good responders to PEG-Asparaginase, 16 (28 %) were intermediate responders
and 6 (11 %) children were poor responders.
The good prognostic genotypes (hyperdiploid and TEL-AML1 / t(12;21) positive
ALL) were associated with a good clinical window response, whereas the poor
prognostic genotype BCR-ABL / t(9;22) was associated with a poor clinical window
response (P = 0.04) (Table 3.2). The 17 T-ALL patients had a significant poorer
response to PEG-Asparaginase compared to the 36 common/pre B cases (P =
0.01).
Table 3.2 Correlation between clinical response to one dose of PEG-Asparaginase and
immunophenotype and genotype in 57 children with newly diagnosed ALL
Clinical response of 57 children with ALL to one dose of PEG-Asparaginase upfront ALL-induction
treatment (day –5), related to immunophenotype and genotype. The clinical response to PEG-
Asparaginase on day 0 was defined as good when the number of leukemic cells had declined to
< 1 x 109/L of peripheral blood, as intermediate when leukemic cells were 1 - 10 x 109/L, and as
poor when leukemic cells were > 10 x 109/L.
Patients included 57
Male/female 36/21
Age (years) median (range) 4.9 (1.4 - 15.1)
WBC (109/L) median (range) 44.4 (11.3 - 417)
Non high risk/high risk 27/30
Immunophenotype (57):
pro B ALL 2
common/pre B ALL 38
T ALL 17
Genotype of precursor B ALL (40):
Hyperdiploid (> 50 chromosomes) 11
TEL-AML1/t(12;21) 8
BCRABL/t(9;22) 2
MLL rearranged (11q23 ) 0
Normal (46 XX/XY) 8
others 11
Pro B Common/pre B T total
MLL
germline
MLL
rearranged
TEL-AML1 hyperdiploid other BCRABL -
Good responder 1 7 7 12 8 35
Intermediate
responder
1 1 3 4 7 16
Poor responder 2 2 2 6
Total 2 0 8 10 18 2 17 57
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Figure 3.1 Clinical response to one dose of 1000 IU/m2 PEG-Asp
PEG-Asp was administered intravenously at day -5, i.e. 5 days upfront regular chemotherapy. A
good clinical response to PEG-Asparaginase was defined as < 1 x 109/L leukemic cells in the
peripheral blood at day 0, an intermediate response was defined as 1 - 10 x 109/L, and a poor
response as > 10 x 109/L leukemic cells in the peripheral blood at day 0. The data of individual
patients are given in gray, medians with ranges (25th and 75th percentiles) are drawn in black.
In vitro cytotoxicity of L-Asparaginase was measured in 41 leukemic cell samples.
Children with a poor or intermediate in vivo response to PEG-Asparaginase
treatment had a median LC50 value of 1.0 IU/ml compared to 0.04 IU/ml for
children with a good clinical response. So poor and intermediate responders were
in vitro 25 fold more resistant to L-Asparaginase (P = 0.02) than children with a
good in vivo response (Figure 3.2). In concordance with earlier studies,33 T-ALL
cells were significantly more in vitro resistant to L-Asparaginase than precursor B-
ALL cells (LC50 median 1.22 IU/ml versus 0.10 IU/ml; P < 0.001). Only one 8-
year old girl with T-ALL and an initial WBC of 132 x 109 /L had a poor clinical
response (WBC 25 x 109 /L at day 0, absolute leukemic cell count 19.3 x 109 /L),
whereas her blasts were in vitro sensitive to L-Asparaginase. She still is in
continuous complete remission.
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Figure 3.2 Comparison between in vivo and in vitro response to L-Asparaginase:
in 41 children in vitro cytotoxicity of L-Asparaginase (LC50 in IU/ml) was measured and related
to the in vivo response to 1000 IU/m2 PEG-Asparaginase given upfront regular chemotherapy.
Good responders (leukemic cells at day 0 < 1 x 109/L) were significantly more sensitive to L-
Asparaginase than intermediate responders (leukemic cells 1 - 10 x 109/L at day 0) (P = 0.03)
and intermediate and poor responders together (leukemic cells > 1 x 109/L at day 0) (P = 0.02).
The sensitivity to L-Asparaginase did not differ between the intermediate and poor responders.
Apoptosis
Analysis of in vivo induced apoptosis by PEG-Asparaginase
We analyzed 25 patients for different apoptotic parameters in time (Figure 3.3). At
diagnosis samples from 13 patients were available, immediately after the PEG-
Asparaginase infusion samples from 21 patients, and on the consecutive days from
10 - 24 patients. The median percentage of ALL cells showing PS externalisation
was 10.5 % before starting treatment (day -5). These values did not significantly
differ in time (Figure 3.3A). The median percent of cells with changes in
mitochondrial transmembrane potential was small at all time-points: before PEG-
Asparaginase exposure 5.4% cells were DIOC6 positive, this did not change in
time (P = NS) (Figure 3.3B). The median percentage of cells with cleaved (and
hence activated) caspase 3 at diagnosis was 2.7% and remained low (P = NS)
(Figure 3.3C). The median percent of cells with PARP inactivation at diagnosis was
2.9% and remained low (P = NS) (Figure 3.3D).
These data show that the drop in white blood cell count and number of
leukemic cells (Figure 3.1) seen after PEG-Asparaginase administration was not
simultaneously associated with an increase in in vivo apoptotic markers. None of
the apoptotic markers was linked to immunophenotype or genotype.
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Figure 3.3A-D In vivo induced apoptosis registered before and during a five day period
after the administration of 1000 IU/m2 PEG-Asparaginase upfront regular chemotherapy. Percent
of cells with PS externalisation (Figure 3.3A), with m depolarisation (Figure 3.3B), caspase 3
activation (Figure 3.3C) and PARP inactivation (Figure 3.3D) are shown.
Analysis of in vitro induced apoptosis by L-Asparaginase
In contrast to data obtained after in vivo exposure, significant changes in apoptotic
parameters were detected after in vitro exposure to L-Asparaginase (Figure 3.3E).
This is in correspondance with earlier studies showing that activation of these
apoptotic markers can be measured after in vitro exposure to L-Asparaginase.19
L-Asparaginase activity and levels of amino acids in serum
The median serum level of asparagine before treatment was 38.7 µM (p25th - 75th:
28.1 - 44.9 µM). In all patients serum asparagine levels decreased below the limit
of detection of 0.2 µM after the administration of PEG-Asparaginase (P < 0.001)
(Figure 3.4A and 3.4B). With the exception of two patients these asparagine levels
remained below 0.2 µM until day 21, so for a total of at least 26 days. The
L-Asparaginase activity in the serum was > 100 IU/L for a total of at least 15 days
(Figure 3.4A). The level of serum aspartic acid (Figure 3.4B) increased after 1 hour
of PEG-Asparaginase infusion from 7.1 µM (p25th - 75th: 4.1 -14.3 µM) to 22.1 µM
(p25th - 75th: 15.5 - 47.3 µM) (P < 0.001), followed by a decrease to median 11.7
(p25th - 75th: 7.3 - 21.3 µM) and 15.5 µM (p25th - 75th: 9.6 - 23.5 µM) at day -3
and day 0. Compared to the level measured at 1 hour after the PEG-Asparaginase
A B
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infusion the serum aspartic acid levels were still increased at both time points (P =
0.02 at day -3 and P = 0.05 at day 0).
Most glutamine levels stayed beyond the upper limit of detection (> 250 µM)
after PEG-Asparaginase treatment (Figure 3.4B). However, glutamic acid levels
significantly increased from median 87.6 µM (p25th - 75th: 57.8 - 124 µM) before
treatment to 310 µM (p25th - 75th: 178 - 396 µM) one hour after therapy (P <
0.001), and to 239 µM (p25th - 75th: 125 - 306 µM) at day -3 (P < 0.001) and 159
µM (p25th - 75th: 127 - 300 µM) at day 0 (P < 0.001) (Figure 3.4B).
The serum peak levels of PEG-Asparaginase did not differ between clinical
response groups. No correlation with age was observed.
Intracellular amino acids levels
In vivo PEG-Asparaginase exposure
Intracellular levels of 20 different amino acids were measured in leukemic cells of
19 children with newly diagnosed ALL and in peripheral blood cells of 9 healthy
control children without bone marrow disease. The protein concentration of ALL
cells was median 176 µg/ml (25th - 75th percentile: 146 - 226 µg/ml) (n = 9),
which significantly differed from the protein content of mononuclear peripheral
blood cells of normal controls (447 µg/ml; 25th - 75th percentile: 347 - 568 µg/ml)
(P < 0.0001). The amino acid levels were therefore expressed as mol per mg of
cellular protein.
The intracellular levels for 16 out of 20 amino acids did not differ between the
ALL cells at diagnosis and normal controls (Table 3.3). Aspartic acid (P < 0.05),
glutamic acid (P < 0.05) and cystathionine (P < 0.01) were 2-fold higher in ALL
compared to normal controls, whereas taurine levels were 5.4-fold lower in
leukemic cells (P < 0.001). PEG-Asparaginase did not affect the intracellular amino
acid levels in time (Table 3.3), as is shown also in Figure 3.5A for asparagine,
aspartic acid, glutamine and glutamic acid.
Figure 3.3E In vitro induced apoptosis after exposure to 10 IU/ml L-Asparaginase over
time for 2 patients.
E
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Figure 3.4A PEG-Asparaginase activity and asparagine levels
The effect of 1000 IU/m2 PEG-Asparaginase administered i.v. 5 days upfront regular
chemotherapy on serum asparagine levels in time. The levels of PEG-Asparaginase (left Y-axis in
IU/L) are given in black, the levels of asparagine (right Y-axis in M) in gray; the lower dotted
line is the detection limit of asparagine, the upper dotted line is the reference L-Asparaginase
activity level of 100 IU/L.
The intracellular amino acid levels at diagnosis and the in vivo response to PEG-
Asparaginase did not correlate (Figure 3.6, Table 3.4). Results were borderline
significant for leucine, but not significant if adjusted for multiple testing. One
remarkable difference demonstrated valine, which was 2 times higher in non-
responding patients.
Since amino acid levels did not change in time, the relation between clinical
response and amino acid levels in time was not further evaluated.
In correspondence with the in vivo data, the levels of intracellular amino acids
did not significantly differ between in vitro L-Asparaginase resistant and sensitive
patients (Table 3.4).
In vitro L-Asparaginase exposure
In contrast to the lack of in vivo intracellular depletion of asparagine and
glutamine (Figure 3.5A), significant intracellular depletion was detected after in
vitro exposure to L-Asparaginase. Leukemic blasts of 6 patients were in vitro
exposed to 0.1 IU/ml L-Asparaginase, 10 IU/ml L-Asparaginase and to culture
medium only as control, and analyzed before exposure and during 72 hours after
exposure. Significant intracellular asparagine depletion was observed with 0.1
IU/ml (data not shown) and 10 IU/ml of L-Asparaginase at all time points tested (P
< 0.05) (Figure 3.5B). Only after exposure to 10 IU/ml of L-Asparaginase,
intracellular glutamine levels declined significantly within 3 hours (P < 0.001),
whereas no significant rise in glutamic acid could be observed (Figure 3.5B).
A
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Figure 3.4B Effect of PEG-Asparaginase on serum amino acid levels
Asparagine, aspartic acid, glutamine and glutamic acid were measured in 24 children with newly
diagnosed ALL before and after in vivo administration of one dose of 1000 IU/m2 PEG-
Asparaginase. Significant changes between the levels at diagnosis and 1 hour after the
administration of PEG-Asparaginase are indicated by P < 0.001.
Clinical toxicity
No clinical toxicity related to PEG-Asparaginase was seen during the window
phase. At day 29 of the induction phase in which patients received twice-weekly
Paronal, one patient out of 57 patients experienced a period of diabetes mellitus.
Another child was diagnosed with transient hyperlipidemia. No clinical signs of
pancreatitis, severe neurotoxicity or thrombotic events were observed.
Allergic reactions
Four infusions with Paronal were planned during induction on day 29, 33, 36 and
40, and only the 30 high-risk patients were scheduled to receive 9 additional
Paronal infusions during intensification after 3 months.
No child demonstrated an allergic reaction to the first Paronal infusion on day
28. One out of 57 children had a grade 3 allergic reaction on the second infusion.
Treatment was switched to Oncaspar and could not completely be finished. So
56/57 patients received the total of four Paronal gifts during induction.
B
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Figure 3.5A 4 intracellular amino acid levels in time in vivo
In vivo effect of one dose of 1000 IU/m2 PEG-Asparaginase on serum amino acid levels of
asparagine, aspartic acid, glutamine and glutamic acid measured in leukemic cells of 19 children
with ALL compared to the levels found in peripheral blood cells of 9 healthy control cases. Data
are given as mol/mg of intracellular protein.
One of 30 high-risk patients relapsed within two months after diagnosis and
changed protocol before the intensification phase. 15 of the remaining 29 (52%)
children demonstrated an allergic reaction. 9 of these 15 could complete the
intensification therapy by switching to Erwinase or to Oncaspar. The allergy rate of
52% was not higher than the 81% allergy rate in a group of 16 high-risk patients
treated with the same ALL-9-HR protocol but without the upfront PEG-Asp window.
Changes in hemostasis (Table 3.5)
At diagnosis data point to enhanced thrombin generation. Consumption
coagulopathy was monitored in 17 patients. On day 0, five days after the
administration of 1000 IU/m2 PEG-Asparaginase many coagulation proteins
demonstrated a significant decrease. The decrease in coagulation factors on day 0
was not related to the clinical response to PEG- Asparaginase. The changes in
coagulation parameters before Paronal administration at day 29 and at the end of
induction on day 43 (after 4 doses of Paronal), demonstrated the same pattern as
for patients who did not receive PEG-Asparaginase window treatment, as published
recently.34
A
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Figure 3.5B 4 intracellular amino acid levels in time in vitro
The effect of in vitro exposure to L-Asparaginase on intracellular amino acid levels of asparagine,
aspartic acid, glutamine and glutamic acid of leukemic cells of 6 patients that were in vitro
exposed to 10 IU/ml L-Asparaginase. Asparagine levels (P < 0.05) and glutamine levels (P <
0.001) decreased significantly before and after incubation with L-Asparaginase.
Outcome and prognostic factors
Survival analysis of in vivo response to PEG-Asparaginase showed that clinically
good window responders had a more favourable outcome than clinically poor
window responders (3-year EFS  SE: 91  6% for good, 81  10% for
intermediate and 33  19% for poor responders (median follow-up 4.1 years,
Figure 3.7A). The Hazard ratio for the good and intermediate responders compared
to the poor responders was 6.4 (95% CI 1.81 - 22.86) (Table 3.6). The prognosis
of good and intermediate responders was significantly higher than for the poor
responder group (P = 0.004, univariate analysis). The P-value of the trend analysis
for all three groups was 0.014.
Patients who were in vitro sensitive or intermediate sensitive to L-Asparaginase
had a 3-year EFS of 93  7% and 100%, which is significantly different from the EFS
of 53  13% for the in vitro resistant patients (Figure 3.7B). The Hazard ratio for the
good and intermediate sensitive patients compared to the resistant patients was 3.7
(95% CI 1.3 - 10.7); (P = 0.014) (Table 3.6). The P-value of the trend analysis for
all three groups was 0.16.
B
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Figure 3.6 4 intracellular amino acids related to clinical response
Intracellular amino acid levels (in mol/mg of intracellular protein) of asparagine, aspartic acid,
glutamine and glutamic acid at diagnosis of 19 children with ALL, related to their clinical
response to one dose of 1000 IU/m2 PEG-Asparaginase 5 days later, as defined in Figure 3.1.
Of the other variables including age, sex, WBC, immunophenotype and genotype,
only WBC (> or < 50 x 109 /L) at diagnosis was significantly related to outcome in
the Cox univariate analysis (P = 0.02) (Table 3.6).
In a multivariate analysis, including clinical response, in vitro L-Asparaginase
resistance, age, white blood cell count and immunophenotype, only the clinical
response was an independent risk factor (P = 0.042) (2 trend 6.602, P = 0.0013).
DISCUSSION
In the present study we investigated the effect of a therapeutic window with one
single dose of PEG-Asparaginase before start of combination chemotherapy on
several pharmacodynamic and pharmacokinetic parameters, and on clinical
response in pediatric ALL.
Clinical response
Monotherapy with 1000 IU/m2 caused a gradual decrease of the leukemic cell
burden in most patients within 5 days of treatment (Figure 3.1). Children with
unfavorable characteristics like T-ALL or BCR-ABL / t(9;22)-positive ALL were in
vivo more resistant to PEG-Asparaginase than children with a more favorable
immunophenotype and genotype. This is in concordance with the fact that T-ALL
cells were found to be in vitro more resistant to L-Asparaginase.33 For BCR-ABL /
t(9;22) the in vivo resistance to L-Asparaginase is a new finding. In the present
study we also showed that in vitro resistance to L-Asparaginase is related to the
clinical response to PEG-Asparaginase as single drug.
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Figure 3.7A EFS and clinical response
Relationship between event free survival (EFS) and clinical response to the PEG-Asparaginase
window. The prognosis differed between good and intermediate responders compared to poor
responders (P < 0.01).
Figure 3.7B EFS and in vitro sensitivity
Relationship between event free survival (EFS) and in vitro sensitivity to L-Asparaginase. The
prognosis differed between the sensitive and intermediate sensitive group compared to the
group resistant to L-Asparaginase (P < 0.01).
Parameters of apoptosis
Apoptotic markers at diagnosis did not predict the clinical response. We were not
able to demonstrate a change in the percentage of in vivo apoptotic cells after
administration of PEG-Asparaginase. If however, ALL cells were in vitro exposed to
L-Asparaginase, a significant increase in time of the apoptotic markers was found,
confirming previous findings.19 Together with the fact that there was a rapid
decrease in leukemic cells upon in vivo PEG-Asparaginase exposure, these findings
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indicate that apparently no apoptotic cells remain in the circulation in vivo. Most
likely, these apoptotic cells are rapidly being removed by phagocytosis.35
L-Asparaginase activity in serum and intracellular amino acids
One dose of 1000 IU/m2 PEG-Asparaginase immediately resulted in complete
serum asparagine depletion with a concomitant rise in serum aspartic acid and
glutamic acid. Our data are in correspondence with previous data observed in a
larger group of patients treated with L-Asparaginase and confirm that PEG-
Asparaginase will yield its pharmacodynamic effects for 2 - 4 weeks.36 However, in
vivo no changes were observed in the levels of intracellular amino acids (including
asparagine, aspartic acid, glutamine and glutamic acid) directly after PEG-
Asparaginase administration nor on successive days thereafter, except for valine.
So far, no explanation can be given for the high level of valine in the non-
responding group. In contrast, in vitro exposure to L-Asparaginase of ALL cells
significantly changed the intracellular asparagine and glutamine levels that
reflected the changes observed in serum suggesting that the surviving leukemic
cells are capable of keeping the intracellular amino acid pools in balance, whereas
those cells that are not capable of doing so die and are immediately removed from
the blood circulation. Therefore the in vivo process of intracellular amino acid
depletion in leukemic cells can not be measured which is in correspondence with
the finding that no in vivo effect on apoptosis parameters could be measured.
These data underline the fact that only in vitro studies have been published that
show a relationship between amino acid depletion and apoptosis,37,38 whereas
literature on in vivo measurements is lacking.
Iwamoto et al.39 recently described the protective effect of mesenchymal cells
in L-Asparaginase cytotoxicity. They postulated that the interaction between ALL
cells and the microenvironment in which these cells reside protected the leukemic
cells from asparagine depletion by a high expression of asparagine synthetase in
these mesenchymal cells. Surviving leukemic cells may therefore be rescued with
asparagine produced by mesenchymal cells. There was no correlation between the
upregulation of asparagine synthetase mRNA and the amount of asparagine in the
leukemic cells (data not shown). This might support the hypothesis that
asparagine and perhaps other amino acids are supplied to leukemic cells by the
microenvironment.
Another possible explanation for the discrepancy of cellular asparagine levels in
vivo and in vitro comes from the Italian group of Bussolati.40,41 In vitro
L-Asparaginase rapidly hydrolyzes asparagine and subsequently glutamine if
asparagine is depleted.42 Since the main amino group for in vivo asparagine
synthesis is provided by glutamine, depletion of glutamine impacts endogenous
asparagine synthesis. However, glutamine is abundantly present in vivo, and
hence a donor for the amino group needed for asparagine synthesis is not lacking.
This theory might also explain our finding that asparagine remains detectable in
leukemic blasts after in vivo exposure to PEG-Asparaginase. Not only Boos et al.42
but also Fine et al.43 emphasized the fact that leukemic cell lines and primary
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samples from leukemic patients are different from each other and cell line data
cannot be extrapolated to primary patients' samples that easily.
At diagnosis the intracellular levels of glutamic acid and cystathionine were
higher and taurine levels were lower in leukemic cells compared to normal
peripheral blood mononuclear cells. Proliferating leukemic cells may produce more
glutamic acid due to a fast turnover of glutamine to provide nitrogen and carbon
needed for the synthesis of purines and pyrimidines energy metabolism.44 It is
known that malignant cells are more dependent on an exogenous source of
asparagine and glutamine than normal cells.45
The high levels of cystathionine and low levels of taurine may be linked to each
other. Leukemic cells were shown to have consistently lower taurine levels
compared to normal lymphocytes and granulocytes.46 A low activity of
-cystathionase in leukemic cells might result in an abnormal methionine-cysteine
pathway leading to higher levels of its starting product cystathionine and lower
levels of the end product taurine.
Chakrabarti et al.47 also tried to explain differences in L-Asparaginase
resistance by differences in intracellular amino acid metabolism. They pointed to a
hypothesis of Ryan and Keefer, that depletion of asparagine might result in
decreased glycine and serine concentrations in L-Asparaginase sensitive but not in
resistant tumor cells.48,49 Asparagine is required for the transamination of
glyoxylate resulting in glycine and serine depletion, which could have severe
consequences for purine biosynthesis.47 However, we did not find evidence to
support these hypotheses since we found no difference in the serine or glycine
content between in vivo good and poor responders to L-Asparaginase nor between
in vitro L-Asparaginase sensitive and resistant leukemic cells.
It has also been suggested that L-Asparaginase treatment caused reduced
incorporation of valine into proteins in L-Asparaginase sensitive cells but not in
L-Asparaginase resistant tumor cells.50 In our group valine levels before
L-Asparaginase treatment were 2 times lower in in vivo good/intermediate
responders compared to poor responders. However, no difference in the level of
valine between in vitro L-Asparaginase resistant and sensitive ALL cells were
observed in the present study.
Clinical toxicity, allergic reactions and changes in hemostasis
There was no acute toxicity of one dose of PEG-Asparaginase in this investigational
window. One extra dose of PEG-Asparaginase did not lead to higher incidence of
allergic reactions during induction treatment and also not during intensification
therapy 3 months later. This is of importance since Silverman et al. proved that
L-Asparaginase tolerance is an important prognostic factor in ALL.2
The single dose of PEG-Asparaginase in this study induced a fall in more than
half of the coagulation proteins. We demonstrated that the serum asparagine
depletion due to one PEG-Asparaginase infusion of 1000 IU/m2 lasted about 4
weeks. This did not result in a persistent inhibition of coagulation protein
synthesis. At day 29, so almost 5 weeks after PEG-Asparaginase administration, all
coagulation parameters had recovered to normal or even increased levels. The
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levels of all coagulation parameters were in the same range as investigated
recently in children treated with the same protocol without the PEG-Asparaginase
window.34 Disturbances in hemostasis due to amino acid depletion are probably a
local effect, i.e. in the liver only.51,52
Outcome and prognostic factors
Both the clinical response to PEG-Asparaginase window therapy and the in vitro
sensitivity to L-Asparaginase are predictive for outcome. The prognostic relevance
of the in vitro sensitivity has been shown previously.5-8 In the present study we
also show that the in vivo response to a window with L-Asparaginase predicts
outcome, which is in concordance with the data of Asselin et al.9 These results
suggest that children with ALL with a poor clinical response to PEG-Asparaginase
might benefit from a more intensive antileukemic therapy.
CONCLUSION
The clinical response to one dose of 1000 IU/m2 PEG-Asparaginase intravenously
as an investigational window is an independent prognostic marker related to
outcome. Children with the favorable common/pre B ALL especially those with TEL-
AML1 positivity and hyperdiploidy show a good clinical response to PEG-
Asparaginase and children with the prognostic unfavorable factors T-cell
immunophenotype or BCR-ABL positivity have a relatively poor response to PEG-
Asparaginase. The in vivo response to PEG-Asparaginase correlates well with in
vitro sensitivity to L-Asparaginase. Intracellular changes in apoptotic features and
amino acids in ALL cells can not be monitored in vivo; this may be explained by
the fact that apoptotic cells are immediately removed from the circulation by
phagocytosis. Otherwise it is possible that in vivo mesenchymal cells from the
bone marrow supply leukemic blasts with asparagine in response to treatment with
L-Asparaginase. Intracellular amino acids concentrations at diagnosis are not
related to PEG-Asparaginase response. One additional dose of PEG-Asparaginase
proved to be safe in children with ALL because it did not cause a higher incidence
of allergic reactions to L-Asparaginase further on in treatment and it caused no
severe toxicities.
Table 3.3 The effect of one single dose of PEG-Asp on intracellular amino acid levels in newly diagnosed ALL
ALL patients Normal controls
WINDOW days -5 (before
Asparaginase)
-4 -3 -2 -1 0
Medians in μmol/mg (p25 - p75)
Essential
amino acids
Isoleucine 5.6 (4.0 - 7.7) 6.0 (3.7 - 8.6) 6.1 (3.6 - 6.8) 6.3 (4.6 - 6.9) 6.2 (4.1 - 7.3) 7.0 (3.2 - 7.6) 5.0 (2.2 - 5.5)
Leucine 4.8 (3.0 - 7.9) 3.4 (2.7 - 6.5) 4.5 (3.1 - 5.7) 4.2 (3.5 - 7.3) 5.5 (4.0 - 6.2) 4.6 (2.7 - 7.0) 8.4 (4.4 - 8.8)
Lysine 4.9 (3.7 - 7.3) 4.6 (3.0 - 5.2) 5.0 (3.7 - 5.5) 3.6 (3.2 - 6.0) 5.3 (3.2 - 7.1) 4.5 (3.8 - 5.9) 7.7 (4.2 - 12.0)
Phenylalanine 3.3 (3.0 - 4.7) 3.6 (2.2 - 4.5) 3.8 (3.0 - 4.4) 4.7 (3.2 - 5.8) 3.9 (2.9 - 5.1) 4.6 (2.3 - 4.8) 3.1 (2.0 - 3.7)
Methionine 3.3 (2.9 - 4.5) 2.8 (2.4 - 3.1) 3.4 (3.1 - 4.9) 3.5 (2.9 - 4.2) 3.6 (2.7 - 4.6) 3.8 (2.3 - 4.0) 2.8 (2.3 - 3.1)
Threonine 5.5 (3.8 - 7.4) 5.5 (4.4 - 7.6) 5.6 (3.6 - 7.7) 6.3 (4.8 - 7.9) 6.9 (5.4 - 8.1) 6.1 (3.9 - 8.8) 7.1 (4.8 - 7.9)
Tyrosine 3.1 (2.6 - 4.7) 4.0 (3.2 - 5.9) 3.7 (3.1 - 4.1) 3.5 (2.8 - 4.1) 3.8 (3.2 - 4.6) 3.3 (2.5 - 4.0) 3.0 (2.1 - 3.6)
Valine 4.1 (3.2 - 5.9) 3.2 (2.9 - 4.3) 3.5 (3.0 - 4.1) 4.1 (3.0 - 5.5) 3.5 (3.0 - 4.4) 3.9 (2.7 - 4.4) 5.3 (2.8 - 6.7)
Histidine 3.0 (2.3 - 3.3) 2.7 (2.2 - 3.5) 3.1 (2.7 - 3.4) 3.2 (2.9 - 3.6) 2.9 3.1 (2.3 - 3.2) 2.4 (1.4 - 2.7)
Arginine 9.6 (5.9 - 12.0) 8.1 (5.6 - 9.9) 7.9 (5.7 - 9.9) 7.2 (5.2 - 11.0) 8.7 (7.3 - 9.6) 8.2 (5.8 - 11.0) 6.2 (4.1 - 8.1)
Non-essential
amino acids
Alanine 8.8 (5.8 - 11.7) 8.9 (5.9 - 24.3) 9.2 (5.8 - 12.5) 9.2 (7.4 - 13.4) 9.2 (5.9 - 12.2) 11.3 (6.3 - 12.7) 12.9 (8.1 - 18.0)
Asparagine 4.7 (4.0 - 6.6) 4.4 (3.1 - 5.3) 4.5 (3.5 - 5.6) 4.9 (3.8 - 6.9) 4.6 (4.1 - 4.9) 5.0 (4.5 - 5.8) 2.9 (1.0 - 4.1)
Aspartic acid 28.8 (24.5 - 32.7) 26.6 (22.0 - 36.5) 33.4 (21.1 - 43.2) 31.0 (23.5 - 41.5) 29.9 (23.3 - 38.3) 29.7 (23.1 - 42.4) 15.71 (12.6 - 18.2)
Glutamic acid 67.7 (48.5 - 76.2) 68.5 (51.2 - 81.2) 62.0 (47.1 - 95.7) 65.9 (41.2 - 90.6) 81.1 (48.3 - 105) 73.4 (47.2 - 116) 33.11 (29.8 - 43.4)
Glutamine 9.8 (47.4 - 18.6) 13.6 (5.7 - 23.1) 11.8 (6.3 - 22.5) 14.1 (5.5 - 22.1) 16.2 (9.2 - 24.7) 21.8 (8.5 - 27.7) 11.1 (5.8 - 13.8)
Cysthationine 17.4 (13.8 - 22.6) 21.0 (14.3 - 26.1) 23.2 (17.7 - 30.7) 24.2 (16.7 - 37.6) 29.4 (19.7 - 42.6) 28.2 (12.4 - 41.3) 8.32 (7.0 - 10.9)
Glycine 16.0 (11.4 - 20.7) 18.9 (14.1 - 24.4) 22.6 (16.0 - 29.6) 13.8 (12.5 - 21.1) 22.7 (17.0 - 35.7) 21.2 (16.2 - 31.9) 23.7 (16.8 - 25.4)
Proline 9.0 (6.8 - 16.2) 9.7 (6.8 - 14.1) 11.3 (6.9 - 14.0) 8.5 (6.1 - 14.1) 13.2 (9.0 - 15.6) 13.8 (9.2 - 15.6) 5.0 (1.7 - 7.1)
Serine 9.2 (6.0 - 11.0) 9.2 (4.9 - 11.6) 7.5 (4.3 - 11.6) 6.5 (5.8 - 9.9) 11.1 (9.7 - 13.2) 9.5 (9.1 - 13.2) 10.3 (6.9 - 12.5)
Taurine 18.8 (10.2 - 47.3) 22.2 (17.6 - 65.1) 31.2 (16.0 - 71.8) 32.9 (23.0 - 54.0) 32.8 (18.7 - 49.1) 27.1 (16.5 - 52.3) 1343 (111 - 196)
Levels of 20 intracellular amino acids in mol/mg cellular protein in leukemic blasts of 19 patients with ALL after one dose of PEG-Asparaginase, compared to the
levels in peripheral blood cells of 9 normal controls. Data are given as medians with interquartile ranges. The amino acids that demonstrate significant different
levels compared to normal are given in bold. Superscripts refer to P values: 1 = P ≤ 0.05, 2 = P ≤ 0.01 and 3 = P ≤ 0.001 for the comparison of patient data
with normal controls.
Table 3.4 Intracellular amino acid levels at diagnosis related to in vitro and in vivo sensitivity
In vitro
ASP resistant
In vitro
ASP sensitive
In vivo
poor responders
In vivo
intermediate/
good responders
Medians in μmol/mg (p25 - p75)
Essential
amino acids
Isoleucine 5.4 (3.6 - 7.3) 7.7 (6.3 - 8.6) 7.3 (5.0 - 11.5) 5.4 ( 4 - 7.1)
Leucine 4.9 (4.1 - 6.9) 4.5 (1.9 - 6.3) 8.7 (6.6 - 10.4) 4.1 (2.7 - 5.7)
Lysine 4.9 (3.4 - 7.3) 5.2 (3.8 - 6.1) 7.3 (5.8 - 8.9) 4.5 (3.2 - 6.1)
Phenylalanine 2.4 (1.7 - 4.7) 2.8 (2.0 - 3.4) 4.3 (3.9 - 4.8) 3.1 (2.7 - 4.2)
Methionine 1.5 (0.6 - 4.0) 1.8 (0.8 - 2.9) 4.1 3.0 (2.6 - 4.5)
Threonine 5.5 (4.3 - 7.4) 6.0 (4.8 - 8.3) 7.6 (2.3 - 9.4) 5.2 (3.3 - 6.4)
Tyrosine 2.6 (2.1 - 3.8) 0.9 4.9 3.0 (2.5 - 3.8)
Valine 3.3 (2.9 - 4.6) 4.4 (1.5 - 4.5) 6.45 (5.2 - 7.3) 3.5 (3.0 - 4.7)
Histidine 1.7 (1.0 - 3.0) 1.7 (1.2 - 3.1) 3.25 3.0 (2.3 - 3.3)
Arginine 10.9 (8.8 - 13.6) 10.4 (8.2 - 13.8) 13.1 (7.4 - 18.4) 9.3 (5.9 - 10.9)
Non-essential
amino acids
Alanine 9.6 (6.4 - 11.5 9.9 (7.0 - 14.5) 13.1 (7.8 - 15.6) 7.3 (5.8 - 11.3)
Asparagine 4.5 (4.1 - 7.5) 5.2 (4.1 - 8.7) 4.7 (4.3 - 9.9) 4.5 (3.8 - 6.0)
Aspartic acid 30.1 (28.4 - 33.0) 31.4 (23.4 - 43.9) 28.8 (26.6 - 31.4) 29.6 (20.2 - 36.7)
Glutamic acid 69.3 (53.2 - 81.1) 72.3 (59.3 - 95.1) 72.9 (54.5 - 84.4) 59.1 (41.3 - 73.0)
Glutamine 17.0 (7.5 - 25.0) 19.4 (8.6 - 28.0) 17.1 (11.0 - 28.0) 8.6 (6.3 - 17.8)
Cystathionine 25.0 (12.8 - 29.1) 25.0 (18.6 - 32.6) 24.3 (11.5 - 54.8) 16.3 (13.8 - 20.9)
Glycine 21.3 (12.3 - 27.8) 20.3 (16.1 - 26.1) 17.8 (7.5 - 21.4) 15.0 (10.3 - 22.1)
Proline 7.0 (5.3 - 14.0) 6.4 (5.3 - 10.8) 15.6 (7.5 - 22.5) 8.6 (6.6 - 11.8)
Serine 9.2 (6.0 - 12.6) 9.4 (6.8 - 14.9) 12.9 (9.5 - 16.1) 8.7 (5.5 - 10.7)
Taurine 25.0 (11.3 - 42.4) 17.5 (10.7 - 42.4) 20.5 (11.4 - 40.3) 18.8 (10.2 - 54.1)
Relationship between intracellular levels at diagnosis of 20 amino acids and in vitro sensitivity to L-Asparaginase or in vivo response to one dose of PEG-
Asparaginase. Data are given as medians with interquartile ranges.
Table 3.5 Coagulation parameters of 57 patients before the window with PEG-Asparaginase at day -5, before starting ALL-9 induction
therapy (day 0), and during 4 Paronal infusions
Day -5 Day 0 Day 29 Day 33 Day 36 Day 40 Day 43
Asparaginase PEG-ASP Paronal Paronal Paronal Paronal
Dose 1000 IU/m2 6000 IU/m2 6000 IU/m2 6000 IU/m2 6000 IU/m2
Screening
APTT
30 - 42 sec
32 (27 - 37)
PT
11.7 - 16 sec
13.9 (12.4 - 15.6)
Thrombin time
22 - 26 sec
27 (25.0 - 30.5)
Procoagulants
Fibrinogen
1.6 - 4.3 g/L
2.7 (2.1 - 3.9) 1.73 (1.3 - 1.9) 1.7 (1.4 - 2.2) 1.5 (1.1 - 1.7) 1.3 (1.1 - 1.6) 1.5 (1.2 - 1.8) 1.9 (1.3 - 2.9)
F V 0.87 (0.64 - 1.19) 0.58 (0.46 - 0.76) 1.493 (1.20 - 1.84) 1.76 (1.23 - 1.94) 1.48 (1.26 - 1.76) 1.70 (1.07 - 2.06) 1.47 (1.04 - 1.93)
F II 0.69 (0.43 - 0.91) 0.62 (0.49 - 0.74) 1.193 (1.04 - 1.45) 1.07 (0.92 - 1.40) 1.10 (0.92 - 1.15) 1.03 (0.90 - 1.29) 1.06 (0.83 - 1.22)
F VII 0.66 (0.52 - 0.78) 0.79 (0.69 - 0.95) 1.09 (0.88 - 1.27) 1.42 (1.08 - 1.76) 1.40 (1.14 - 1.77) 1.39 (1.14 - 1.68) 1.29 (0.98 - 1.69)
F IX 1.17 (0.98 - 1.35) 0.423 (0.33 - 0.51) 1.863 (1.54 - 2.27) 0.963 (0.70 - 1.42) 1.02 (0.62 - 1.50) 0.76 (0.61 - 1.15) 0.99 (0.57 - 1.30)
F X 0.95 (0.70 - 1.26) 0.682 (0.53 - 0.75) 1.473 (1.16 - 1.79) 1.30 (0.98 - 1.57) 1.20 (0.95 - 1.33) 1.13 (0.84 - 1.35) 1.17 (0.74 - 1.30)
Anticoagulants
AT 0.75 (0.66 - 0.86) 0.542 (0.48 - 0.65) 1.373 (1.30 - 1.55) 0.922 (0.82 - 1.02) 0.86 (0.69 - 1.08) 0.75 (0.64 - 1.00) 0.87 (0.65 - 1.03)
Prot C 0.71 (0.55 - 0.87) 0.53 (0.45 - 0.64) 2.093 (1.51 - 2.43) 1.25 (1.06 - 1.55) 1.38 (0.95 - 1.67 1.27 (1.00 - 1.41 1.15 (0.97 - 1.61
Prot S 0.72 (0.60 - 0.87) 0.373 (0.33 - 0.54) 1.033 (0.87 - 1.17) 0.633 (0.46 - 0.75) 0.57 (0.42 - 0.71) 0.59 (0.42 - 0.71) 0.60 (0.50 - 0.77)
Thrombin generation
F1+2 pmol/L
69 - 229 pmol/L
576 (259 - 1067) 365 (211 - 588) 2011 (130 - 290) 230 (167 - 293) 267 (178 - 344) 427 (189 - 623) 243 (161 - 362)
TAT g/L
1.5 - 4.1 g/L
13 (7.9 - 48.2) 5.23 (3.5 - 9.1) 5.0 (4.0 - 10.6) 4.9 (3.3 - 7.2) 4.6 (3.5 - 6.4) 5.1 (3.6 - 15.7) 5.5 (3.8 - 7.0)
Fibrinolysis
Alpha-2-antipl 1.08 (1.02 - 1.20) 0.703 (0.62 - 0.86) 1.583 (1.42 - 1.64) 1.073 (0.94 - 1.13) 1.04 (0.83 - 1.19) 0.93 (0.73 - 1.19) 1.02 (0.81 - 1.47)
Plasminogen 1.01 (0.79 - 1.18) 0.563 (0.52 - 0.70) 1.223 (1.10 - 1.34) 0.763 (0.69 - 0.90) 0.74 (0.66 - 0.93) 0.75 (0.60 - 0.92) 0.79 (0.65 - 1.02)
PAP g/L
80 - 450 g/L
641 (456 - 913) 2553 (204 - 355) 292 (194 - 397) 1393 (106 - 182) 157 (100 - 192) 157 (122 - 228) 181 (128 - 269)
D-dimer
0.1 - 0.55 mg/L
0.42 (0.27 - 0.85) 0.35 (0.19 - 0.59) 0.113 (0.07 - 0.19) 0.09 (0.06 - 0.12) 0.11 (0.07 - 0.17) 0.10 (0.06 - 0.17) 0.12 (0.09 - 0.21)
Results of procoagulant and anticoagulant parameters, of parameters of thrombin generation and of fibrinolysis of 57 patients before the window with PEG-
Asparaginase (day –5), before starting ALL-9 induction therapy (day 0), and related to 4 Paronal infusions (days 29 - 43). Data represent percentages or as
indicated otherwise. Normal reference ranges are 80 - 130%, or as indicated in italic. Data are given as medians with interquartile ranges. Superscripts refer to p
values: 1 = P ≤ 0.05, 2 = P ≤ 0.01 and 3 = P ≤ 0.001 related to the previous measurement.
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Table 3.6 Univariate analyses not stratified for treatment arm
P-value Hazard ratio 95% CI
Age1 0.918 0.9 0.2 4.3
Sex 0.214 0.4 0.1 1.8
WBC2 0.022 6.1 1.3 28.7
Immunophenotype3 0.344 1.9 0.5 7.0
Genotype4 0.115 5.3 0.7 41.7
Clinical response to PEG-Asparaginase5 0.004 6.4 1.8 22.9
L-Asparaginase sensitivity (in vitro)6 0.014 3.7 1.3 10.7
Results of univariate Cox proportional hazards regression analyses not stratified for ALL-9
treatment arm (standard risk / high risk). Only WBC, clinical response to the PEG-Asparaginase
window therapy and in vitro sensitivity to L-Asparaginase are significantly related to outcome.
1 < or > 10 years
2 < or > 50 x 109/L
3 T versus precursor B-ALL
4 hyperdiploidy and TEL-AML1 compared to the others
5 good and intermediate clinical responders compared to poor responders to PEG-Asp
6 in vitro sensitive and intermediate sensitive compared to resistant to L-Asparaginase
Pharmacokinetic and pharmacodynamic effects of PEG-Asp
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INTRODUCTION
L-Asparaginase (L-Asp) plays a well-established role in the treatment of children
with acute lymphoblastic leukemia (ALL). L-Asp is postulated to exert its antitumor
activity by hydrolyzing asparagine (Asn) to aspartic acid and ammonia, thereby
depleting the leukemic cells from Asn, leading to impaired protein synthesis and
leukemic cell death. L-Asp may also act by depleting glutamine. Different
preparations and ways of administering L-Asp result in different plasma activities.
The half-life of Erwinia-L-Asp is shorter than that of Escherichia coli L-Asp, which is
in turn shorter than that of the polyethylene glycol (PEG)-conjugated form of L-
Asp.1 PEG-Asp shows less immune response and a prolonged half-life of 5.7 days
compared to 1.3 days for native L-Asp. These variations are related to differences
in the extent of Asn depletion.2
Pharmacokinetics and pharmacodynamics of PEG-Asp are not well characterized
in the cerebrospinal fluid (CSF). The L-Asp activity in the CSF is less than 1% of
the corresponding plasma activity using native E. coli-L-Asp. Yet, L-Asp is believed
to play a role in the prevention of meningeal leukemia probably by depleting the
pool of Asn in the CSF. It is not known whether an incomplete depletion of Asn in
the CSF results in a suboptimal antileukemic effect. In Rhesus monkeys and in a
number of adult patients, Riccardi et al3 demonstrated that, after native E. coli L-
Asp, CSF-Asn levels were depleted to < 0.2 μM. Several groups showed that a
plasma E. coli-L-Asp activity > 100 IU/L leads to an Asn depletion of < 0.2 μM in
the plasma and CSF.2,4 Müller et al5 demonstrated that after one dose of 1000
IU/m2 PEG-Asp intravenously (i.v.) as second-line treatment, the plasma L-Asp
activity was still ≥ 100 IU/L after 14 days in 44/66 patients. Unfortunately, no CSF
levels were measured in their study.
Recently, Avramis et al6 showed that PEG-Asp (1 x 2500 IU/m2) intramuscularly
(i.m.) reached an L-Asp plasma activity > 100 IU/L accompanied by Asn levels < 3
μM during 3 - 14 days in 95% of the patients. CSF-Asn concentrations fell to 0.6
μM at day 28. In the present paper, we report on 24 newly diagnosed children with
ALL treated in our center with a single dose of PEG-Asp (Oncaspar™) 1000 IU/m2
i.v., 5 days before starting induction chemotherapy according to the ALL-9 study of
the Dutch Childhood Leukemia Study Group (DCLSG).
MATERIAL AND METHODS
The bone marrow, blood and CSF were obtained at diagnosis. From day -5 till
day 0, peripheral blood samples were collected daily, and later on twice a week. At
day 0, a second lumbar puncture (LP) was performed at the start of combination
induction therapy (dexamethasone, vincristine, and intrathecal triple therapy
during the first 4 weeks, daunorubicine only in case of initial high-risk criteria). A
third CSF sample was drawn at day 15.
The quantification of L-Asp activity was performed by incubating the samples
with an excess amount of L-aspartic acid β-hydroxamate (AHA) at 37 °C. L-Asp
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hydrolyzed AHA to L-aspartic acid and hydroxylamine, which was detected at 710
nm after condensation with 8-hydroxychinoline and oxidation to indooxine. This
method allowed the quantification of 2.5 IU/L L-Asp in human serum with
coefficients of variation for intra- and interday variability of 1.98 - 8.77% and 1.73
- 11.0%, and an overall recovery of 101 ± 9.92%.7 Asn levels in the plasma and
CSF were measured using the RP-HPLC technique following precolumn derivation
with o-phthaldialdehyde and fluorescence detection according to Lenda and
Svenneby.8 The lower limit of detection (LOD) was 0.2 μM.
RESULTS AND DISCUSSION
All patients reached an L-Asp activity ≥ 100 IU/L for at least 10 days (Figure 4.1).
A peak level of 744 ± 132 IU/L (mean ± SD) was reached 1 h after the PEG-Asp
infusion, declining to 483 ± 101 IU/L (mean ± SD) after 5 days and to 212 ± 66
IU/L (mean ± SD) on day 7, 12 days after the PEG-Asp administration; on day 15
of the treatment schedule, 20 days after the PEG-Asp infusion, L-Asp activity had
declined to 39 ± 28 IU/L (mean ± SD). Avramis showed that the mean peak of
PEG-Asp activity was 1000 IU/L when measured 5 days after a dose of 2500 IU/m2
i.m. was given to children with ALL, declining to about 100 IU/L on day 24.6
We also analyzed all CSF samples for L-Asp activity and detected no activity
above the limit of quantification (2.5 IU/L).
Figure 4.1 Plasma L-Asparaginase activity levels
Sequential analysis of plasma L-Asparaginase activity (IU/L) after 1000 IU/m2 of PEG-Asp i.v.
given 5 days before starting combined induction chemotherapy (CT).
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In all patients, plasma Asn levels declined below the LOD of 0.2 μM (Figure
4.2A). From the point of view of peripheral treatment intensity, the results of Asn
plasma concentrations after 1000 IU/m2 PEG-Asp indicate a treatment intensity
comparable to that observed with native unpegylated L-Asp (10,000 IU/m2).2
Riccardi et al3 showed that Asn depletion in CSF was only achieved after plasma
Asn depletion. However, no complete Asn depletion in the CSF occurred in our
patient group (Figure 4.2B): pretreatment starting levels at day -5 ranged from
3.5 to 7.2 μM (mean 5.1 ± 1.1 μM), decreasing to a mean concentration of 1.58 ±
0.66 μM at day 0 just before starting induction chemotherapy. At day 14 (19 days
after the administration of PEG-Asp), the mean CSF Asn concentration was 2.2 ±
0.67 μM. The Asn concentration never dropped below the LOD (0.2 μM). We also
spiked CSF samples with L-Asp, incubated the samples at 37 °C and analyzed
them for Asn by HPLC. No Asn was detected in the spiked samples; thus, we are
sure that we determined Asn in the CSF samples. CSF-Asn concentrations in the
study of Avramis fell from a median pretreatment level of 2.3 to 1.1 μM on day 7
and 0.6 μM on day 28,6 demonstrating that i.m. PEG-Asp also does not fully
deplete CSF Asn. These Asn levels are still high above the detection limit of 0.01
μM in their study. The study of Avramis differs from our study in terms of the dose
of PEG-Asp (2500 vs 1000 IU/m2), the route of PEG-Asp (i.m. vs i.v.), and
concomitant chemotherapy (prednisone p.o., vincristine i.v., and intrathecal
cytarabine/methotrexate vs none in the first 5 days). The influence of concomitant
antileukemic treatment on the pharmacokinetic and pharmacodynamic effects of L-
Asp is not clear.
It has been suggested that the CSF-Asp activity never exceeds 0.2% of the L-
Asp activity in plasma.3 One explanation for the lack of Asn depletion in CSF may
be that the pegylated form of L-Asp results in CSF-Asp levels that are even less
than 0.2% of the plasma activity. We also analyzed all CSF samples for PEG-Asp
activity and detected no activity above the limit of quantification (2.5 IU/L).
Another explanation could be that the central nervous system is capable of
synthesizing Asn locally despite the depletion of the systemic Asn pool. To
maintain sufficient amino acids in the CSF, a net amino-acid entry from blood to
CSF against a concentration gradient has been demonstrated in sheep.9
So, despite the fact that a dose of 1000 IU/m2 PEG-Asp results in plasma Asn
levels < 0.2 μM, the human body is still capable of maintaining the CSF Asn levels.
Although PEG-Asp may have the advantage of fewer injections, this might be
counterbalanced by less effective killing of blasts in the CSF. It is yet unknown
whether an impaired depletion of Asn in CSF by PEG-Asp has an effect on the
incidence of CNS relapse in this group of patients.
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Figure 4.2 Asparagine levels in time
(A) Sequential analysis of plasma (■) asparagine levels (μM) after 1000 IU/m2 of PEG-Asp i.v.
given 5 days before starting combined induction chemotherapy (CT).
(B) Sequential analysis of CSF (□) asparagine levels (μM) after 1000 IU/m2 of PEG-Asp i.v. given
5 days before starting combined induction chemotherapy (CT). The dotted line depicts the
results of Avramis after 2.500 IU/m2 PEG-Asp given i.m. and combined with induction
chemotherapy during the first 5 days.
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ABSTRACT
Alterations in hemostasis have frequently been
observed in children with acute lymphoblastic
leukemia. Thrombotic events are well documented
in patients receiving L-Asparaginase as a single
agent or in combination with other
chemotherapeutic drugs. The present prospective,
randomized study evaluated the effect of two
different L-Asparaginase preparations, native
Escherichia coli L-Asparaginase (Crasnitin; Bayer
AG, Leverkusen, Germany; n = 10) and L-
Asparaginase derived from Erwinia chrysanthemi
(Erwinase®; Porton Pruducts, London, UK; n = 10)
on the changes in parameters concerning
hypercoagulability. Patients were randomized to
receive a total of eight doses of 10 000 IU/m2 L-
Asparaginase intravenously with intervals of 3 days
during induction therapy. Before starting L-
Asparaginase treatment all patients had already
demonstrated an increased thrombin generation
shown by the elevated levels of prothrombin F1+2
and thrombin antithrombin complex (TAT),
presumably due to therapy with prednisone,
daunorubicin and vincristine. A significant decrease
in alpha2-antiplasmin and plasminogen levels was
measured in the E. coli L-Asparaginase but not in
Erwinase-treated patients. Increased thrombin
generation combined with a decrease in α2-
antiplasmin and plasminogen levels may lead to a
state of increased risk for thrombosis due to a delay
in fibrin elimination in E. coli L-Asparaginase-
treated patients only.
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INTRODUCTION
L-Asparaginase has proven to be an important element in the treatment of
childhood acute lymphoblastic leukemia (ALL). As a side effect, L-Asparaginase can
diminish synthesis of several coagulation factors and inhibitors1 that can lead to an
increased risk for thrombosis.2-4 This suggests that the balance between
coagulation and fibrinolysis is shifted towards fibrin formation and deposition.
The changes observed in coagulation parameters in patients treated with L-
Asparaginase have not, however, been consistent in different series of patients,5-7
which can be related to differences in age, genetic predisposition for
hypercoagulability, co-administration of other chemotherapy and the product of L-
Asparaginase used. Due to a shorter half life the same dosage of Erwinase®
(Porton Pruducts, London, UK) shows less antileukemic activity than various kinds
of Escherichia coli L-Asparaginase.8,9 It is suggested that different E. coli L-
Asparaginase preparations influence fibrinolytic proteins in a different way.10 In a
previous study we saw that decreased coagulation factor synthesis in particular
antithrombin was in part counterbalanced by the effect of prednisone.11,12 The
imbalance in coagulation factors was less pronounced in children treated with
Erwinase® than in children treated with E. coli L-Asparaginase. The European
Organization for Research and Treatment of Cancer Children's Leukemia Group
(EORTC-CLG) randomized 700 children with ALL for E. coli L-Asparaginase or
Erwinase®. Abnormalities in hemostasis, not further specified, were more frequent
in the E. coli L-Asparaginase than in the Erwinia arm of the study (30.2% versus
11.9%, P < 0.0001).7
Several highly sensitive and specific tests for activation of the hemostatic
system are available (Figure 5.1). Measurement of the activation peptide
prothrombin fragment 1+2 (F1+2) provides information on the cleavage of the
prothrombin molecule by activated factor X. The protease inhibitor complex
thrombin antithrombin (TAT) reflects the in vivo thrombin generation process.
Activation of the fibrinolytic system leads to plasmin formation, which lyses cross-
linked fibrin to fibrin degradation products. This will generate increased levels of
plasma D-dimer. The plasmin-α2-antiplasmin (PAP) complex level will be raised in
case of increased fibrinolytic activity due to binding of the active proteolytic
enzyme plasmin by α2-antiplasmin (α2-AP).
In order to study the effects of different kinds of L-Asparaginases, we first
analyzed the data of a randomized study comparing E. coli L-Asparaginase
(Crasnitin®; Bayer, Leverkusen, Germany) and L-Asparaginase derived from
Erwinia chrysanthemi (Erwinase®) in childhood ALL. We studied the effects of L-
Asparaginase on thrombin generation measuring F1+2 and TAT and on fibrin
degradation by measuring α2-AP, plasminogen and PAP, D-dimers and fibrinogen.
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Figure 5.1 Diagram on thrombin generation and fibrinolysis
Diagram showing the biochemical steps in the generation of stable inactive enzyme-inhibitor
complexes. Prothrombin fragment 1+2 (F1+2) is generated by the cleavage of prothrombin by
activated FX. Thrombin antithrombin complexes (TAT) reflect the thrombin generation process.
Lysis of fibrin will generate fibrin degradation products (FbDp) which in turn increase the levels
of D-dimer. The binding of plasmin by alpha-2-antiplasmin leads to the formation of the plasmin-
alpha-2-antiplasmin complex (PAP).
METHODS
Patients
Twenty children, consecutively admitted to our hospital with newly diagnosed ALL
between June 1989 and December 1990, were entered in the study. There were 10
boys and 10 girls, varying in age from 10 months to 12.3 years (mean 6.1 years).
The characteristics of the 20 patients are given in Table 5.1. The groups did not
differ significantly with respect to the given characteristics. The induction
treatment was according to the ALL-7 protocol of the Dutch Childhood Oncology
Group, formerly the Dutch Childhood Leukemia Study Group,13 which is based
upon the Berlin-Frankfurt-Munster (BFM) 86 protocol14 (Figure 5.2). After written
informed consent the patients were randomized on day 18 for E. coli L-
Asparaginase or Erwinase® administered every 3 days starting at day 19 as 10 000
IU/m2 in a 1-h infusion given at 1400-h each time. A total of eight doses were
given during induction. No transfusions with fresh frozen plasma or antithrombin
concentrate were administered to the children. The local ethical committee
approved the study.
thrombin
fibrinogen fibrin
plasmin
prothrombin
Xa
α2-antiplasmin PAP
FbDp
(D-dimer)
AT
TAT
F1+2
plasminogen
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Table 5.1 Characteristics of 20 patients at diagnosis
Escherichia coli
L-Asparaginase-treated
children n =10
Erwinia
L-Asparaginase-treated
children n =10
Male/female 5/5 5/5
age (years) 5.5 (2.5 - 9.4) 5.1 (0.8 - 12.6)
Hb (mmol/l) 5.4 (4.3 - 7.5) 4.3 (2.6 - 9.1)
WBC (109/l) 10.8 (4.3 - 38.7) 62.8 (4.6 - 585)
Thr (109/l) 81 (16 - 310) 37 (< 10 - 141)
Immunological phenotyping
Null ALL 0 1
Common ALL 7 5
Pre B ALL 2 0
T ALL 1 4
Data given are number of patients or median (range). Ten patients treated with E. coli L-
Asparaginase and 10 treated with Erwinia L-Asparaginase. The immunological phenotyping is
included. Hb, hemoglobin; WBC, white blood count; Thr, trombocytes; ALL, acute lymphoblastic
leukemia.
Samples
A circadian variation of the fibrinolytic activity in blood has only been
demonstrated for tissue-type plasminogen activator (tPA) and plasminogen
activator inhibitor (PAI).15 Other coagulation parameters vary little or not at all
during the day. In order to eliminate any influence of circadian variation, we
planned all measurements at 1400-h. Blood samples were collected before each L-
Asparaginase administration at 1400-h from the infusion line (Venisystems
Butterfly 21 gauge; Abbott, Ireland). The venous blood samples were collected in
cups containing 3.8% trisodium citrate. The samples were chilled immediately in
an ice bath, centrifuged at 20.000 rpm for 30 min at + 4 °C. The supernatant was
withdrawn and stored at -80 °C until the time of analysis.
Figure 5.2 DCOG-ALL-7 induction therapy
First part of the induction therapy for acute lymphoblastic leukemia according to the DCOG-
ALL-7 study. Methotrexate intrathecal was admitted according (acc.) to age.
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Coagulation assays
The values of activation markers like F1+2, TAT, PAP and D-dimer are similar in
children and adults, as was demonstrated by Ries et al.16 So we were able to adapt
the reference values for adults as provided by the manufacturers.
F1+2 was measured using a commercial solid phase enzyme-linked
immunosorbent-assay (Enzygnost F1+2; Dade Behring GmbH, Marburg, Germany)
following the manufacturer's instructions.17 We adopted the reference values (5th
to 95th percentile) provided by Dade Behring, 0.44 - 1.11 nmol/l.
TAT was determined with a commercial solid phase enzyme-linked
immunosorbent assay (Enzygnost TAT, Behringwerke AG, Marburg, Germany)
following the manufacturer's instructions.18 We constructed our own pediatric
reference values on 62 healthy children between 1 and 15 years old; reference
values for TAT plasma levels were median 2.7 µg/l (5th to 95th percentile 1.1 - 4.3
µg/l). These reference values were in line with the values as determined by Ries et
al.16
Alpha2-antiplasmin (α2-AP) was determined in a kinetic test.19 The normal
reference interval lies between 80 and 120% (Dade Behring GmbH).
Plasminogen was also determined in a kinetic test.20 The normal reference
interval lies between 75 and 140% (Dade Behring GmbH).
PAP was measured by a sandwich enzyme immunoassay of Dade Behring GmbH
following the manufacturer's instructions.21 The normal reference range (percentile
2.5 - 97.5) of this enzyme immunoassay lies between 120 and 700 µg/l (Dade
Behring GmbH) as determined in 466 healthy adults. There are no differences in
normal values between children and adults.16
D-Dimer levels were measured using a commercial enzyme-linked
immunoassay (Asserachrom D-Di; Diagnostica Stago, Asnières, France) following
manufacturer's instructions.22,23 The lower limit of sensitivity was 500 ng/ml, levels
above the 500 ng/ml point to an increased breakdown of fibrin monomers.
Fibrinogen was examined according to the Clauss method.24 Normal values
range between 2 and 4 g/l.
Determinations of PAP and D-dimer were only done at day 19, before the first
L-Asparaginase administration, at day 25 after two L-Asparaginase administrations
and at day 34, after five infusions of L-Asparaginase.
Statistics
Repeated measurements analysis of variance (SAS PROC MIXED; SAS Institute,
Cary, North Carolina, USA) was used to evaluate the differences between and
within both experimental groups. This method was used after logarithmic
transformation of TAT, F1+2 and D-dimer to obtain approximate normal
distributions. P = 0.05 (two sided) was considered the limit of significance. The
Mann Whitney U test was used to calculate differences in the various parameters
at day 19 between the two groups of patients.
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RESULTS
Groups were comparable regarding various baseline coagulation/fibrinolytic
parameters on day 19 at the start of L-Asparaginase treatment.
Prothrombin fragment 1+2
To obtain approximate normal distributions these data were analyzed after
logarithmic transformation. All patients demonstrated high levels of F1+2 before
the start of L-Asparaginase therapy (Figure 5.3). During and after administration
of L-Asparaginase, no significant differences of F1+2 in time evolved in comparison
with the values before starting L-Asparaginase on day 19. Also within each of the
two groups analyzed separately no differences at the various time points compared
with day 19 were found (P > 0.1). Adjusted for baseline values at day 19, the
mean value of F1+2 at the various time points was 0.08 nmol/l lower in the E. coli
L-Asparaginase-treated patients than in the Erwinase®-treated children, but this
did not reach statistical significance (P = 0.1). The mean values of F1+2 varied
between 1.3 (SEM 0.1) and 2.3 nmol/l (SEM 0.8) in the E. coli L-Asparaginase-
treated group and between 1.5 (SEM 0.1) and 2.9 nmol/l (SEM 1.1) in the
Erwinase®-treated children at the different time points (Figure 5.3).
Thrombin antithrombin
To obtain approximate normal distributions these data were analyzed after
logarithmic transformation. High levels of TAT were already found in all 20 patients
before starting L-Asparaginase (Figure 5.3). Within each of the two groups no
significant changes of TAT occurred during treatment (P > 0.1). The TAT levels at
the various time points did not significantly differ between the E. coli L-
Asparaginase-treated patients and the Erwinase®-treated children. The mean
values of TAT ranged between 6.6 (SEM 1.5) and 27 (SEM 19.3) µg/l in the E. coli
L-Asparaginase-treated children and between 7.3 (SEM 1.4) and 55.4 (SEM 36)
µg/l in the Erwinase®-treated group (Figure 5.3).
Figure 5.3 Parameters of trombin generation
Geometric means ± Standard error over time of prothrombin fragment 1+2 (F1+2) in mmol/L
and thrombin-antithrombin complexes (TAT) in μg/L for 10 patients treated with Escherichia coli
L-Asparaginase and 10 patients treated with Erwinase® monitored from the first infusion with L-
Asparaginase 10.000 IU/m2 intravenously until the last infusion. Range of normal values of
F1+2: 0.44 - 1.11 mmol/L, range of normal values of TAT: 1.1 - 4.3 µg/L.
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Alpha2-antiplasmin
The mean α2-AP values in the E. coli L-Asparaginase-treated patients declined from
110% (SEM 3.6) before starting L-Asparaginase to 88% (SEM 4.6) at day 25,
before starting the third L-Asparaginase infusion, and thereafter values stayed
stable (Figure 5.4). Using RmANOVA, adjusted for baseline values at day 19, the
mean values of α2-AP at the various time points were 18.2 units lower in the
children treated with E. coli L-Asparaginase (P < 0.001) than in the children
treated with Erwinase®. In the Erwinase®-treated patients the mean α2-AP values
did not differ from baseline values at day 19 but stayed within the normal range
with mean values ranging from 97% (SEM 3.4) to 106% (SEM 4.2) (Figure 5.4).
Plasminogen
In the E. coli L-Asparaginase group plasminogen levels started at a mean of 102%
(SEM 6) and decreased to 72% (SEM 6) before the third L-Asparaginase
administration and thereafter mean values remained stable between 74 and 79%
(Figure 5.4). In the Erwinase®-treated patients the mean plasminogen value
before starting L-Asparaginase therapy was 89% and mean values stayed between
84% (SEM 5.9) and 89% (SEM 5.5) (Figure 5.4). Adjusted for baseline values at
day 19, the mean value of plasminogen at the various time points was 17.5 units
lower in the E. coli L-Asparaginase-treated children (P = 0.013) than in the
children treated with Erwinase®.
Plasmin-alpha2-antiplasmin
In the E. coli L-Asparaginase group the mean PAP values at day 19, 25 and 34
were respectively 233 (SEM 25.7), 145 (SEM 35) and 178 (SEM 33) µg/l. The
corresponding values for the Erwinase®-treated children were, respectively, 298
(SEM 72), 289 (SEM 53) and 287 (SEM 46) µg/l as demonstrated in Figure 5.4.
Using RmANOVA it was found that the mean value of PAP at the various time
points adjusted for baseline values at day 19 was 120 µg/l lower in the E. coli L-
Asparaginase group (P = 0.04) than in the Erwinase® group.
D-Dimer
To obtain approximate normal distributions these data were analyzed after
logarithmic transformation. In the E. coli L-Asparaginase group the mean D-dimer
values at day 19, 25 and 34 were, respectively, 162 (SEM 14.5), 152 (SEM 43)
and 214 (SEM 100) ng/ml (Figure 5.4). The corresponding values for the
Erwinase®-treated children were, respectively, 238 (SEM 58), 202 (SEM 41) and
264 (SEM 71) ng/ml. All individual values were within the normal range pointing to
no degradation of fibrin to fibrin monomers. No active fibrinolysis was monitored.
Adjusted for baseline values at day 19 the mean value of D-dimer at the various
time points did not significantly differ between the E. coli L-Asparaginase-treated
children and the Erwinase®-treated patients (P = 0.4).
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Mean values at day 19 started in the E. coli L-Asparaginase-treated group at 1.4
g/l (SEM 0.2) with a nadir of 0.9 g/l (SEM 0.1) at day 25 to gradually increasing
values of 1.5 g/l (SEM 0.16) at day 40. In the Erwinase®-treated children
fibrinogen levels start at day 19 at 1.0 g/l (SEM 0.1), gradually increasing to 2.3
g/l (SEM 0.2) at day 40.
During the study in none of the 20 patients did any clinical signs of serious
bleeding or thrombotic events occur.
Figure 5.4 Parameters of fibrinolysis
Means ± SEM over time of (A) α2-antiplasmin (%) and (B) of plasminogen (%) for 10 patients
treated with E. coli L-Asparaginase and 10 patients treated with Erwinase® monitored from the
first infusion with L-Asparaginase 10.000 IU/m2 intravenously until the last infusion. Adjusted for
baseline values at day 19, the mean values of α2-antiplasmin are significantly lower in the E. coli
L-Asparaginase-treated children (P = 0.001) compared with the Erwinia-treated children. The
mean values of plasminogen are significantly lower in the E. coli L-Asparaginase- treated
children (P = 0.013) than in the Erwinase®-treated children. Range of normal values of α2-
antiplasmin: 80 - 120%; range of normal values of plasminogen: 75 - 140%.
(C) Means ± SEM in time of plasminogen-α2-antiplasmin (PAP) in μg/l monitored from the first
infusion, the third and the last infusion with L-Asparaginase 10.000 IU/m2 intravenously. A
significant decrease in PAP is found in E. coli L-Asparaginase-treated children between day 19
and day 25 (P = 0.03). Range of normal values: 120 - 700 μg/L.
(D) Geometric means ± SEM in time of D-Dimer in ng/ml monitored from the first infusion, the
third and the last infusion with L-Asparaginase 10.000 IU/m2 intravenously. Normal values <
500 ng/ml.
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DISCUSSION
Children suffering from ALL are at risk for increased bleeding tendencies as well as
for thrombotic events. Activation of the coagulation system can be attributed to
the malignant disease.4 Additionally, chemotherapeutic regimens contain several
antileukemic drugs that can influence the balance between bleeding and
thrombosis. The most important drugs that influence the coagulation system are
prednisone and L-Asparaginase.
In a former study we demonstrated that the largest changes in coagulation
proteins were monitored in the first part of ALL induction treatment consisting of
intravenous vincristine, prednisone, daunorubicin and intrathecal methotrexate.
During the second phase of induction treatment when L-Asparaginase was added,
only minor additional changes in plasma coagulation factors were found.11,12 A
remarkable shortening of the APTT most likely due to a rise in factor VIII and IX,
together with a progressive hypofibrinogenemia and a significant rise in both the
AT and protein C activities, were responsible for an unstable balance between
coagulation and bleeding factors before L-Asparaginase was added to the
treatment. All these changes could probably be attributed to the use of
prednisone.25,26 We did not find an additional effect of L-Asparaginase on the
coagulation proteins that are involved in fibrin formation.11
The changes observed in coagulation proteins are related to the product and
the dose of L-Asparaginase used.5,6,27,28 We now know that different L-
Asparaginase preparations manifest different pharmacokinetic and
pharmacodynamic properties. The influence on fibrinolytic proteins will be
different.10 In the present randomized prospective study we analyze the process of
thrombin generation and fibrinolysis by two different L-Asparaginase preparations.
All patients demonstrate increased thrombin generation already before starting L-
Asparaginase, pointing to a state of hypercoagulability demonstrated by elevated
levels of F1+2 as well as TAT (Figure 5.3). The administration of L-Asparaginase,
either generated from native E. coli or from Erwinia chrysanthemi, does not lead to
a further increase or any decrease in the levels of TAT and F1+2. As prednisone
therapy continues during the second part of ALL induction treatment the raised
levels of F1+2 and TAT might be attributed to the concomitant use of
corticosteroids.25 Considering that the half-lives of F1+2 and TAT are respectively
90 and 3 minutes and that both parameters were taken at the same time for each
investigation, we conclude that thrombin generation is not clearly influenced by
the administration of L-Asparaginase in the way it was given in this study. The
collection of blood samples from metal butterfly needles is comparable with a
direct venipuncture and not to the situation with peripheral catheters in situ.29
Therefore a reliable interpretation of F1+2 and TAT complexes is possible, pointing
to a state of hypercoagulability in all patients, presumably due to the concomitant
use of prednisone.
The statistically significant decline in both α2-AP and plasminogen in the E. coli
L-Asparaginase-treated children in relation to the parallel reduction in PAP levels
points in this study to a decrease in synthesis of α2-AP and plasminogen,
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respectively. This decline does not occur in the Erwinase®-treated children (Figure
5.4). The presumed effect of prednisone on α2-AP and plasminogen levels is
negligible, as is demonstrated by the normal values of both proteins before
starting L-Asparaginase. Patients on long-term steroid therapy demonstrate a
hypercoagulable and hypofibrinolytic state due to elevations of several coagulation
factors and due to elevations of PAI-1.30 This hypofibrinolytic state will possibly be
induced by prednisone in the same way in all our patients. So, from this
randomized study, we can conclude that the decrease in PAP levels, due to a
decrease in α2-AP and plasminogen synthesis, will cause a delay in fibrin
elimination and therefore might lead to a hypercoagulable state in the E. coli L-
Asparaginase-treated patients only and not in the Erwinase®-treated children.
The D-dimer levels stayed within the normal range during L-Asparaginase
treatment. Statistical analysis reveals no difference on the various time points
between E. coli L-Asparaginase and Erwinase®-treated children (Figure 5.4). The
normal values of D-dimer even at baseline can be explained by
hypofibrinogenemia in all 20 patients induced by initial prednisone therapy. This
implies that active fibrinolysis after the introduction of L-Asparaginase potentially
leading to fibrin degradation is not observed irrespective of the differences in
pharmacokinetics between these two L-Asparaginases.
The present study shows different effects of different kinds of L-Asparaginase
on the coagulation system.8 The two L-Asparaginase preparations differ in half-life
with different influences on the amino acid metabolism. A dose-dependent
influence of L-Asparaginase preparations on protein synthesis has also been found.
The half life of native E. coli L-Asparaginase is 1.24 days whereas the half life of
Erwinase® is 0.65 days.8,31 The effects measured in our study are the result of
10,000 IU/m2 of L-Asparaginase administered every 3 days. In the Gruppo Italiano
Malattie Ematologiche dell'Adulto (GIMEMA) study32 E. coli L-Asparaginase was
given daily in a lower dose of 6000 IU/m2 and also at this dose an increase in
hypercoagulability parameters during treatment with E. coli L-Asparaginase was
found. Nowak-Gottl33 demonstrated less changes in hemostasis in children treated
with 2500 IU/m2 of the native E. coli L-Asparaginase preparation compared with
5000 IU/m2 of the same L-Asparaginase. In another non-randomized study they
showed that the downregulation of coagulation proteins like fibrinogen,
plasminogen and α2-AP was more pronounced in children treated with Medac L-
Asparaginase (Medac Therapeutics, Wedel, Germany) than in children treated with
the original native product of Bayer (Crasnitin®) or Erwinase®.10 In their report a
significant enhanced thrombin generation also with increased levels of D-dimers
was found. So, different effects on the coagulation system are not only found
between L-Asparaginase generated from E. coli or from Erwinia chrysanthemi, but
also among different commercial E. coli preparations.
We conclude that the leukemia itself together with initial treatment with
prednisone during ALL induction leads to a situation of increased thrombin
generation as is demonstrated by increased F1+2 and TAT levels. Addition of L-
Asparaginase to the induction therapy leads to a decreased fibrinolytic potential
due to decreasing levels of α2-AP and plasminogen in children treated with E. coli
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L-Asparaginase but not in children treated with Erwinase®. Therefore, the use of
prednisone in combination with E. coli L-Asparaginase (Crasnitin®, Bayer) leads to
an increased risk for thrombosis in children with ALL. Ongoing studies have to
clarify how new formulations like pegylated L-Asparaginase and recombinant L-
Asparaginase influence the coagulation system, and such studies have to be
combined with pharmacokinetic and pharmacodynamic data.
Hypercoagulability by L-Asparaginase
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ABSTRACT
Alterations in hemostasis are frequently observed in
children with acute lymphoblastic leukemia (ALL).
In the present study we analyzed age-related
disturbances in coagulation and fibrinolysis
parameters during the induction phase of the DCOG-
ALL-9 protocol. 64 children were classified by age
into three groups (1 - 5, 6 - 10, 11 - 16 years), and
studied during induction treatment of ALL including 4
weeks of dexamethasone, followed by 2 weeks
tapering of dexamethasone during which 6,000
IU/m2 Paronal® (total 4 doses) was administered
intravenously twice weekly. Blood samples were
collected immediately before each Paronal® infusion
to analyze procoagulant (fibrinogen, F II, F V, F VII,
F IX, F X) and anticoagulant factors (AT, protein C,
protein S), parameters of thrombin generation
(F1+2, TAT) and fibrinolysis (α2-antiplasmin,
plasminogen, PAP, D-dimer).
Children were in a hypercoagulable state after 4
weeks of dexamethasone due to upregulation of
coagulation parameters. Upregulation was highest in
the two youngest age groups. During Paronal®
treatment the 11 - 16 year olds showed lower values
in procoagulant and, even more, in anticoagulant
factor levels compared to the younger children.
Activation markers of thrombin generation and
fibrinolysis did not change over time during the
study period. The fibrinolytic potential was
significantly more disturbed in children older than 11
years as a result of decreasing levels of
α2-antiplasmin and plasminogen during Paronal®
treatment.
A more severe decline of anticoagulant and
fibrinolytic parameters in children between 11 and
16 years of age underline that these children are at
higher risk of thrombosis during ALL induction
treatment.
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INTRODUCTION
Alterations in hemostasis are frequently observed in children with acute
lymphoblastic leukemia (ALL). Although the process of increased thrombin
generation is already active at diagnosis,1 thrombo-embolism, does not occur until
anti-leukemic therapy is started, typically during the induction phase of therapy.
The pathogenesis of this increased thrombotic risk is not fully understood. It
includes a combination of variables related to the disease itself, its treatment and
the host. As most drugs are given as combination chemotherapy, assessing how
single agents affect the coagulation system is quite difficult.
L-Asparaginase and steroids have been studied most extensively in this
respect. L-Asparaginase is an enzyme that converts the non-essential amino acid
asparagine into aspartic acid and ammonia. The resulting inhibition in protein
synthesis explains both for its antileukemic effect and its toxicity on the
coagulation system. Different kinds of L-Asparaginase have different half-lives and
different peak activities.2,3 The extents of asparagine depletion, antileukemic effect
and disturbance of the coagulation system are dependent on doses and type of
L-Asparaginase preparation used.
Different investigators have shown that prednisone therapy is associated with
higher F VIII, von Willebrand factor, F II and antithrombin (AT), and with lower
fibrinogen levels.1,4 Two trials in children with ALL5,6 – randomizing dexamethasone
versus prednisone – demonstrated no apparent differences in incidences of
clinically overt thrombotic events.
In an earlier randomized study7 we reported on the differences in
hypercoagulability between two L-Asparaginase preparations: Crasnitin® (Bayer)
and Erwinase® (Ipsen). Treatment with the E. coli L-Asparaginase Crasnitin® caused
a delay in fibrin elimination and thus increased the risk of thrombosis, unlike
Erwinase® treatment.
Andrew et al. as early as the late 1980's introduced the concept of
developmental hemostasis,8 which recently was confirmed by Monagle et al.9 From
age-related changes in the coagulation system this concept proposes that
hemostasis in childhood is age-dependent, i.e. the youngest children are the best
protected from thrombosis. In confirmation of this concept, Barry et al. and
Moghrabi et al. pointed to an effect of age on the risk for symptomatic thrombo-
embolic disease during Dana-Farber Cancer Institute ALL treatment protocols.10,11
Patients aged 10 -18 years were more likely to experience L-Asparaginase related
toxicity than were younger children (thrombotic events 11% versus 2%), even
when stratified by risk group. Reports on changes in the coagulation system
related to L-Asparaginase treatment in children of different age groups are lacking
so far.
The current report analyses the effect of age on disturbances in coagulation and
fibrinolysis in children with newly diagnosed ALL.
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1 8 15 22 29 36 43
Dexamethasone p.o. 6 mg/m2
Vincristine i.v. 2.0mg/m2
(Daunorubicin i.v. 25 mg/m2)*
Paronal i.v. 6.000 IU/m2
MTX/DAF/ARA-Ci.th.(acc. to age)
days
( ) ( )( )( )
*Highriskpatients only
METHODS
Patients and therapy
Subjects eligible for this study were all children with newly diagnosed ALL
consecutively admitted to our hospital between April 1997 and October 2000. The
family history was checked for thrombophilia. Still, a possible familiar
thrombophilic risk factor was not an exclusion criterion. Routine screening for
thrombophilia was not done. None of the subjects had a history of bleeding or
thrombotic disorders. Prior to instituting therapy informed consent was obtained
from parents or guardians in accordance with the Declaration of Helsinki.
Therapy was according to the ALL-9 protocol of the Dutch Childhood Oncology
Group based on the earlier ALL-6 treatment strategy.12 Non-high risk ALL was
defined as WBC < 50 x 109/L, no mediastinal mass, no t(9;22), no t(4;11) or MLL
rearrangement, no T-cell phenotype and no central nervous system or testicular
involvement. All other leukemias were defined as high risk. The induction phase for
all patients is depicted in Figure 6.1. Four doses of Paronal® (6,000 IU/m2, E. coli
L-Asparaginase from Medac GmBH Germany) were administered intravenously in
one-hour infusions twice a week.
All children had a central venous device. Minor allergic reactions (grade I or II)
were counteracted by lowering the infusion rate. Consequently, before starting the
next Paronal® infusion, these patients were given an antihistaminic drug, e.g.
clemastine, and eventually steroids.
Sampling
During induction on days 29, 33, 36 and 40, blood samples were collected from
the venous device immediately before each Paronal® infusion and on day 43. Blood
samples were collected in tubes containing 3.8% trisodium citrate, chilled
immediately in an ice bath and centrifuged at 20,000 rpm for 30 minutes at +4 ºC.
The supernatant was withdrawn and stored at -80 ºC until the time of analysis.
Figure 6.1 Induction therapy according to the DCOG-ALL-9 study
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Coagulation assays
All coagulation assays were done with commercially available reagents and
methods, as described previously.7 All assays were performed on the Sysmex CA
1500 from Dade Behring (Germany). Reagents were supplied by Stago (France) or
Dade Behring (Marburg, Germany).
Procoagulants
Factors II, V, VII, IX and X were measured in a one-stage assay using
commercially available deficient plasma (Dade Behring, Marburg, Germany).
Anticoagulants
Antithrombin (AT) and protein C activities were measured functionally by a
chromogenic assay (Dade Behring), protein C antigen by an enzyme-linked
immunoadsorbent assay (Asserachrom, Stago, France). Total and free protein S
levels were measured by quantitative ELISA (Asserachrom, Stago).
Thrombin generation
The fibrinogen concentration was measured according to the "Clauss" method;13
normal reference ranges 2 - 4 g/L. The activation markers F1+2 and TAT were
measured using commercially available ELISA techniques (Dade Behring). We
adopted the reference values (5th - 95th percentile) for F1+2 provided by Dade
Behring: 0.44 - 1.11 nmol/l. We constructed our own pediatric reference values for
TAT on 62 healthy children between 1 and 15 years old: median 2.7 μg/l (5th - 95th
percentile: 1.1 - 4.3 μg/l).
Fibrinolysis
Alpha-2-antiplasmin (α2-AP) and plasminogen were determined in a kinetic test
(Dade Behring). For the activation marker PAP, a commercially available ELISA
technique was used (Dade Behring). The normal reference range (2.5th - 97.5th
percentile) is 120 - 700 g/l (Dade Behring) as determined in 466 healthy adults.
There are no differences in normal values between children and adults.14
D-dimer levels were measured using an enzyme-linked immunoassay (Biopool,
Ireland). The lower limit of sensitivity was 0.5 mg/ml, levels > 0.5 mg/ml point to
an increased breakdown of fibrin monomers.
Normal values
In this manuscript we compared our data with reference values of Monagle et al.9
except for protein S. We only measured antigen levels because of the interference
of protein S activity levels with high factor VIII levels or hyperbilirubinemia. Stago
data reported by Monagle and colleagues are compared with our Dade data.
Statistics
In concordance with previous studies, our results are reported for children aged 1
to 5 years, 6 to 10 years, and 11 to 16 years. Only for protein S values for boys
and girls separately were calculated.15,16
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The results are expressed as means and ranges (= minimum-maximum) so as
to enable comparison with the data of Monagle et al. TAT, F1+2, PAP and D-dimer
were transformed logarithmically in order to approximate normal distributions; for
these variables data are given as medians (minimum-maximum). Repeated
Measurements Analysis of Variance (SAS PROC MIXED) was used to evaluate
differences between and within the different age groups. Interaction terms for age
groups and time were used to evaluate whether the profiles of mean values over
time (measurement days) of the 3 age groups deviated from parallelism. In case of
significant time effects, comparisons were made with the first measurements on day
29. P = 0.05 (two-sided) was considered the limit of significance.
Data performed with Dade reagents are also evaluated with the outcomes of the
various parameters expressed as the percentage of the predicted mean value,
taking account of age and gender, if such reference values were available from
Monagle et al.
RESULTS
Clinical data
After informed consent, 72 children consecutively admitted to our hospital with
newly diagnosed ALL were enrolled in the study. Due to incomplete coagulation
data, however, eight children were excluded from analysis. Characteristics of the
remaining 64 children are shown in Table 6.1. All 64 completed the remission-
induction phase. No septic periods occurred during the period analyzed. None of
the children was treated with antithrombin concentrate or fresh frozen plasma.
One child, a nine-year-old boy, experienced a clinical thrombotic event. After a
short period of severe headache he suddenly demonstrated a left sided
hemiparesis one week after the last dose of Paronal®. An MR angiography showed
a cerebral sinovenous thrombosis. At the time, AT was 65%, protein C activity
71%, protein C antigen 58%, protein S free 51% and total protein S 79%. He
recovered completely.
Clinical complications such as pancreatitis, diabetes mellitus or hyperlipidemia
were not observed. One child experienced an allergic reaction grade II to the
fourth Paronal® infusion but after anti-allergic treatment the total dose could be
administered.
Coagulation data
Tables 6.2 - 6.5 provide the results over time from before each Paronal® infusion
on day 29, 33, 36, and 40 and from day 43 for the group as a whole and for the
three different age groups. Except for 2 parameters, protein S total and log (TAT),
the profiles over time did not significantly differ between the age groups. This
points to a general parallel change of coagulation parameters over time for the
separate age groups.
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Table 6.1 Characteristics of 64 patients
* mean (range)
Procoagulants (Table 6.2)
Raw data of factor V demonstrated no change over time or between age group. All
mean values except 2 were significantly higher as compared to mean reference
values. Although there were significant differences between study days for the
data expressed as % of mean (P = 0.02), none of the differences with day 29 was
significant. Factors II, IX and X all declined significantly (P < 0.001) compared to
day 29 values. In addition, there were significant differences between age groups.
The same applies to the data expressed as percentages of the age specific normal
reference values. Factor VII is the only protein whose level increased significantly
over time for the group as a whole, and there were no significant differences
between age groups.
Anticoagulants (Tables 6.3A and 6.3B)
All anticoagulants demonstrated a significant decline over time (P < 0.001). In
addition, for all parameters there were significant effects of age group. The AT,
protein C and S values generally were lower in the children aged 11 - 16 years as
compared to others. AT is shown in Figures 6.2A and 6.2B: while mean levels were
well above the mean reference value at day 29, all mean values were below at
later days.
While free protein S levels demonstrated the same profile over time for the
three age groups, this was not the case for total protein S (P = 0.005). However,
within each age group all levels were significantly lower than those on day 29. No
differences in free and total protein S between boys and girls were found (data not
shown).
Characteristics n
Non high risk / high risk 48 / 16
Male / female 42 / 22
Age years 6.7 (1 - 16.7)*
WBC (x 109/L) at diagnosis
< 50 50
50-100 9
>100 5
Age-group
1-5 years (F / M) 35 (12 / 23)
6-10 years (F / M) 15 (5 / 10)
11-16 years (F / M) 14 (5 / 9)
Immunophenotyping
c ALL 48
pre B ALL 12
T ALL 4
Table 6.2 Procoagulant factors
Data (percentages) are given as means (minimum-maximum). Reference mean values with 95% reference ranges for the different age groups according to
Monagle9 are given in italics. P-values from ANOVA comparisons between study days of raw data and of data expressed as % of normal are denoted by p days, p
age denotes ANOVA comparisons between the different age groups.
Paronal 6000 IU/m2
Day 29

Day 33

Day 36

Day 40

Day 43 Raw data
P days P age
% of normal
P days P age
Procoagulants
F V 139 148 137 140 139 0.08 0.07 0.02 0.42
1 - 5 years
(97; 67 - 127%)
140
105 - 189
157
64 - 284
146
77 - 272
142
88 - 197
150
61 - 282
6 - 10 years
(99; 56 - 141%)
141
81 - 216
146
65 - 231
136
69 - 210
153
110 - 49
142
90 - 186
11 - 16 years
(89; 67 - 141%)
136
94 - 204
120
49 - 198
113
49 - 180
121
32 - 200
117
46 - 188
F II 134 120 113 116 112 < 0.001 < 0.001 < 0.001 < 0.001
1 - 5 years
(89; 70 - 109%)
139
88 - 207
126
93 - 194
120
65 - 146
122
84 - 195
120
88 - 176
6 - 10 years
(89; 67 - 110%)
132
93 - 163
114
88 - 156
114
87 - 142
123
79 - 195
120
93 - 143
11 - 16 years
(90; 61 - 107%)
128
104 - 149
108
81 - 134
91
71 - 112
89
69 - 119
88
55 - 125
F VII 113 147 153 164 161 < 0.001 0.48 < 0.001 0.33
1 - 5 years
(111; 72 - 150%)
112
54 - 183
142
64 - 239
150
80 - 285
157
99 - 270
153
94 - 216
6 - 10 years
(113; 70 - 156%)
119
77 - 186
159
97 - 218
157
95 - 232
182
101 - 313
188
106 - 359
11 - 16 years
(118; 69 - 200%)
113
58 - 177
141
85 - 204
156
90 - 318
161
106 - 234
157
90 - 265
F IX 168 110 107 95 92 < 0.001 0.005 <0.001 < 0.001
1 - 5 years
(85; 44 - 127%)
171
82 - 240
119
46 - 200
117
26 - 217
104
43 - 186
107
49 - 216
6 - 10 years
(96; 48 - 145%)
170
87 - 222
101
49 - 183
106
40 - 153
93
42 - 159
88
15 - 136
11 - 16 years
(111; 64 - 216%)
153
41 - 212
96
50 - 153
74
40 - 112
73
38 - 131
65
30 - 100
F X 154 132 123 127 116 < 0.001 < 0.001 < 0.001 0.01
1 - 5 years
(98; 72 - 125%)
163
62 - 232
145
70 - 249
136
70 - 189
139
79 - 197
126
74 - 200
6 - 10 years
(97; 68 - 125%)
145
112 - 201
119
77 - 183
117
73 - 207
124
91 - 177
124
97 - 153
11 - 16 years
(91; 53 - 122%)
137
95 - 200
110
73 - 154
90
58 - 149
98
54 - 157
87
44 - 154
Table 6.3A Anticoagulant factors
Data (percentages) are given as means (minimum-maximum).
A. Reference mean values with 95% reference ranges for the different age groups according to Monagle9 are given in italics. P-values as in Table 6.2.
Table 6.3B Anticoagulant factors
B. Only raw data (percentages) are given. P-values from ANOVA comparisons between study days are denoted by p days, p age denotes ANOVA comparisons between the
different age groups.
Paronal 6000 IU/m2
Day 29

Day 33

Day 36

Day 40

Day 43 Raw data
P days P age
% of normal
P days P age
Anticoagulants
AT 153 106 98 91 86 < 0.001 < 0.001 < 0.001 < 0.001
1 - 5 years
(116; 101 - 131%)
157
103 - 202
113
78 - 142
106
72 - 144
102
71 - 147
94
62 - 138
6 - 10 years
(114; 95 - 134%)
154
130 - 183
100
83 - 117
92
71 - 116
84
59 - 109
84
56 - 112
11 - 16 years
(111; 96 - 126%)
144
118 - 168
95
71 - 120
78
88 - 95
67
42 - 87
71
42 - 114
Prot C act 172 123 114 110 100 < 0.001 0. 005 < 0.001 0. 07
1 - 5 years
(96; 65 - 127%)
174
100 - 329
129
45 - 216
123
55 - 171
118
78 - 188
109
53 - 186
6 - 10 years
(100; 71 - 129%)
174
132 - 258
119
82 - 186
113
68 - 177
111
71 - 162
104
69 - 147
11 - 16 years
(94; 66 - 118%)
167
84 - 228
111
42 - 142
89
39 - 165
87
34 - 138
79
37 - 144
Prot C ag 150 107 101 99 92 < 0.001 0.008
1 - 5 years 152
70 - 285
113
35 - 175
109
57 - 156
107
61 - 198
101
38 - 144
6 - 10 years 152
108 - 194
102
57 - 158
97
63 - 144
99
58 - 137
94
76 - 120
11 - 16 years 141
89 - 176
95
41 - 133
78
39 - 115
73
36 - 113
70
36 - 106
Prot S free 102 68 60 59 58 < 0.001 0.001
1 - 5 years 104
11 - 154
73
37 - 124
65
28 - 94
65
40 - 101
64
24 - 114
6 - 10 years 102
83 - 120
64
44 - 95
60
41 - 96
61
33 - 92
64
46 - 90
11 - 16 years 98
74 - 142
59
42 - 81
46
35 - 59
42
28 - 53
41
22 - 61
Prot S total 106 83 79 79 81 < 0.001 < 0.001
1 - 5 years 109
59 - 153
86
46 - 150
86
51 - 156
86
51 - 149
89
53 - 124
6 - 10 years 107
86 - 145
78
58 - 96
76
54 - 93
80
50 - 100
88
77 - 98
11 - 16 years 99
81 - 114
78
72 - 92
61
44 - 86
56
39 - 71
58
42 - 81
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Table 6.4 Parameters of thrombin generation
Data are given as means, or as medians when the distribution was skewed, and minimum-
maximum. P-values from ANOVA comparisons between study days are denoted by p days, p age
denotes ANOVA comparisons between the different age groups.
Thrombin generation (Table 6.4)
For fibrinogen differences were found between age groups (P = 0.005) as well as
between study days (P < 0.001). Compared to general reference values, fibrinogen
levels were decreased on day 29 in all age groups. They further declined
significantly on day 33 - 36, and increased significantly (P < 0.001) to levels still
below the normal reference levels on day 43.
Irrespective of age, F1+2 levels did not change over time during Paronal®
treatment (P = 0.33). The profiles over time of mean logarithmically transformed
TAT levels differed between age groups. Comparisons within each age group
showed significant differences with day 29 for age group 6 - 10 years and 11 - 16
years. For both these groups values at day 36 and 43 were significantly lower.
Fibrinolysis (Table 6.5)
α2-AP, plasminogen and PAP levels decreased significantly over time (P < 0.001).
For α2-AP and plasminogen also significant differences between age groups were
found (p < 0.001), but not for PAP (P = 0.73). Irrespective of age, D-dimers
demonstrated no changes over time.
Paronal 6000 IU/m2
Day 29

Day 33

Day 36

Day 40

Day 43 Raw data
P days P age
Thrombin generation
Fibrinogen g/L 1.20 0.92 0.94 1.10 1.60 < 0.001 0.005
1 - 5 years 1.34
0.1 - 2.6
1.08
0.1 - 2.0
1.15
0.1 - 2.5
1.29
0.1 - 2.4
1.64
0.5 - 2.7
6 - 10 years 1.13
0.5 - 1.9
0.81
0.5 - 1.6
0.84
0.1 - 1.6
1.18
0.1 - 2.2
1.47
0.1 - 2.2
11 - 16 years 0.93
0.6 - 1.6
0.51
0.1 - 1.0
0.45
0.1 - 0.9
0.60
0.1 - 0.7
1.57
0.1 - 5.9
F1+2 nmol/L median 1.10 1.08 1.19 1.09 1.15 0.14 0.33
1 - 5 years 0.91
0.49 - 20.54
0.98
0.44 - 2.07
1.10
0.35 - 111.9
1.01
0.52 - 6.92
1.02
0.6 - 3.3
6 - 10 years 1.32
0.6 - 3.99
1.16
0.55 - 2.36
1.47
0.45 - 2.78
1.25
0.56 - 127
1.47
0.58 - 3.13
11 - 16 years 1.46
0.72 - 2.04
1.29
0.48 - 2.08
1.51
0.57 - 2.41
1.23
1.0 - 2.29
1.28
0.85 - 1.98
TAT μg/L median 6.5 4.3 4.0 3.2 4.8 < 0.001 0.31
1 - 5 years 5.5
1.6 - 414
4.1
1.5 - 11.8
5.5
1.6 - 2157
4.2
1.9 - 148
6.4
2.0 - 46.3
6 - 10 years 7.4
1.8 - 54.4
5.8
2.3 - 36
3.9
1.5 - 15.8
2.4
1.4 - 4.6
5.1
2.5 - 12.1
11 - 16 years 6.5
2.6 - 27.7
3.5
2.1 - 8.6
3.0
1.7 - 5.2
3.2
2.0 - 7.3
3.3
2.2 - 9.0
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Table 6.5 Parameters of fibrinolysis
Data are given as means, or as medians when the distribution was skewed, and minimum-
maximum. P-values as in Table 6.4.
DISCUSSION
More intensive thrombin generation and reduced antithrombotic potential are
thought to be key factors for thrombo-embolic complications in children treated for
ALL. Most of the thrombotic events occur during induction therapy.17 In the
present study we analyzed changes in coagulation parameters in children treated
for ALL according to the DCOG-ALL-9 protocol. We report changes in the group as
a whole and age dependent changes.
New data on developmental hemostasis have recently been published by Monagle
et al.9 We used these reference values, even though most of our coagulation
parameters were determined with materials from a different manufacturer.
Practically, results obtained with reagents from different manufacturers should give
the same pattern over time, especially when calibrated against international
standards. Therefore, we feel the use of analyzers/reagents from different companies
is acceptable in pediatrics, provided good laboratory practice is adhered to.
Paronal 6000 IU/m2
Day 29

Day 33

Day 36

Day 40

Day 43 Raw data
p days p age
Fibrinolysis:
α2-AP 136 99 92 88 91 < 0.001 < 0.001
1 - 5 years 142
101 - 282
108
68 - 198
1.03
54 - 135
98
50 - 141
104
65 - 174
6 - 10 years 128
109 - 180
87
51 - 156
89
49 - 124
90
45 - 141
91
68 - 114
11 - 16 years 127
95 - 198
85
40 - 129
64
36 - 99
58
37 - 82
66
40 - 115
Plasminogen 116 82 79 89 85 < 0.001 < 0.001
1 - 5 years 123
108 - 234
91
57 - 153
87
48 - 145
94
50 - 142
95
59 - 144
6 - 10 years 111
82 - 140
73
51 - 99
80
41 - 132
106
50 - 375
94
62 - 128
11 - 16 years 105
81 - 131
67
48 - 97
55
41 - 75
57
33 - 77
60
43 - 84
PAP μg/L median 215 91 93 88 82 < 0.001 0.73
1 - 5 years 199
51 - 945
97
17 - 553
128
28 - 272
101
4 - 330
83
37 - 306
6 - 10 years 251
70 - 918
88
32 - 406
78
14 - 461
87
18 - 306
77
31 - 523
11 - 16 years 252
3 - 1403
73
28 - 459
95
24 - 325
58
16 - 475
85
21 - 317
D dimer mg/L median 0.12 0.12 0.11 0.10 0.12 0.12 0.25
1 - 5 years 0.10
0.03 - 0.47
0.12
0.05 - 0.23
0.09
0.05 - 0.23
0.09
0.03 - 0.33
0.11
0.07 - 0.52
6 - 10 years 0.13
0.09 - 0.31
0.12
0.07 - 0.39
0.09
0.07 - 0.33
0.10
0.08 - 0.31
0.12
0.03 - 0.41
11 - 16 years 0.18
0.05 - 0.47
0.12
0.03 - 0.24
0.16
0.05 - 0.24
0.13
0.06 - 0.28
0.17
0.06 - 0.22
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A raw data
B % of normal reference values
Figure 6.2 Plasma levels of AT in time
(A) Plasma levels in time of AT during the induction phase of the DCOG ALL-9 treatment
schedule. Observed raw data are given as means ± SEM.
(B) Means ± SEM per age group with data expressed as percentage of the normal reference
mean values per age group according to Monagle.9
The four week period of dexamethasone resulted in a hypercoagulable state on
day 29 due to upregulation of all coagulation parameters except fibrinogen, as
described earlier by Mall et al.18 The underlying mechanism of rising levels of
coagulation proteins with administration of corticosteroids remains to be
unraveled. Some insight comes from an animal study performed by Sevaljevic et
al.:19 they demonstrated that corticosteroids downregulate fibrinogen on a
transcriptional level.
In the present study, there were slight signs of thrombin generation but not of
fibrinolysis before the first dose of Paronal®. When dexamethasone doses were
tapered off from day 29 until day 43, treatment with four doses of 6,000 IU/m2 of
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Paronal® resulted in significant declining levels of nearly all coagulation proteins
measured, most prominently in the children aged 11 - 16 years. A similar pattern
was seen if data were expressed as percentages of age-related reference values.
Patterns of decline and recovery of the coagulation protein levels were parallel for
the three age groups. While pretreatment levels were reached by day 43 in the
younger children, recovery took longer in the oldest group. This effect might in
part be ascribed to different biological half-lives: F VII with a markedly short half-
life hardly demonstrated changes in time, and AT and protein S with half-lives of
about 60 hours tended to recover more slowly.
The activation markers F1+2 and D-dimer of thrombin generation and
fibrinolysis showed no consistent change in any of the age groups, only slightly
increased levels of TAT pointed to a persistent consumption of AT. Precursor B-ALL
and T-ALL demonstrated the same TAT levels in the different age groups, in
contrast to findings reported by Giordaneo et al.20 PAP levels of the oldest group
even declined to 58 g/L. The decrease in α2-AP and plasminogen in relation to the
parallel reduction in PAP levels points to a decrease in synthesis of α2-AP and
plasminogen during L-Asparaginase treatment in induction.7 A state of decreased
fibrinolytic potential remained. The highest risk of thrombosis seemed to present
itself at the end of Paronal treatment for the children aged 11 - 16 years, seeing
the more severe decline of anticoagulant and fibrinolytic parameters and the
slower recovery to normal levels compared to the younger children.
Monagle and colleagues demonstrated a reduced risk of thrombosis without
higher risk of bleeding in young children.9 The fibrinolytic state found in younger
children is comparable to that in adults.14 Only adolescents have been found to
have an impaired fibrinolytic response to venous occlusion when this was
compared to the fibrinolytic response of adults.21 Adolescents might therefore have
a higher risk of thrombosis. Then, interference of a disease like ALL and treatment
with steroids and L-Asparaginase might even increase the risk of thrombosis. As
we demonstrated here, the younger the child with ALL, the better he/she will be
protected from thrombo-embolic complications. Not only on account of
physiological mechanisms, but also because steroids and L-Asparaginase have
lesser impact on coagulation protein synthesis.
Extracellular amino acid depletion by L-Asparaginase influences the hepatic
synthesis of proteins.22 The influence of L-Asparaginase differed for the
biosynthesis of various coagulation proteins in our study: most protein levels
significantly decreased during L-Asparaginase treatment. Nevertheless, F V and F
VII levels stayed in the same normal range or even increased during
L-Asparaginase therapy. This might be due to increased production of F V by
reticulo-endothelial cells when production by hepatocytes is impaired. F VII has the
shortest half-life (4 - 7 hours) of the vitamin K dependent clotting factors. If
enough vitamin K becomes available, the production of F VII would probably be
adjusted immediately.
It is well known that different L-Asparaginase preparations have different
pharmacokinetic and pharmacodynamic properties.3,23,24 This is reflected by the
observed variability in coagulation parameters following therapy with different
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L-Asparaginase preparations, as we demonstrated in a randomized study.7 Nowak-
Gottl25-28 reported that children treated with Paronal show more changes than
those treated with an L-Asparaginase product such as Crasnitin. Regrettably, they
did not measure activation markers like PAP.29,30
L-Asparaginase alone may not be a major determinant in thrombo-embolism,
but other agents – especially steroids – were likely to modify the effects of L-
Asparaginase on hemostasis. Higher doses of steroids, as dictated by the DFCI-
protocols, lead to a much greater increase in levels of procoagulant factors and to
suppression of the fibrinolytic potential.31,32 These effects were thought to be
responsible for the high incidences of thrombo-embolic events in the DFCI-studies.
Not only higher doses of steroids but also the co-administration of L-Asparaginase
might raise the risk of thromboembolic disease.30 Monotherapy with L-Asparaginase
even leads to a more severe fall in coagulation proteins compared to concomitant
treatment with corticosteroids.29,30
There is discussion about the possible effects of hereditary prothrombotic risk
factors.33,34 Realizing that as such they have little importance in the development
of thrombo-embolic events in childhood, we think that in a hypercoagulable
situation due to antileukemic therapy with corticosteroids and L-Asparaginase they
indeed may be of influence. This would as well explain the low rate of symptomatic
thrombosis. We did not monitor these risk factors. Nevertheless, both the COALL
study – even using high dose L-Asparaginase (45.000 IU/m2) – and the PARKAA
study (prophylactic antithrombin replacement in kids with ALL on L-Asparaginase)
could not confirm a role of prothrombotic risk factors in the development of
thromboses during their treatment regimens.33,35
Recently, Weyrich et al. identified that mammalian target of rapamycin (mTOR)
inhibition induced platelet activation by thrombin and blocked clot retraction36 The
mTOR signaling pathway is a kinase, regulating cell growth. Possibly the inhibitory
effect of L-Asparaginase on mTOR37 leads as well to diminished clot retraction. This
may explain that the risk for thrombosis by L-Asparaginase is in part
counterbalanced by a diminished clot retraction.
CONCLUSION
We demonstrated that L-Asparaginase induced disturbances in coagulation and
fibrinolysis in children with newly diagnosed ALL are age specific. Twice weekly
doses of 6,000 IU/m2 of Paronal® administered after four weeks of dexamethasone
resulted in a higher risk of thrombosis for especially children aged 11 - 16 years.
ALL and effects of age on hemostasis
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Intrathecal triple therapy   
VCR i.v. 2mg/m2         
DNR i.v. 25mg/m2       
DEXA p.o. 6mg/m2
6 MP p.o. 50mg/m2
PARONAL i.v.  (6000 IU/m2)          (10.000 IU/m2)
I I I I I I I # I I I weeks
1 15 29 43 104 125 146 days
induction intensification
INTRODUCTION
L-Asparaginase is an important drug in the treatment of childhood acute
lymphoblastic leukemia (ALL). Its influence on the coagulation system has been
extensively studied.1 L-Asparaginase is an enzyme leading to serum depletion of
asparagine and glutamine. Consequently, protein synthesis is depressed leading to
coagulation protein deficiencies as a side effect of antileukemic treatment. The
effect on antithrombotic proteins might induce an increased risk for thrombosis,
while the effects on procoagulant proteins might increase the bleeding risk. L-
Asparaginase is usually given in combination with other chemotherapeutic drugs
among which especially corticosteroids may also influence the coagulation system.
Corticosteroids may induce hypofibrinogenemia potentially leading to bleeding, but
also increase the risk for thrombotic events by the induction of a hypofibrinolytic
state in combination with an increase in procoagulant factors.2 So, in general, it is
difficult to analyze which coagulation disorders in children with ALL are due to L-
Asparaginase and which are due to concomitant use of other drugs such as
corticosteroids. In this study, we analyzed the influence of both these drugs
(Paronal® and dexamethasone) in one group of children during two different parts
of ALL therapy.
METHODS
During induction, according to the DCOG (Dutch Childhood Oncology Group)-ALL-9
treatment schedule,3 24 children with high-risk ALL were treated with among
others dexamethasone from day 1 to day 29 followed by 15 days of tapering to
zero and four doses of Paronal® (6000 IU/m2) on days 29, 33, 36 and 40. During
the intensification phase of this protocol, the treatment included one weekly dose
of Paronal® (10000 IU/m2) during 9 weeks and 7 days of dexamethasone once
every 3 weeks during the same 9 weeks (Figure 7.1).
Figure 7.1 DCOG-ALL-9 treatment strategy
The induction and intensification part for only HR patients are given. Data are analyzed during
induction treatment (days 29 - 43) and during intensification treatment (days 104 - 134).
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Blood samples were collected immediately before each Paronal® infusion to
analyze procoagulant (fibrinogen, F II, F V, F VII, F IX, F X) and anticoagulant
factors (antithrombin, protein C, protein S) and parameters of thrombin generation
(F1+2, thrombin-antithrombin (TAT) complex) and fibrinolysis (α2-antiplasmin,
plasminogen, plasmin-α2 antiplasmin (PAP) complex, D-dimer).
RESULTS
After 4 weeks of dexamethasone on day 29, all procoagulant and anticoagulant
factors demonstrated high levels, and a hypofibrinogenemia was observed (Figures
7.2 and 7.3). The four doses of Paronal® and tapering of the dose of dexamethasone
(days 29 - 43) had the following effects on the procoagulant parameters:
 after an initial further decrease, fibrinogen levels stabilized at low levels or
increased slightly (Figure 7.2A);
 F V levels stabilized at high levels (Figure 7.2B);
 F II, IX and X normalized (Figure 7.2C);
 only F VII increased to supranormal levels (Figure 7.2C);
 the anticoagulant parameters (AT, protein C and S) and the fibrinolytic potential
(plasminogen and α2-antiplasmin) decreased significantly leading to a
hypercoagulable state (Figures 7.3A and B);
 as a result of decreased protein synthesis of plasminogen and α2-antiplasmin,
PAP too decreased significantly (Figure 7.3C);
 D-dimers demonstrated no changes, nor did TAT and F1+2, pointing to no signs
of increased fibrinolysis or thrombin generation (Figure 7.3C).
In the intensification phase, only 11 children could be analyzed up to the sixth
Paronal® infusion because at that point already 13 of 24 children had switched to
another L-Asparaginase product (Erwinase or PEG-asparaginase) because of
allergic reactions.
Interestingly, the effect of 1 weekly dose of L-Asparaginase with 1 week
dexamethasone every 3 weeks during intensification was completely different
compared to the effect during induction therapy, when dexamethasone was
administered daily and L-Asparaginase twice a week:
 The levels of fibrinogen decreased significantly in relation to the 7-day
administration of dexamethasone (P < 0.0001) (Figure 7.2A) and recovered
during weekly L-Asparaginase administration in the absence of dexamethasone.
 F V did not demonstrate any durable changes (Figure 7.2B).
 F II, VII, IX and X increased during 1-week dexamethasone treatment and
normalized afterwards during weekly administration of L-Asparaginase (Figure
7.2C).
 The levels of anticoagulant proteins and plasminogen and α2-antiplasmin hardly
changed during this treatment phase (Figures 7.3A and B).
 No signs of increased thrombin generation and of fibrinolysis were monitored
(Figure 7.3C).
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Figure 7.2 Plasma levels of procoagulant parameters during induction and
intensification treatment
Plasma levels of fibrinogen (A), factor V (B) and vitamin K-dependent clotting factors (II, VII, IX
and X) (C) during the induction and the intensification phase of the DCOG-ALL-9 treatment
schedule.
During induction, dexamethasone 6 mg/m2 was given for 4 weeks followed by tapering to zero in
15 days; Paronal® 6000 IU/m2 was given twice a week on days 29, 33, 36 and 40.
Intensification started at day 104 with Paronal® 10000 IU/m2weekly and with 1 week
dexamethasone 6 mg/m2 every 3 weeks.
The dexamethasone periods are drawn in gray, and arrows mark the Paronal® infusions. Data
are given as means with standard error of the means. Normal reference ranges are marked with
dotted lines. Differences between groups were calculated using one-way analysis of variance
with Bonferroni’s multiple comparison test to determine significance; P = 0.05 (two sided) was
considered the limit of significance. The sign * refers to significant differences for comparison
with previous measurements.
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Figure 7.3 Plasma levels of anticoagulant parameters, parameters of fibrinolysis
and of thrombin generation during induction and intensification
Plasma levels of anticoagulant proteins (antithrombin, protein C, free protein S and total protein
S (A) and of plasminogen and α2-antiplasmin (B). Data are given as means with standard error
of the means. Normal reference ranges are marked with dotted lines. For the activation markers
thrombin–antithrombin complex, F1+2, plasmin–antiplasmin complex and D-dimers, data are
given as medians with 25th and 75th percentiles (C). Normal reference ranges are shown
between brackets.
The dexamethasone periods are drawn in gray, and arrows mark the Paronal® infusions.
Differences between groups were calculated using one-way analysis of variance, with
Bonferroni’s multiple comparison test to determine significance; P = 0.05 (two sided) was
considered the limit of significance. The sign * refers to significant differences for comparison
with previous measurements.
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DISCUSSION
The half-life of Paronal® has been calculated to be 23.0 ± 2.5 h.4 It could be
speculated that once a week 10,000 IU/m2 of Paronal® would allow a recovery
from diminished protein synthesis by L-Asparaginase, while twice weekly 6,000
IU/m2 of Paronal® would lead to a cumulative effect with no time for recovery. But,
it could also be hypothesized that the higher dose of Paronal® in the intensification
phase would have led to prolonged inhibition of coagulation protein synthesis. Our
data however, showed that the schedule of Paronal® once a week 10000 IU/m2
resulted only in minor changes in coagulation proteins. One week of
dexamethasone every 3 weeks in the intensification phase only, led to a significant
decline in the level of fibrinogen (Figure 7.2A), which was followed a week later by
a significant increase, whereas the combination of Paronal® and dexamethasone,
as applied in induction, resulted in a severe decline in anticoagulant proteins and
in a decreased fibrinolytic potential.
Based on these data, a hypercoagulable state was diagnosed during induction
treatment only, whereas during intensification with a higher dose of Paronal® in a
weekly schedule combined with only 1 week of dexamethasone every 3 weeks, the
risk for thrombosis was minimal. We conclude that there is a crucial interaction
between L-Asparaginase and dexamethasone in maintaining the balance between
bleeding and thrombosis during therapy in childhood ALL and the effects on the
coagulation system depend on the specific schedule of administration of these
drugs.
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The main aim of this thesis was to study the pharmacokinetic and
pharmacodynamic effects of one dose of PEG-Asparaginase in children with acute
lymphoblastic leukemia (ALL) in order to get insight into the mechanisms of
resistance to this drug. The second aim was to study which disturbances occur in
coagulation parameters upon administration of L-Asparaginase.
PHARMACOKINETICS
Currently three preparations of L-Asparaginase are available. Each preparation, E.
coli derived L-Asparaginase (Paronal), its pegylated form (Oncaspar) and the
product from Erwinia chrysanthemi (Erwinase), have different half-lives1 and peak
activities.2 A L-Asparaginase activity of higher than 75 to 100 IU/L was shown to
deplete asparagine from the serum of humans during several days.2,3 Equivalent
doses for optimal efficacy have been determined for different L-Asparaginase
preparations, indicating that 1 dose of 1000-2500 IU/m2 PEG-Asparaginase in 2
weeks is as effective as 5000 - 10.000 IU/m2 E. coli L-Asparaginase every 3 days
and 10.000 - 25.000 IU/m2 Erwinia L-Asparaginase every 2 days in the same 2
weeks:2,4-8
The administration of 1000 IU/m2 PEG-Asparaginase i.v. as monotherapy given
upfront of regular chemotherapy in newly diagnosed children with ALL resulted into
an enzyme activity of  100 IU/L for at least 10 days (this thesis). This resulted in
a complete depletion of serum asparagine levels ( 0.2 M) in all patients.
However, no complete asparagine depletion in the cerebrospinal fluid (CSF)
occurred. Similar data were recently also found by Rizzari et al.9 who used the
same dose of PEG-Asparaginase during ALL induction therapy. In a randomized
study by Avramis et al. between native E coli L-Asparaginase (6000 IU/m2 3 times
per week) and PEG-Asparaginase (2500 IU/m2 once) in children with standard risk
ALL, CSF asparagine fell to median 0.6 M on day 28 in the PEG-Asparaginase
treated children and to 0.3 M in the native E. coli L-Asparaginase treated group.10
In relapsed ALL patients weekly 2500 IU/m2 PEG-Asparaginase resulted in low but
still detectable concentrations of CSF asparagine (0.2 - 3 M).11 Several groups
have reported that sufficient CSF asparagine depletion ( 0.2 M) was obtained
when plasma L-Asparaginase activity was  100 IU/L.6,12-14 Ahlke et al.6 and Rizzari
et al.14 demonstrate complete CSF asparagine depletion (<0.2 M) during 28 days
using either 10.000, 5000 or 2500 IU/m2 E. coli L-Asparaginase or 10.000 IU/m2
Erwinia L-Asparaginase in comparable treatment schedules: 8 times L-
Asparaginase at 3 day intervals. The activity of native L-Asparaginase in CSF is
only about 0.2% of the L-Asparaginase activity in plasma.15 Berg et al.16 found
1000 - 2500 IU/m2 PEG-Asparaginase (Oncaspar) once in 2 weeks
5000 - 10.000 IU/m2 E. coli L-Asparaginase (Paronal) once in 3 days for 2 weeks
10.000 - 25.000 IU/m2 Erwinia L-Asparaginase (Erwinase) once in 2 - 3 days for 2 weeks
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that 2500 IU/m2 PEG-Asparaginase depleted asparagine in serum whereas variable
amounts were still detected in the CSF of monkeys. The St Jude Children's
Research Hospital Memphis analyzed the three different L-Asparaginase
preparations at equivalent dosages in children with newly diagnosed ALL.17 Median
CSF asparagine concentrations were always higher in patients receiving PEG-
Asparaginase compared to those receiving native E. coli L-Asparaginase or
Erwinase. It is important to notice that this was not a randomized study. Children
received E. coli L-Asparaginase in induction, and PEG-Asparaginase in reinduction.
Patients who developed clinical allergy to L-Asparaginase were switched to
Erwinase.
Combining our and previous results implies that L-Asparaginase and PEG-
Asparaginase may not cross the blood-brain barrier. We assume that (PEG)-
Asparaginase depletes the plasma asparagine pool and that CSF asparagine is
primarily derived from the systemic asparagine pool.15 It has been suggested that
asparagine enters from the blood to the CSF against a concentration gradient18 or
that the central nervous system (CNS) may be capable of synthesizing asparagine
locally despite depletion of the plasma asparagine pool.19 It is not known whether
an incomplete depletion of asparagine in the CSF results in a suboptimal
antileukemic effect. However, depletion of asparagine in the CSF may be
advocated to prevent meningeal leukemia. Treatment schedules including (PEG)-
Asparaginase should therefore include additional CNS prophylactic therapy.
The importance of intensive L-Asparaginase therapy in pediatric ALL has been
underlined by randomized studies of the Dana Farber Cancer Institute (DFCI)20 and
the European Organization for Research and Treatment of Cancer (EORTC).21 Both
studies randomized between native E. coli L-Asparaginase and Erwinia L-
Asparaginase at identical dose schedules. The DFCI prescribed 25.000 IU/m2 once
weekly and the EORTC 10.000 IU/m2 every 3 days of both drugs respectively.
Erwinia L-Asparaginase was associated with less toxicity but a higher number of
induction failures and relapses including those occurring in the CNS. Patients
receiving Erwinia L-Asparaginase did not experience continuous asparagine
depletion in contrast to children treated with E. coli L-Asparaginase. This may be
explained by the fact that Erwinia L-Asparaginase has a shorter half-life than E.
coli L-Asparaginase.1 The data showed that a continuous depletion of asparagine is
associated with a better clinical outcome than intermittent depletion.
The duration of L-Asparaginase treatment is also of prognostic importance.20
Treatment with L-Asparaginase for more than 25 weeks during the reinduction
phase of therapy resulted in a lower relapse rate than when children tolerated
L-Asparaginase for a shorter period.22-24
Intensified extended use of L-Asparaginase therapy proved to compensate for
treatment reduction in a study published by Pession et al.: standard risk patients
treated according the BFM like treatment protocol received a treatment reduction
in the second part of reinduction and were randomized for inclusion of 10.000
IU/m2 native L-Asparaginase for 20 weeks.23 The group with intensified L-
Asparaginase treatment had a 10% rise in the 10-year disease free survival
compared to the group without L-Asparaginase intensification.
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Therefore, current and future treatment protocols of different study groups
worldwide include intensified L-Asparaginase therapy. Also, plasma L-Asparaginase
activity levels should be preferably monitored to adapt dosage in order to get
continuous and complete asparagine depletion.
PHARMACODYNAMICS AND MECHANISM OF L-ASPARAGINASE RESISTANCE
Cell line studies showed that in vitro resistance to L-Asparaginase was mediated by
upregulation of asparagine synthetase (AS) mRNA.25,26 In this thesis we found that
depletion of asparagine in plasma upon in vivo exposure to PEG-Asparaginase
induced the level of AS mRNA in leukemic cells of children with ALL. However, both
baseline and in vivo L-Asparaginase induced levels of AS mRNA did not differ
between clinically good, intermediate and poor responders to this drug. Previous
studies showed that TEL-AML1 positive ALL patients are in vitro more sensitive to
L-Asparaginase than TEL-AML1 negative patients.27,28 However, TEL-AML1 positive
cells expressed higher baseline levels of AS than their TEL-AML1 negative
counterparts and both subtypes of ALL did not differ in their capacity to upregulate
AS upon exposure to L-Asparaginase.29 In addition, the baseline AS mRNA level
and in vitro L-Asparaginase resistance did correlate in TEL-AML1 negative
precursor B-ALL but not in TEL-AML1 positive ALL.29 Taken together these studies
imply that AS levels or upregulation of these levels is not a major cause of
L-Asparaginase resistance in pediatric ALL. However, recently Su et al.
demonstrated in ALL cell lines that measurement of asparagine synthetase protein,
rather than mRNA, might serve as an indicator of L-Asparaginase sensitivity.30
Ongoing studies, using novel antibodies directed against asparagine synthetase,
are addressing this issue in pediatric ALL.
Since AS is only one enzyme out of a complex network of enzymes involved in
the metabolism of amino acids, we also studied whether changes occurred in the
intracellular amount of individual amino acids that may point to causes of
resistance to L-Asparaginase. We found that the intracellular amount of 20 amino
acids did not change upon in vivo L-Asparaginase treatment of children with ALL.
Remarkably, L-Asparaginase treatment did not affect the percent of apoptotic cells
in the peripheral blood, despite the fact that the leukemic cell count decreased
upon treatment. In contrast, in vitro exposure to L-Asparaginase resulted in an
intracellular depletion of asparagine and induced apoptosis as was detected by
phosphatidyl serine externalization (Annexin V-positivity), caspase 3 activation and
PARP inactivation (Ref 31 and this thesis). Therefore, the fact that no increase in
the percent of apoptotic cells was detected in vivo suggests that the apoptotic
leukemic cells are immediately removed from the blood circulation by
phagocytosis. The exposure of phosphatidyl serine at the outer cell membrane of
apoptotic cells is known to attract macrophages for that purpose.32
The fact that no changes in the intracellular amino acid levels were detected in
the remaining viable leukemic cells is intriguing. This suggests that the surviving
and hence resistant leukemic cells have used a rescue mechanism since
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L-Asparaginase clearly reduces intracellular asparagine levels when tested in vitro.
It has been shown that the microenvironment may supply asparagine and other
amino acids such as found by in vitro experiments using mesenchymal cells.33 It is
yet unknown whether this rescue mechanism also occurs in vivo. However, one
can envision that targeting ALL cells by reducing the expression of asparagine
synthetase of the bone marrow mesenchymal cells may improve the effectiveness
of L-Asparaginase therapy. Another explanation for the unchanged intracellular
amino acid levels is that leukemic cells may use glutamine, present in excess in
the plasma, as source for the amino moiety needed for de novo asparagine
synthesis. The observed upregulation of AS expression upon L-Asparaginase
exposure may then be used to re-synthesize sufficient asparagine using plasma
glutamine. In addition, other tissues (e.g. liver) may re-synthesize asparagine
although this will be immediately depleted again when L-Asparaginase plasma
levels are still high enough. In vitro, this rescue mechanism may not occur since
glutamine is being depleted from the culture medium due to an excess of
L-Asparaginase that is known to have some glutaminase activity too.34
Recent studies have shown that inhibition of glutamine synthetase potentiates
the toxicity of L-Asparaginase in cell lines derived from rhabdomyosarcoma and
osteosarcoma.35 In principle, inhibition of glutamine synthetase may also trigger
apoptosis of leukemic cells and may overcome L-Asparaginase resistance in
childhood ALL. However, glutamine starvation induces severe toxic effects on other
organ systems. Glutamine plays a crucial role as source of nitrogen and carbon for
DNA synthesis, as source of energy between organs, and is used for urea synthesis
in the liver, renal ammonia genesis and gluconeogenesis in both liver and kidney.
Therefore, it is unlikely that inhibition of glutamine synthesis will be effective
without side effects in a clinical setting.36
Of interest is that the baseline amino acid profile in ALL cells differed from
normal cells. Aspartic acid, glutamic acid and cystathionine levels were higher, and
taurine levels lower compared to normal peripheral blood mononuclear cells. In
addition, the total protein content of leukemic cells was ~2-fold lower than normal
lymphocytes. Proliferating leukemic cells may produce more aspartic acid and
glutamic acid due to a fast turnover of asparagine and glutamine.37 The high levels
of cystathionine and low levels of taurine might be related to a low activity of
-cystathionase in leukemic cells.38 This enzyme converts cystathionine into
cysteine (needed for taurine and glutathione production) and a lower cystathionase
activity interferes with the methionine-cysteine metabolism pathway by
accumulation of cystathionine. Glutathione plays an important role in the
detoxification of antioxidants and drugs in cells. Previous studies showed, however,
that the intracellular glutathione content is higher in leukemic cells than in
controls39 and that the glutathione level is not correlated with cellular resistance to
L-Asparaginase or other drugs in pediatric ALL.40,41 In this thesis we found that the
baseline levels of amino acids in leukemic cells do not differ between in vitro
L-Asparaginase sensitive and resistant cases nor between clinically good and poor
responders to L-Asparaginase. Therefore, the observed difference in amino acid
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levels between leukemic cells and normal lymphocytes presumably reflects a
difference in metabolic activity and/or cell type.
Genome wide approaches have been used to identify genes and gene
expression profiles associated with drug resistance of leukemic cells.42,43 Gene
expression patterns were identified that discriminated ALL cells resistant to single
antileukemic drugs like L-Asparaginase. Over-expression of genes encoding
ribosomal proteins was associated with L-Asparaginase resistance42 and discordant
sensitivity to vincristine.43 L-Asparaginase has been shown to inhibit the
mammalian target of rapamycin (mTOR) signaling pathway that is involved in
ribosomal protein synthesis in leukemic cells.44 Although ribosomal protein
inhibitors might theoretically sensitize leukemic cells to L-Asparaginase they might
on the other hand increase vincristine resistance due to the observed discordant
response to these two drugs.43 Ongoing clinical trials indicate that mTOR inhibitors
may have clinical potential as anticancer agents.45 However, the interference
between mTOR pathway members is highly complex and therefore also the
specificity of mTOR inhibitors is low.46 Interestingly, not only asparagine but also
glutamine starvation targets the mTOR signaling pathway suggesting that L-
Asparaginase may inhibit this mTOR pathway also through its glutaminase
activity.44
Response to L-Asparaginase in childhood ALL
In this thesis we showed that the in vivo response to a single dose of 1000 IU/m2
PEG-Asparaginase in children with newly diagnosed ALL is an independent
prognostic marker for long-term clinical outcome.47 Previous studies showed that
in vitro resistance to L-Asparaginase is linked to an unfavorable prognosis in
pediatric ALL.48-50 Not surprisingly, in vivo response to PEG-Asparaginase
correlated well with the in vitro sensitivity to L-Asparaginase (this thesis).
Favorable genotypes, e.g. TEL-AML1 positive ALL and hyperdiploid ALL, are
characterized by a high in vitro sensitivity to L-Asparaginase and by a good in vivo
response to PEG-Asparaginase. Unfavorable subtypes like T-ALL and BCR-
ABL/t(9;22) precursor B-ALL demonstrated a relative in vivo resistance to PEG-
Asparaginase (this thesis). T-ALL cells were also shown to be relatively resistant to
L-Asparaginase compared to B-lineage ALL.51 The in vivo response or the in vitro
resistance to PEG-Asparaginase might be used to stratify patients for risk-adapted
L-Asparaginase dosage and administration schedules.
HEMOSTASIS
One of the main side effects of L-Asparaginase therapy are thrombo-embolic
complications. These complications seem to be caused by a relationship between
asparagine depletion and reduced protein synthesis in the liver. Consumption
coagulopathy or a direct enzymatic breakdown of coagulation proteins52 do not
explain these complications.
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At the time of diagnosis of ALL we monitored an increased thrombin generation
and disseminated intravascular coagulation. This is in concordance with the
findings of Mitchell et al.53 and Uszinsky et al.54 Cancer cells may directly
synthesize procoagulant molecules and inflammatory cytokines. Malignant cells can
interact with vascular endothelial cells to produce a prothrombotic state by
comprising their anticoagulant properties and increasing the release of
procoagulant proteins like F VIII from endothelial stores.55 The window therapy
with 1000 IU/m2 PEG-Asparaginase resulted in a sharp decrease of all coagulation
parameters due to protein synthesis inhibition by L-Asparaginase (this thesis).
Native E coli L-Asparaginase53 compared to the pegylated L-Asparaginase used in
our studies yielded comparable coagulation disturbances as a risk factor for
thrombosis.
Most of the thrombotic events occur during induction therapy.56 The rate of
thrombosis was 5.2% in a meta-analysis of 1752 children with ALL.57 We analyzed
two induction schedules: in the DCOG-ALL-7 study 10.000 IU/m2 native E. coli L-
Asparaginase (Crasnitin) or Erwinia L-Asparaginase (Erwinase) was given twice a
week after 18 days of prednisone whereas in the DCOG-ALL-9 study 6000 IU/m2
Paronal was administered twice a week after 28 days of dexamethasone
treatment. The different half-lives of these three L-Asparaginase products resulted
in different effects on hemostasis: Erwinase with a half-life of only 7 hours
demonstrated the least effects on coagulation protein synthesis, whereas
Crasnitin administered in the same dose with a half-life of 18 hours and Paronal
with a half-life of 23 hours showed a significant decline in coagulation protein
synthesis. Of all coagulation proteins measured only factor V demonstrated no
severe impaired production. The fact that factor V is also produced by
reticuloendothelial cells may counteract the effect of impaired production in the
liver by hepatocytes due to L-Asparaginase therapy.58 Randomized studies of the
DFCI and the EORTC confirmed that native L-Asparaginase led to an increased risk
for thrombo-embolic events compared to Erwinase (but a decreased risk of
leukemic relapse) if administered in the same dose schedule.20,21
The period of prednisone or dexamethasone treatment before the first infusion
with L-Asparaginase differed between the two induction schedules we studied.
More upregulation of coagulation proteins was noticed in the ALL-9-treatment
schedule after 4 weeks of dexamethasone, compared to the ALL-7 schedule after
18 days of treatment with prednisone. Nevertheless, the tapering of corticosteroid
treatment together with the twice-weekly administration of L-Asparaginase
resulted in a hypercoagulable state in both schedules mainly due to a decrease in
antithrombotic proteins and proteins involved in fibrinolysis. The interaction
between L-Asparaginase and corticosteroids is crucial in disturbing the balance
between the risk on bleeding and thrombosis. A multi-center prospective study of
300 patients of the German BFM and 120 patients of the German COALL study
group confirmed these data: venous thromboembolism occurred in 10% of
patients treated according to the BFM schedule during induction and in 1.7%
during re-induction (total 11.7%), but thrombotic events occurred in only 0.8%
during induction and in 1.7% during re-induction in the children treated according
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to the COALL protocol (total 2.5%).59 The difference in thrombotic incidence was
due to differences in dose-schedule of steroids and L-Asparaginase. In BFM
protocols L-Asparaginase is administered from early induction concurrent with
steroids, like in the Dutch protocols. In the COALL regime L-Asparaginase is
administered during consolidation without corticosteroids. One week only of
dexamethasone every 3 weeks in combination with weekly L-Asparaginase during
consolidation also caused much less hypercoagulability than the combination of bi-
weekly L-Asparaginase with continuous dexamethasone treatment (this thesis).
It is known that older children are at higher risk for thrombo-embolic
events.20,22,60 We provided evidence that older children demonstrate more
inhibition in coagulation protein synthesis compared to younger children after
L-Asparaginase therapy (this thesis). These findings can explain why the risk of
thrombosis or bleeding after L-Asparaginase therapy is age-dependent.61-63
The question remains why a relatively low rate of symptomatic thrombosis of
5% during ALL induction treatment is found57 if we take notice of all coagulation
disturbances found. Children with hereditary prothrombotic risk factors, i.e. factor
V Leiden, the prothrombin variant, the MTHFR mutation, deficiencies of protein C,
S or antithrombin are not at a high risk to develop thrombosis.64 However, the
combination of one of these risk factors together with a hypercoagulable situation
due to antileukemic therapy with corticosteroids and L-Asparaginase may induce
thrombotic events.59,65 However, the COALL study, using high dose L-Asparaginase
(45.000 IU/m2) as well as the PARKAA study (prophylactic antithrombin
replacement in kids with ALL on L-Asparaginase) could not confirm a role of
prothrombotic risk factors in the development of thromboses during their
treatment regimens.65,66 Notably, the main goal of the PARKAA study was to
determine if prophylactic treatment with antithrombin would reduce the incidence
in thrombotic events. However, this appeared not to be the case.
The effect of L-Asparaginase on hemostatic protein synthesis was linked to
depletion of free asparagine and glutamine in the liver.58,67 Bushman proved that
L-Asparaginase affected plasma levels of antithrombin by interfering with
translation and/or secretion of the antithrombin protein in liver cells.67 As
coagulation proteins are mainly produced by the liver, disturbances in the
synthesis of these proteins due to amino acid starvation are thus believed to be
due to an effect of L-Asparaginase on protein synthesis in the liver.
The mTOR signaling pathway regulates cell growth by controling translation.46
Rapamycin and L-Asparaginase inhibit the mTOR pathway, thereby interfering with
the synthesis of ribosomal proteins.68 Weyrich et al. recently identified that
rapamycin inhibits platelet activation induced by thrombin and blocks clot
retraction.69 Possibly the inhibitory effect of L-Asparaginase on mTOR also
diminishes the clot retraction. This may explain that the risk for thrombosis is in
part counterbalanced by a diminished clot retraction, and thus accounts for the
relatively low rate of symptomatic thrombosis during ALL induction treatment. To
better understand the process of thrombin generation and fibrinolysis during
L-Asparaginase therapy, further evaluation of these processes with newly
developed techniques like modern thromboelastography might be considered.
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In conclusion, the type and the dose of L-Asparaginase, the timing of
concomitant corticosteroid therapy and the age of the patient, determine the effect
of L-Asparaginase on the coagulation system. These factors should be taken into
account when new treatment regimens are developed for children with ALL. Older
children with one or more inherited prothrombotic defects receiving a combination
of L-Asparaginase with concomitant corticosteroid treatment in induction therapy
appear to be at highest risk of thrombosis. In our opinion, only for these children
the use of low molecular weight heparins70,71 should be investigated in order to
decrease the risk of thrombotic complications.
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SUMMARY
Acute lymphoblastic leukemia (ALL) is the most common cancer in children and
adolescents. Treatment outcome has improved impressively through the years. In
the 1990's the five-year event free survival rates generally ranged from 70% to
85%. Risk factors for treatment failure are age and leukocyte count at diagnosis,
immunophenotype, genotype and early response to chemotherapy. Different clinical
outcomes associated with various subtypes of ALL are partly attributed to drug
sensitivity or resistance of leukemic cells due to differences in molecular
pharmacodynamics. Drug resistance is an important cause of treatment failure.
Therefore, a better understanding of the responsible mechanisms of resistance to
chemotherapy in ALL is needed.
Together with vincristine, a corticosteroid and sometimes an anthracycline,
L-Asparaginase forms the backbone of induction treatment for childhood ALL.
L-Asparaginase is also an important component of reinduction and intensification
phases of combination chemotherapy. Intensified L-Asparaginase therapy improved
treatment outcome compared to that achieved with less intensive L-Asparaginase
therapy.
PART I
Part I of this thesis focuses on the pharmacokinetics and pharmacodynamics of
L-Asparaginase. L-Asparaginase hydrolyzes asparagine into aspartic acid and
ammonia, which reduces the availability of asparagine for protein synthesis.
Resistance to L-Asparaginase has been associated with upregulation of asparagine
synthetase (AS) mRNA expression in cell line studies, but inconsistent data were
found in primary patient samples. In chapter two we investigated whether baseline
levels of AS mRNA before start of treatment and/or PEG-Asparaginase-induced
changes in AS mRNA expression in leukemic cells were associated with the clinical
response to PEG-Asparaginase given as monotherapy upfront combination
chemotherapy in children with ALL. The baseline AS expression levels were in the
same range as in lymphocytes of healthy controls. In all patients upregulation of AS
mRNA in the leukemic cells occurred within 24 hours after in vivo PEG-Asparaginase
exposure and thereafter the expression levels did not further change. However, the
level of upregulation of AS was not associated with a poor clinical response to PEG-
Asparaginase. In addition, baseline and L-Asparaginase induced changes in AS mRNA
expression did not differ between in vitro L-Asparaginase resistant T and L-
Asparaginase sensitive c/preB ALL cases. Moreover, TEL-AML1 rearranged and
hyperdiploid cases did not show an impaired in vivo upregulation of AS that might
have explained their high in vitro sensitivity to L-Asparaginase. Therefore, the AS
upregulation which is a consequence of amino acid deprivation by L-Asparaginase, is
not the key-factor explaining resistance to L-Asparaginase in pediatric ALL.
In chapter three we studied mechanisms of L-Asparaginase resistance other
than AS mRNA upregulation by determining several apoptotic features and both
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serum and intracellular amino acid levels. Remarkably, the percentage of apoptotic
cells and apoptotic read-out markers in leukemic cells did not change in vivo after
administration of PEG-Asparaginase. Also in vivo no changes were observed in the
levels of intracellular amino acids, including asparagine, aspartic acid, glutamine and
glutamic acid, whereas these amino acids were affected in the serum of these
patients. In contrast, in vitro exposure of patients' leukemic cells to L-Asparaginase
induced apoptosis and affected the intracellular levels of amino acids. These data
suggest that changes in apoptotic features and in intracellular amino acid levels can
not be detected in freshly obtained patients' samples during treatment, since these
affected cells are presumably quickly eliminated from the peripheral blood. Hence,
only cells survive that do have an unchanged amino acid composition.
The intracellular levels of aspartic and glutamic acid were higher compared to
normal cells. This might be related to a fast turnover of asparagine and glutamine in
the proliferating leukemic blasts. The baseline intracellular levels of cystathionine
were higher and taurine levels were lower in leukemic cells at diagnosis compared to
normal cells. This may point to a low activity of -cystathionase in leukemic cells
resulting in an abnormal methionine-cysteine pathway, that reduces the conversion
of cystathionine into taurine.
In vivo responsiveness to PEG-Asparaginase was monitored by analyzing the
decrease in leukemic cells during a therapeutic window with this drug before start of
combination chemotherapy. We found that children with unfavorable
immunophenotypic or genotypic characteristics (T-ALL and BCR-ABL positive ALL)
were in vivo more resistant to PEG-Asparaginase than children with a favorable
genotype (TEL-AML1 positive and hyperdiploid ALL). We also showed that in vitro
sensitivity to L-Asparaginase was related to a good clinical response to PEG-
Asparaginase. The clinical response to PEG-Asparaginase as well as the in vitro
sensitivity to L-Asparaginase are predictive for long-term clinical outcome in pediatric
ALL. One additional dose of PEG-Asparaginase did not increase clinical toxicity with
regard to the allergic reactions to next L-Asparaginase infusions nor with regard to
changes in coagulation parameters or the incidence of thrombosis later on during
therapy.
The pharmacokinetics of PEG-Asparaginase are not well characterized in
cerebrospinal fluid (CSF). In chapter four we analyzed the kinetics of one dose of
PEG-Asparaginase in the CSF. Despite the fact that a dose of 1000 IU/m2 PEG-
Asparaginase resulted in plasma activity levels > 100 IU/L and thus, as expected,
plasma asparagine levels < 0.2 M for more than 10 days, asparagine was still
detectable in the CSF. Thus, PEG-Asparaginase at this dose could not fully deplete
asparagine in the CSF.
Chapter 9
128
PART II
The toxic effect of L-Asparaginase therapy is related to decreased protein synthesis.
Important side effects of L-Asparaginase are disturbances in the coagulation system.
In part II the results of studies focusing on these side effects are described.
Changes observed in coagulation parameters in patients treated with L-
Asparaginase have not been consistent in different series of patients, which can be
related to differences in age, genetic predisposition for hypercoagulability, co-
administration of other chemotherapy and the product of L-Asparaginase used. In
chapter five we describe a randomized study in childhood ALL, in which native E. coli
L-Asparaginase (Crasnitin®, Bayer, Leverkusen, Germany) is compared to L-
Asparaginase derived from Erwinia chrysanthemi (Erwinase®, Porton Products,
London, United Kingdom). Initial treatment with prednisone during ALL induction gave
rise to increased thrombin generation as was demonstrated by increased F1+2
(prothrombin fragment 1+2) and TAT (thrombin-antithrombin complex) levels.
Addition of L-Asparaginase to the induction therapy lead to a decreased fibrinolytic
potential due to decreased levels of alpha2-antiplasmin and plasminogen in children
treated with E. coli L-Asparaginase but not in children treated with Erwinase. Thus, the
use of prednisone in combination with E. coli L-Asparaginase (Crasnitin, Bayer) but
not Erwinase led to an increased risk for thrombosis.
Older children seem to be at higher risk for thrombo-embolic events during
L-Asparaginase therapy than younger children. However, till date no studies on age-
related changes in coagulation parameters due to L-Asparaginase have been
performed. In chapter six we report on the effect of age on changes in coagulation
and fibrinolysis in children with newly diagnosed ALL during induction therapy, which
were treated according to the DCOG-ALL-9 treatment schedule. The effects of a four-
week period of dexamethasone resulted in a hypercoagulable state due to
upregulation of all coagulation parameters except fibrinogen. Thereafter, during
tapering of dexamethasone and during administration of L-Asparaginase it appears
that larger effects on the levels of coagulation proteins were found in older children.
All anticoagulant proteins (AT, protein C and protein S) declined significantly, the
more so in children aged 11 - 16 years. The fibrinolytic potential was decreased most
in the oldest group of children and recovery to normal levels of alpha2-antiplasmin
and plasminogen took longer in older children compared to younger children. In
conclusion, the sum of changes in coagulation proteins induced by L-Asparaginase
contributes to the increased risk for thrombosis in children between 11-16 years of
age.
In addition to the clinical and biological effects of one in vivo systemic dose of
PEG-Asparaginase as described in chapter four, we also measured the effects of
monotherapy with one dose of PEG-Asparaginase on the coagulation system in this
chapter. At diagnosis data pointed to enhanced thrombin generation. Consumption
coagulopathy was monitored in 17 patients. Giordano et al. suggested that T ALL had
higher TAT (thrombin-antithrombin complex) levels than precursor B at diagnosis. We
could not confirm this: both precursor B and T ALL patients demonstrated equally
increased levels at diagnosis. Uszinsky et al. suggested that about 70% of children
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with ALL had high TAT levels at diagnosis related to the disease. We analyzed 38
children at diagnosis and found 35 (92%) patients with increased TAT levels at
diagnosis.
A profound decrease in nearly all coagulation factors was observed five days after
PEG-Asparaginase administration, with a decrease in thrombin generation and in
fibrinolytic potential. No clinical thrombo-embolic complications were seen in this
period.
L-Asparaginase is mostly used in combination with other drugs, like corticosteroids.
Chapter seven reports on changes in coagulation parameters in two different
combination chemotherapy schedules in a group of high-risk ALL patients. During
induction therapy according to the DCOG-ALL-9 protocol dexamethasone was
administered daily for 4 weeks followed by 2 weeks of tapering during which native
L-Asparaginase was given twice a week; during intensification one weekly dose of
the same native L-Asparaginase was combined with one week dexamethasone every
three weeks. During induction the same observations were made as described in
chapter six, i.e. patients had an increased risk for thrombosis during the induction
phase of combination chemotherapy. However, during intensification the levels of the
coagulation proteins did not significantly change. Only fibrinogen changed
significantly upon administration of dexamethasone during 7 days. One week of
dexamethasone therapy every 3 weeks combined with weekly infusions of Paronal
caused much less hypercoagulability compared to weekly Paronal after a prolonged
period of dexamethasone and tapering dexamethasone to zero. We concluded that
concomitant treatment of L-Asparaginase and dexamethasone interferes with the
balance between bleeding and thrombosis during L-Asparaginase therapy in
childhood ALL.
PART III
Finally, our findings presented in this thesis are put in perspective and possible
directions for the future are discussed in chapter 8.
Chapter 9
130
SAMENVATTING
Algemeen
Acute lymfatische leukemie (ALL) is de meest voorkomende vorm van kanker op de
kinderleeftijd. In Nederland wordt elk jaar bij 120 kinderen deze diagnose gesteld.
De behandeling bestaat uit chemotherapie gedurende twee jaar. De kans op
genezing is de laatste decennia aanzienlijk toegenomen. Met behulp van
combinatiechemotherapie geneest 80 - 85%. Toch geneest dus nog een aanzienlijk
percentage niet. Hierdoor blijft recidief-ALL van alle vormen van kinderkanker de
belangrijkste doodsoorzaak. Risicofactoren voor het terugkomen van de ziekte zijn:
de leeftijd, het aantal witte bloedcellen (leukemiecellen) bij diagnose, het
immunophenotype (het differentiatie-stadium van de leukemiecel), het genotype (de
aanwezigheid van bepaalde chromosomale afwijkingen in de leukemiecel) en de
eerste reactie op de ingestelde behandeling. Het verschil in behandelingsresultaten
van alle subtypes van ALL wordt voor een deel toegeschreven aan de gevoeligheid of
ongevoeligheid van leukemiecellen voor de medicijnen.
L-Asparaginase
De behandeling van ALL is vastgelegd in protocollen. Elk type leukemie wordt
tegenwoordig volgens een eigen protocol behandeld.
De inductietherapie van een behandelingsprotocol voor ALL is erop gericht om in
4 tot 6 weken een complete morfologische remissie te bewerkstelligen. L-
Asparaginase neemt naast vincristine, een corticosteroid en soms een anthracycline,
een zeer belangrijke plaats in bij de inductiebehandeling. Na de inductie volgt een
behandeling gericht op het voorkomen van uitbreiden van de leukemie naar de
hersenen, vervolgens een re-inductie- en/of een intensificatie fase. Uiteindelijk volgt
een onderhoudsbehandeling, waardoor de totale behandeling 2 jaar duurt.
Toevoegen van L-Asparaginase aan de inductie-, re-inductie- en aan een eventuele
intensificatie fase is in de behandeling van grote waarde gebleken. Een meer
intensieve behandeling met L-Asparaginase verbeterde de uiteindelijke kans op
genezing.
In hoofdstuk 1 beschrijven we de ontwikkeling van L-Asparaginase, via een bij
toeval ontdekt geneesmiddel tot een onmisbaar product in de behandeling van ALL
bij kinderen. Elk geneesmiddel zal zich op een bepaalde manier in het menselijk
lichaam gedragen. Pharmacokinetiek is het bestuderen van de opname, de verdeling,
het metabolisme en de uitscheiding van medicijnen in het menselijk lichaam.
Pharmacodynamiek beschrijft de relatie tussen de pharmacokinetiek van bepaalde
medicijnen en hun pharmacologische effect op de ziekte. Verschillende medicijnen,
dus ook de verschillende vormen van L-Asparaginase, zullen een verschil in
pharmacodynamiek vertonen. De gevoeligheid (de sensitiviteit) en de ongevoeligheid
(de resistentie) voor medicijnen kunnen door verschillen in pharmacodynamiek
worden bepaald. Resistentie tegen geneesmiddelen tegen leukemie is een
belangrijke oorzaak van therapiefalen. Daarom is een beter begrip noodzakelijk van
het mechanisme dat eventuele resistentie tegen L-Asparaginase veroorzaakt.
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DEEL I
Pharmacokinetiek en pharmacodynamiek van L-Asparaginase
Deel I van dit proefschrift is gericht op de pharmacokinetiek en de
pharmacodynamiek van L-Asparaginase. L-Asparaginase is een enzym dat
asparagine omzet in aspartaat en ammoniak. Dit leidt tot een tekort aan het
aminozuur asparagine waardoor er minder asparagine beschikbaar komt voor de
aanmaak van eiwitten. Waarschijnlijk beschikken juist leukemiecellen niet over het
enzym asparagine-synthetase dat de vorming van asparagine weer stimuleert, om
dit tekort aan asparagine op te vangen. Het tekort aan asparagine zal leiden tot
afsterven van de leukemiecellen. Laboratorium studies op gekweekte cellijnen (in
vitro-studies) wezen erop dat leukemische cellijnen die ongevoelig waren voor L-
Asparaginase wel asparagine-synthetase konden produceren. Hierdoor werd dus de
antileukemische werking van L-Asparaginase tenietgedaan. Bij leukemiecellen van
patiënten was hier tot op heden geen onderzoek naar gedaan.
In hoofdstuk 2 beschrijven wij onze studie naar de concentraties mRNA van
asparagine-synthetase bij diagnose van de leukemie, dus voordat de behandeling is
begonnen, en na behandeling met 1 gift PEG-Asparaginase. Wij onderzochten of de
veranderingen in de expressie van het mRNA van asparagine-synthetase gekoppeld
waren aan de klinische respons op PEG-Asparaginase. De asparagine-synthetase
expressie was bij diagnose even hoog in ALL-cellen als in gezonde witte bloedcellen.
Bij alle kinderen met ALL maten wij binnen 24 uur na de behandeling met PEG-
Asparaginase een duidelijke 'opregulatie' van het asparagine-synthetase. Deze
toegenomen concentraties bleven in daarop volgende dagen gelijk. Opvallend was
dat de mate van opregulatie niet gecorreleerd was aan een slechtere klinische reactie
op PEG-Asparaginase. Bovendien verschilde de expressie van asparagine-synthetase
bij diagnose en na behandeling met PEG-Asparaginase niet tussen T-ALL cellen die in
vitro (buiten het lichaam getest) voor L-Asparaginase relatief ongevoelig zijn en de
voor L-Asparaginase gevoelige voorloper B-ALL-cellen. Kinderen met de
chromosomale afwijking TEL-AML1 of met hyperdiploïdie (meer dan 50
chromosomen) in hun leukemiecellen vertoonden geen lagere waardes van de
asparagine-synthetase expressie, die hun hogere gevoeligheid voor L-Asparaginase
zou hebben kunnen verklaren. Kennelijk is opregulatie van asparagine-synthetase,
die optreedt als reactie op het tekort aan asparagine dat door L-Asparaginase wordt
veroorzaakt, dus in vivo, niet een belangrijke oorzaak van resistentie tegen het
middel L-Asparaginase.
In hoofdstuk 3 zochten we naar andere mechanismen die resistentie tegen
L-Asparaginase zouden kunnen verklaren. We keken naar het fenomeen apoptose
(gereguleerde celdood) en we onderzochten het effect van L-Asparaginase op de
aminozuren in de leukemiecellen en in het bloed. Vreemd genoeg veranderden de
apoptose-parameters die wij testten niet wanneer de kinderen waren behandeld met
PEG-Asparaginase, terwijl er klinisch toch een duidelijke afname was van het aantal
leukemiecellen. Ook de concentraties van aminozuren in de leukemiecellen bleven
hetzelfde, in tegenstelling tot de waardes in het bloed van de patiënten. Als we
daarentegen dezelfde leukemiecellen buiten het lichaam (in vitro) bloot stelden aan
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L-Asparaginase konden we wel apoptose meten en ook veranderingen in de
intracellulaire aminozuren registreren. Dit betekent dus dat we veranderingen in
apoptose en in de concentraties van aminozuren in de leukemie cellen in vivo niet
kunnen vastleggen. Kennelijk worden leukemiecellen die aangepakt zijn door
L-Asparaginase onmiddellijk uit de bloedcirculatie verwijderd. Alleen cellen met een
normale aminozuursamenstelling kunnen overleven.
Bij diagnose waren de concentraties van aspartaat en glutamaat in de
leukemiecellen hoger dan in gezonde witte bloedcellen. Dit kan misschien verklaard
worden door het feit dat leukemiecellen zich snel delen en daardoor een hoge
turnover van asparagine en glutamine in aspartaat en glutamaat hebben. Ook het
cystathionine-gehalte was bij diagnose hoger, terwijl taurine juist een lagere
concentratie had ten opzichte van normale cellen. Dit wijst waarschijnlijk op een lage
activiteit van het enzym -cystathionase in leukemiecellen, waardoor minder
cystathionine in taurine kan worden omgezet.
De in vivo respons van de leukemie voor PEG-Asparaginase konden we bepalen
aan de hand van de afname van het aantal leukemische cellen tijdens de 5 dagen
tussen de gift PEG-Asparaginase en de start van de verdere chemotherapie. Kinderen
met een ongunstig immunophenotype of genotype (zoals T-cel-leukemie en
Philadelphia chromosoom positieve leukemie) waren in vivo meer resistent voor PEG-
Asparaginase dan kinderen met een gunstig genotype (zoals TEL-AML1 positieve
leukemie of hyperdiploïdie). Bovendien vonden we dat die leukemie die in vitro
gevoelig was voor L-Asparaginase ook een goede klinische respons in vivo op PEG-
Asparaginase vertoonde. De klinische respons op PEG-Asparaginase bleek net zoals
de in vitro gevoeligheid voor L-Asparaginase de overlevingskans op lange termijn te
kunnen voorspellen.
Deze ene extra gift PEG-Asparaginase zorgde later in de behandeling niet voor
extra toxiciteit. Het aantal allergische reacties op L-Asparaginase bij volgende giften
van dit medicijn was niet verhoogd. Ook traden er niet meer complicaties, zoals
bloedingen of tromboses, op door veranderingen in de stolling die veroorzaakt
kunnen worden door L-Asparaginase.
De pharmacokinetiek van PEG-Asparaginase in de hersenvloeistof (liquor) is niet
goed bekend. In hoofdstuk 4 onderzochten we de kinetiek van 1 dosis PEG-
Asparaginase in de liquor. Met 1 gift PEG-Asparaginase bereikten we, zoals verwacht,
gedurende 10 dagen een L-Asparaginase concentratie in het bloed van meer dan 100
IU/L en hiermee een volledige depletie van asparagine (< 0.2 M). Toch konden we
in de liquor nog steeds asparagine aantonen. Deze dosering PEG-Asparaginase leidde
dus niet tot een volledige depletie van asparagine in de hersenvloeistof.
DEEL II
L-Asparaginase en de bloedstolling
De effectiviteit van L-Asparaginase berust op het teweeg brengen van een compleet
tekort aan asparagine in bloed en dus in de leukemiecellen. Dit tekort aan
asparagine is echter ook de oorzaak van bijwerkingen van L-Asparaginase. Een
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verminderde eiwitaanmaak door een tekort aan asparagine in de lever veroorzaakt
stoornissen in de aanmaak van stollingseiwitten. In deel II richten we ons op deze
bijwerking van L-Asparaginase.
De veranderingen die door L-Asparaginase in de bloedstolling ontstaan zijn
afhankelijk van, de leeftijd van de patiënt, de aanleg voor trombose, andere
tegelijkertijd toegediende medicatie en het soort L-Asparaginase dat wordt
voorgeschreven. In hoofdstuk 5 beschrijven wij een gerandomiseerde studie,
waarin kinderen met ALL volgens een zelfde protocol werden behandeld, met als
enige verschil Crasnitin (L-Asparaginase geproduceerd uit een E. coli-stam) in de
ene groep en Erwinase (een L-Asparaginase gemaakt van Erwinia chrysanthemi) in
de andere groep. De eerste fase van de inductiebehandeling met o.a. prednison
leidde tot toegenomen stolselaanmaak (thrombinegeneratie). Het toevoegen van L-
Asparaginase aan de behandeling veroorzaakte alleen in de groep behandeld met
Crasnitin een forse afname van de stollingseiwitten die nodig zijn om een stolsel
weer af te breken, de fibrinolyse. Een toegenomen thrombinegeneratie tezamen met
een afgenomen potentie voor fibrinolyse leidt tot een verhoogd risico op trombose.
De oorzaak van het feit dat dit alleen gebeurde in de groep die met prednison en
Crasnitin was behandeld en niet in de groep die met prednison en Erwinase was
behandeld, bleek te liggen in verschillen in de pharmacokinetiek van deze twee L-
Asparaginases.
Uit ervaring weten we dat oudere kinderen vaker een trombose krijgen tijdens de
inductiebehandeling van ALL dan jongere kinderen. Tot nu toe was er geen
onderzoek gedaan naar het effect van L-Asparaginase op stollingseiwitten bij
kinderen van verschillende leeftijdscategorieën. In hoofdstuk 6 hebben we gekeken
of de leeftijd van kinderen met ALL van invloed was op het effect van de L-
Asparaginase-behandeling op de stolselaanmaak en de stolselafbraak. Bij alle
kinderen leidde 4 weken behandeling in de inductie met dexamethason tot een zeer
actieve thrombinegeneratie doordat bijna alle stollingsfactoren werden opgejaagd
door corticosteroïden. Tijdens het afbouwen van de dexamethason en het
tegelijkertijd starten van de behandeling met L-Asparaginase daalden alle
stollingsparameters fors, door een verminderde eiwitaanmaak bij het tekort aan
asparagine dat L-Asparaginase had bewerkstelligd. De grootste daling in de
stollingseiwitten die tegen trombose beschermen en van de eiwitten die een gemaakt
stolsel moeten afbreken, trad op bij kinderen ouder dan 11 jaar. Bovendien duurde
ook het herstel naar normale waardes langer bij de oudere kinderen dan bij jongere.
Deze leeftijdsafhankelijke verschillen in door steroïden en L-Asparaginase
veroorzaakte veranderingen in de bloedstolling verklaren voor een deel het
verhoogde risico op trombose tijdens de inductiebehandeling van ALL bij de oudere
kinderen.
In hoofdstuk 4 analyseerden we het effect van 1 dosis PEG-Asparaginase als
monotherapie op de bloedstolling. Bij diagnose van ALL vertoonden de kinderen een
geactiveerde stolling, zowel een toegenomen thrombinegeneratie als ook tekenen
van verhoogde stolselafbraak. Dit is een bekend gegeven bij kwaadaardige
aandoeningen. Deze afwijkingen bleken in onze studie niet gecorreleerd aan een
bepaald type leukemie, zoals anderen wel eens beschreven hadden. De concentratie
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van bijna alle stollingseiwitten nam fors af na 1 gift PEG-Asparaginase. Dit leidde bij
geen van de kinderen tot een klinische complicatie.
L-Asparaginase wordt meestal met andere middelen gecombineerd in de
behandeling van ALL. Vooral de combinatie met corticosteroïden lijkt van invloed op
het effect van L-Asparaginase op de stolling. In hoofdstuk 7 beschrijven we het
effect van 1 soort L-Asparaginase in relatie tot twee verschillende schema's van de
corticosteroïd medicatie. Kinderen met ALL werden tussen 1997 en 2004 in de
inductie met de combinatie dexamethason en L-Asparaginase behandeld en tevens in
een fase van intensificatie. In de inductie bestaat de behandeling onder andere uit 4
weken dexamethason en daarna 4 giften L-Asparaginase in 2 weken, terwijl in de
intensificatie steeds 1 week dexamethason per 3 weken wordt gecombineerd met
negen wekelijkse giften L-Asparaginase. De stollingswaarden veranderden aanzienlijk
in de inductie zoals beschreven in hoofdstuk 6. Echter tijdens de intensificatie
veranderden de stollingsuitslagen niet noemenswaardig. Er was tijdens de fase van
intensificatie, gelet op de stollingsparameters, geen verhoogd risico op trombose.
Het effect van gelijktijdige behandeling van corticosteroïden en L-Asparaginase op de
stolling is dus afhankelijk van het precieze toedieningschema van deze combinatie.
DEEL III
Conclusie
We kunnen stellen dat L-Asparaginase steeds belangrijker wordt in de behandeling
van ALL bij kinderen. Intensief gebruik is van groot belang voor een maximale
overlevingskans van kinderen met ALL. De balans tussen maximale effectiviteit en
minimale toxiciteit verdient veel aandacht. In hoofdstuk 8 analyseren we in een
algemene discussie alle verkregen data in relatie tot beschikbare kennis uit de
literatuur. Hieruit volgen een aantal aanbevelingen voor de toekomst, zoals het
meten van de L-Asparaginase-activiteit om op individuele basis de dosering aan te
passen om een algehele asparaginedepletie te bewerkstelligen. De klinische respons
op L-Asparaginase voorspelt de overlevingskans en kan in de toekomst gebruikt
worden in de keus voor bepaalde behandelstrategieën. Studies zullen moeten
uitwijzen of het gebruik van bloedverdunners bij oudere kinderen leidt tot minder
tromboses tijdens de inductiebehandeling van ALL.
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Jarenlang had ik al actief en met veel plezier in de kinderoncologie gewerkt in het
academische milieu van het Sophia Kinderziekenhuis, toen moest het er toch nog
van komen:
Rob Pieters werd tot hoogleraar kinderoncologie in het Sophia Kinderziekenhuis
benoemd met in zijn kielzog een groep jonge enthousiaste nieuwe
kinderoncologen! Dit moest voor mij het moment worden om ruim baan te maken
voor aanstormend talent. Ik stelde voor om de zorg van de benigne hematologie
en de hemostase op mij te nemen, en op mijn vraag of ik dat niet zou kunnen
combineren met enig onderzoek, sprak Rob:
"dan moet je ook promoveren…"
Maar voordien waren daar eerst Dr. George van Zanen en zeker ook Dr. Karel
Hählen. De liefde voor kinderen met een ernstige ziekte zoals kanker en het
zorgvuldig toepassen van protocollaire geneeskunde heb ik van hen geleerd.
Met Prof. Dr. Rob Pieters als promotor werd ik rustig maar nadrukkelijk
geïntroduceerd in de wereld van wetenschappelijk denken. Logisch redeneren en
precies formuleren bleken niet eenvoudig. Gelukkig heb jij de onderzoekslijnen
helder voor de geest, waardoor de positie van de kinderoncologie in Rotterdam op
een zeer hoog plan is getild. Ik voel me vereerd dat ik met dit proefschrift een
klein steentje heb kunnen bijdragen.
Natuurlijk ben je als clinicus èn aio èn 50-plusser een vreemde eend in de bijt.
Vooral het net geïnstalleerde research-laboratorium op de 15e moest hier even aan
wennen! Het is prima gegaan. Dr. Monique den Boer, hoofd van het research-
laboratorium kinderoncologie, wees mij de meest geroutineerde analistes toe en
hield zelf de touwtjes van het onderzoek strak in handen. Als geen ander ben jij,
Monique, in staat geweest om de onderzoeksresultaten en de voor mij zo lastige
statistiek in goed Engels te formuleren. Dank voor alle aandacht die je hieraan
hebt besteed.
De overige leden van de kleine commissie naast Rob Pieters en Monique den
Boer, Prof. dr. Pieter Sonneveld, Prof. dr. Huib Pols en Dr. Frank Leebeek wil ik
bedanken voor hun bereidheid het manuscript op snelle wijze kritisch te
beoordelen.
Het echte werk is gedaan aan de bench: Nathalie Reniers beet het spits af en
leerde mij niet alleen de beginselen van de moleculaire biologie, maar ook vele
finesses van de computer. Hoewel je uit Rotterdam bent vertrokken, zien we
elkaar gelukkig nog steeds. Karin Kazemier mocht het werk afmaken. Ongelooflijk
dat iemand zoveel dingen tegelijk kon doen. Altijd drie stappen verder met je
gedachtes dan ik, maar ook altijd even behulpzaam in weer recapituleren.
Beneden op het laboratorium speciële hematologie werd ondertussen minstens
zo hard gewerkt. Rolinda Stigter en Carla van Kessel hebben tussen de bedrijven
door met een voor analistes kenmerkende precisie alle stollingstesten uitgevoerd.
Nog steeds voeren we zeer verhelderende discussies over de interpretatie van
technieken en hun uitkomsten.
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Met al die stollingsuitslagen ging ik naar Wim Hop, de statisticus. Uren zaten we
samen in dat kleine kamertje aan de kop van de faculteit (dus een prachtig
uitzicht). Het belang van ANOVA en SAS PROC MIXED is goed tot mij
doorgedrongen!
Als derde laboratorium dat participeerde in dit onderzoek noem ik het
laboratorium van de Klinische Genetica (sectie Chemische Basisdiagnostiek -
Metabole) waar Wistaria onder leiding van Dr. Jan Huijmans alle intracellulaire
aminozuurmetingen heeft uitgevoerd: onverstoorbaar, en altijd even vriendelijk.
Vòòr meten komt een goed protocol schrijven, patiënten en ouders inlichten en
vooral materiaal voor laboratorium onderzoek verzamelen: wie konden dat beter
coördineren en uitvoeren dan Eline Visser en Inekee van der Vaart. Eigenlijk zijn
zij de motor van ons research instituut. Geweldig dat ook ik van jullie diensten
gebruik heb mogen maken.
Altijd even behulpzaam waren ook Jeanine Arnolds en Jacqueline Dito van ons
secretariaat. 'Even' helpen bijvoorbeeld met elektronisch een artikel "submitten":
alles wil geleerd zijn.
De 'finishing touch' is gebeurd door Margo Terlouw, een oude bekende van het
specieel hematologisch laboratorium waar zij vroeger als analiste werkte. De
precisie van toen komt nu fantastisch van pas bij het redigeren van proefschriften.
Geweldig bedankt voor je leuke ideeën en je vlotte uitwerking.
Dank voor de samenwerking met de SKION, waardoor de window met PEG-
Asparaginase in de behandelstrategie van ALL-9 kon worden opgenomen.
Het laboratorium van Prof. dr. Joachim Boos en Dr. Claudia Lanvers in Münster
was vooral in het begin nauw betrokken bij zowel de planning van de PEG-
Asparaginase window, als ook bij de technische uitvoering: 'Ich bedanke mich für
die schöne Zusammenarbeit mit Ihnen'.
Wetenschappelijk leren denken is eigenlijk het belangrijkste doel van onderzoek
doen. Dr. Jules Meijerink vind ik zo'n echte wetenschapper. Erg kritisch, maar ook
zeer fair. Dank voor je geduld en begrip in menig gesprek over jou passie: de
wetenschap.
Wetenschap kost tijd, erg veel tijd zelfs. Toch heb ik een groot deel van het
onderzoek in werktijd kunnen doen, mede dankzij o.a. Auke Beishuizen en later
Marjon Cnossen. De hematologie moest wel doordraaien: zij deden de poli's en
consulten, ik hoefde alleen maar mee te denken. Ook Desirée Bezemer, Andrieca
de Vries en Inge van der Sluis droegen hun steentje bij tijdens hun stage
hematologie binnen hun fellowship kinderoncologie. Alle kinderoncologen toonden
zeer warme belangstelling. Vooral kamergenote Friederieke Hakvoort heeft het
misschien moeten ontgelden wanneer er weer iets mis ging met bijvoorbeeld de
computer, op de valreep mijn excuses. Het ga jullie goed in Italië!
Al die andere collegae en lieve mensen van de laboratoria, de polikliniek, de
afdelingen moeten zich realiseren dat het schrijven van een proefschrift deels een
eenzame exercitie is, maar het kan nooit zonder teamwerk. De afdeling
kinderoncologie/hematologie van het Sophia Kinderziekenhuis is een prachtig
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team; ik ben er trots op al zolang lid van dit team te zijn en ben trouwens niet van
plan weg te gaan!
En tenslotte de allerbelangrijkste groep: ik wil nadrukkelijk de ouders en hun
kinderen bedanken die ermee akkoord gingen om deel te nemen aan het
onderzoek. De zorgen rond de behandeling van een kind met leukemie zijn enorm,
toch konden en kunnen ouders en kinderen in die moeilijke fase het opbrengen om
in wetenschappelijk onderzoek te participeren. Hopelijk kunnen andere kinderen
van de resultaten van dit onderzoek profiteren.
Het thuisfront heeft waarschijnlijk bij het afronden van het boekje toch wel wat te
lijden gehad. Lieve Rolf, nog even en we hebben het rijk alleen! Alle kinders prima
geparkeerd, daar kunnen we trots op zijn. Er komt steeds meer tijd voor ons
samen. Hans, Frank en Carolien zijn allen volwassen met eigen toekomstplannen.
Ik geniet van jullie.
Het grootste probleem van het afgelopen jaar was mijn tuin: serieus verwaarloosd!
Dat is het eerstvolgende project na de promotie.
Inge Appel


